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Hip fracture is one of the major public health problems (Kanis et al., 2013). 
Clinical consequences of fracture include short and long-term morbidity 
characterized by pain, limitation of function, decreased health-related quality of 
life (HRQoL), and increased mortality (Teng, Curtis and Saag, 2008). Hip 
fracture is the most serious osteoporotic fracture, and its consequences measured 
in mortality, morbidity and cost approximate to all other fragility fractures 
combined (Hernlund et al., 2013). To outline the magnitude, every 6–7th woman 
over 50 years will experience a hip fracture (Kanis et al., 2013), a figure close 
to the risk of coronary heart disease (Berry et al., 2012). The related hospitali-
zation cost is comparable to that of myocardial infarction and stroke (Singer et 
al., 2015). Moreover, the all-cause mortality at 1 year after hip fracture exceeds 
the population-expected mortality by 3–4 times (Abrahamsen et al., 2009; 
Haentjens et al., 2010), the risk comparable to the severest life-threatening 
diseases such as metastatic cancer or dementia (Quan et al., 2011; Todd et al., 
2013). In addition, less than half of all survivors recover in full (Melton, 2003).  
However, public awareness of the problem is low, and identifying indi-
viduals with a high risk of fracture remains a challenge (Harvey et al., 2017). 
Besides, there is a marked heterogeneity of hip fracture prevention and care 
among European countries (Hernlund et al., 2013; Svedbom et al., 2013). Given 
the aging population and a projected increase in hip fractures, a change in policy 
is warranted (Cheng, Levy and Lefaivre, 2011; Hernlund et al., 2013). Aware-
ness of the disease and its consequences must be increased to attenuate the 
public health impact (Harvey et al., 2017). Quantifying the hip fracture burden 
on patients and society is important to raise awareness, identify the most 
vulnerable at-risk groups, draw attention to gaps and inequalities in care pro-
vision, and guide prevention policies and interventions (Kanis et al., 2013; 
Harvey et al., 2017). 
The health and economic burdens of hip fracture were modeled recently for 
all European countries (Ström et al., 2011; Hernlund et al., 2013; Svedbom et 
al., 2013). In 2010, the number of people with incident hip fractures was 
estimated at 615,000 and prevalent fractures at 3.3 million in Europe, 3/4 of the 
fractures were among women. The cost of hip fractures amounted to 20 billion 
euros, 2/3 of that incurred in those aged above 80 years. For comparison, the 
societal cost of lung cancer has been estimated at 19 billion and breast cancer at 
15 billion euros in Europe (Luengo-Fernandez et al., 2013), dementia at 105–
160 billion (Gustavsson et al., 2011; Wimo et al., 2011; Olesen et al., 2012; 
DiLuca and Olesen, 2014), Parkinson’s disease at 14 billion (Gustavsson et al., 
2011; Olesen et al., 2012; DiLuca and Olesen, 2014), stroke at 27–64 billion 
(Leal et al., 2006; Gustavsson et al., 2011; Olesen et al., 2012; DiLuca and Olesen, 
2014), and coronary heart disease at 45 billion (Leal et al., 2006). Overall, the 
reduced survival, reduction in HRQoL and high costs pose a significant clinical 
and economic burden on the European population (Hernlund et al., 2013; 
Papadimitriou et al., 2017).   
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According to the limited data on hip fracture in Estonia, the number of 
people ≥50 years of age with incident hip fractures was estimated at 1600 each 
year, and prevalent fractures as high as 7300 persons a year (Hernlund et al., 
2013; Svedbom et al., 2013). The disease burden was estimated at 1400 quality-
adjusted life years (QALY) lost each year. The first-year hip fracture cost 
burden was estimated at 5580 euros per patient, and the total societal cost at 
15 million euros or 12 euros per person. For comparison, the healthcare cost of 
lung cancer has been estimated at 7 euros and breast cancer at 13 euros per 
person in Estonia (Luengo-Fernandez et al., 2013). The hip fracture costs were 
projected to increase by 17% by 2025 (Hernlund et al., 2013; Svedbom et al., 
2013).  
However, the epidemiologic and cost data for estimating disease burden in 
the study were incomplete for deriving sound estimates for policy. For example, 
the hip fracture incidence for Estonia was derived from a regional estimate 
(Haviko, Maasalu and Seeder, 1996) and using the unpublished hip fracture 
rates from Finland (Svedbom et al., 2013), the mortality estimate was derived 
from Sweden (Kanis et al., 2003; Johnell et al., 2004; Borgström et al., 2007), 
and the HRQoL loss estimate from a systematic review (Peasgood et al., 2009). 
Resource use and cost data were adjusted from neighboring countries, Finland 
and Sweden (Nurmi et al., 2003; Borgström et al., 2006; World Bank, 2008). 
The need for reliable country-specific estimates was evident.  
This series of studies was undertaken to assess the health and economic 
impact (incidence, loss of HRQoL, resource use and costs, and excess mortality) 
of hip fracture in Estonia, to enable estimation of the total societal burden and 
improve future predictions. The results can be used as a platform for 
prioritization of hip fracture in health and social policy agendas, draw attention 
to gaps and inequalities in care, and suggest that implementation of fracture 
prevention programs and optimal post fracture rehabilitation and social care are 
warranted. The results can also be used in economic evaluations for selecting 
cost-effective interventions for hip fracture prevention and care. To our 
knowledge, this is the first population-based research in Eastern Europe that 













2. LITERATURE REVIEW  
2.1. Hip fracture as a public health problem 
Hip fracture is a major public health issue associated with excess morbidity, 
mortality, disability, and subsequent hospital and social costs as well as 
impairment in HRQoL (Melton, 2003; Johnell and Kanis, 2006; Borgstrom et 
al., 2013). Hip fracture is usually a clinical consequence of osteoporosis that 
increases with age, and it is estimated that up to 6% of men and 21% of women 
50–84 years have osteoporosis (Hernlund et al., 2013). To outline the magni-
tude, the lifetime probability of hip fracture at the age of 50 ranges from 4% to 
25% (Ström et al., 2011) and the excess all-cause mortality from 5% to 40% 
during the first year after fracture (Haentjens et al., 2010). In addition, less than 
half of all survivors regain the level of function they had prior to the fracture 
(Melton, 2003). Hip fracture is the most serious osteoporotic fracture: it 
accounts for the highest excess mortality, disability, and subsequent health care 
and social costs (Melton, 2003; Johnell et al., 2004; Johnell and Kanis, 2006; 
Borgstrom et al., 2013; Hernlund et al., 2013; Kanis et al., 2013). The burden of 
hip fractures has increased considerably throughout the world over the last few 
decades as the number of elderly persons has increased (Johnell and Kanis, 
2006). Given the aging of the population globally, hip fractures will become an 
increasing public health problem (Johnell and Kanis, 2006; Cheng, Levy and 
Lefaivre, 2011; Kanis et al., 2013).  
Hip fracture is usually a low-energy or fragility fracture that may be defined 
as a fall from a standing height or less, or trauma that in a healthy individual 
would not give rise to fracture (Melton et al., 1997; Hernlund et al., 2013). About 
one-third of elderly individuals fall annually, with the result that 5% will sustain 
a fracture and 1% will suffer a hip fracture (Hernlund et al., 2013). The risk of 
falling increases with age and is somewhat higher in elderly women than in 
elderly men (Hernlund et al., 2013). The leading cause of hip fracture in persons 
aged 50 years and over is considered osteoporosis, defined as a value for bone 
mineral density (BMD) ≤2.5 standard deviations (SD) below the young female 
adult mean (Kanis et al., 2002). However, not all hip fractures occur at 
osteoporotic BMD values (Melton et al., 1997; Johnell et al., 2005; Roux and 
Briot, 2017). Other risk factors include female sex, premature menopause, 
advanced age, previous fragility fracture, glucocorticoid therapy, family history 
of hip fracture, a low bodyweight, smoking, and excessive alcohol consumption 
(Kanis et al., 2002). The hip fracture could be a result of poor health: the severe 
pre-fracture conditions such as diabetes, cardiac disease, cancer, dementia, 
Parkinson’s disease, chronic obstructive pulmonary disease, stroke, hypothy-
roidism, low muscle strength, poor walking ability are all risk factors for falls 
(Jørgensen et al., 2014).  
Hip fracture is a fracture of the proximal femur, either through a femoral 
neck or through a trochanteric region (pertrochanteric fracture) (Hernlund et al., 
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2013). Subtrochanteric fractures (in a region up to 5 cm distal to lesser 
trochanter) are also defined as hip fractures (Lix, Azimaee and Osman, 2012) and 
included in most hip fracture incidence and mortality studies (Brauer and Coca-
Perraillon, 2009; Cheng, Levy and Lefaivre, 2011; Dimai et al., 2011; 
Michaëlsson et al., 2014; Omsland et al., 2014), despite that most of these are 
not low-energy fractures (Nieves et al., 2010). Hip fracture nearly always 
necessitates hospitalization and surgical intervention (Kanis et al., 2013).   
A hip fracture can have a profound impact on physical function and activity 
(Kerr et al., 2017). The impact accumulates over time through a cycle of impair-
ment, as fracture leads to long term decline in physical function, including loss 
of muscle, activity avoidance and reduced physical capacity, which in turn leads 
to greater risk of fracture and further physical restrictions. The cycle of 
impairment is complex, as other physical, psychosocial and treatment-related 
factors, such as comorbidities, fears, and beliefs about physical activity and 
fracture risk influence physical function and everyday activity (Kerr et al., 
2017).  
Patients experiencing a hip fracture are at considerable risk for premature 
death (Magaziner et al., 1997; Abrahamsen et al., 2009; Klop et al., 2014). Up 
to 20% of patients die in the first year following hip fracture (Abrahamsen and 
Vestergaard, 2010; Haentjens et al., 2010). It is estimated that approximately 
30% of excess deaths are causally related to hip fracture, and most excess 
deaths are a result to serious life-threatening comorbidities (Kanis et al., 2003). 
The diseases associated with excess mortality are dementia, cancer, diabetes and 
cardiac disease (Hu et al., 2012; Martinez-Laguna et al., 2017). Other risk factors 
for the excess mortality include advanced age, male sex, poor preoperative 
health status, poor walking capacity, poor activities of daily living, poor mental 
state, and multiple comorbidities (Hu et al., 2012). A number of these factors 
are also related to frailty that is defined by weight loss, weakness, poor energy, 
slow walking, and low physical activity (Fried et al., 2001; Ensrud et al., 2007). 
Frailty is associated with falls, disability, hospitalization, and mortality (Xue, 
2011; Romero-Ortuno and Kenny, 2012). 
 
 
2.2. Measures of hip fracture burden 
Disease burden is the impact of a health problem in a given area that can be 
compared across diseases, geographies and time to inform policy and health 
system performance, prioritize investments in research, and monitor progress 
(Kassebaum et al., 2016). In order to quantify the burden of disease and 
facilitate rational decision making for resource allocation, it is important to 
estimate the impact of a disease using measures that can be compared across 
diseases, interventions, populations, and time (Drummond et al., 2015).  
The impact of hip fracture has been measured by disease frequency, the cost 
of illness, excess mortality, and summary measures of population health that 
combine mortality with morbidity (Hernlund et al., 2013).  
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2.3. Incidence of hip fracture 
There are marked geographical differences in hip fracture incidence worldwide 
(Kanis, Odén and McCloskey, 2012). The highest rates of hip fracture in 
women have been observed in Northern Europe, e.g., Scandinavian countries 
(540–570/100 000) and Ireland (410/100 000), whereas the lowest rates are in 
the developing countries, e.g., Ecuador (73/100 000) (Kanis, Odén and 
McCloskey, 2012). The difference in incidence is approximately 10-fold, whereas 
the reasons for this variation are not well known (Kanis, Odén and McCloskey, 
2012). It is hypothesized that the hip fracture rates correlate with the degree of 
urbanization across geographies and cultures (Ballane et al., 2014). Within 
countries, the age-standardized incidence in women is approximately two times 
higher than that in men (Kanis, Odén and McCloskey, 2012). 
While the total number of individuals affected by hip fracture may be 
expected to increase globally, incidence rates appear to be stabilizing, with age-
adjusted decreases being observed in many European countries and in the US, 
the trend being more pronounced in women than in men (Brauer and Coca-
Perraillon, 2009; Abrahamsen and Vestergaard, 2010; Korhonen et al., 2013; 
Siggeirsdottir et al., 2014). It is assumed that hip fracture rates decrease due to 
the improvement in nutritional status, increases in BMD and body mass index 
(BMI), osteoporosis medication use, and lifestyle interventions such as smoking 
cessation and fall prevention (Ballane et al., 2014). Conversely, in the developing 
countries (Asia, South America) the continuous rise of hip fracture rates is still 
prevailing, though the absolute risks are still smaller (Ballane et al., 2014). A 
better understanding of the variations and trends in hip fracture rates can 
provide important clues to etiology and prevention of fractures (Cheng, Levy 
and Lefaivre, 2011; Cooper et al., 2011). 
Data on recent trends in hip fractures from Eastern European countries are 
limited. However, the difference in incidence between Eastern and Western 
European countries has been noted before, for example in 1995–2004 the 
incidence was significantly higher in Western than in Eastern Germany, and 
differences between East and West have decreased since unification (Icks et al., 
2013). Recent data from Poland indicate a relatively low incidence in both 
women and men (Wilk et al., 2013), whereas Lithuania and Russia have moderate 
rates (Lesnyak et al., 2012; Tamulaitiene and Alekna, 2012). The difference in 
risks between Western and Eastern Europe is greater in women than in men 
(Kanis, Odén and McCloskey, 2012). 
Geographically, Estonia lies between the high-incidence Scandinavian 
countries and low to moderate-incidence Eastern European countries (Cheng, 
Levy and Lefaivre, 2011; Kanis, Odén and McCloskey, 2012; Kanis et al., 2017). 
The hip fracture incidence data for Estonia are available for women, and the 
age-standardized (to the WHO world population) risk for women ≥ 50 years is 
estimated at 225 cases per 100 000 person-years (Haviko, Maasalu and Seeder, 
1996; Kanis, Odén and McCloskey, 2012). Another report imputed data from 
the unpublished Finnish incidence rates estimated that 1600 hip fractures (75% 
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in women) are sustained in Estonia each year, with the age-standardized (to the 
EU standard population) incidence at 238/100 000 in men and 440/100 000 in 
women (Svedbom et al., 2013). The number of incident fractures was assumed 
to increase by 400 by 2025 (Svedbom et al., 2013). Along with countries with 
comparable risk estimates (Poland, Mexico, Spain, USA) Estonia belongs to the 
medium risk tertile of countries (Kanis, Odén and McCloskey, 2012).  
 
 
2.4. Resource use and cost related to hip fracture 
The cost of illness is a measure of burden quantified in monetary terms, encom-
passing the resource use and financial cost related to the disease (Larg and John 
R. Moss, 2011). Cost-of-illness studies have been used to generate public interest, 
to inform the planning of health services and encourage policy debate, and 
prioritizing research (Larg and John R. Moss, 2011). It has also been argued that 
for health policy decisions, the cost estimates are easy to relate to, compared to 
the use of health measures (DiLuca and Olesen, 2014). In addition, costs of 
illness are an input in economic evaluations (Hodgson, 1994; Drummond et al., 
2015), and it is preferable to use country-specific estimates as the costing studies 
are context-specific and cannot be used to inform policy debate in other popu-
lations (Drummond et al., 2015).  
Several studies have assessed the costs related to hip fracture (Tamulaitiene 
and Alekna, 2012; Ireland and Kelly, 2013; Castelli et al., 2015; Marques et al., 
2015; Leal et al., 2016). However, most studies estimate only the direct health 
care costs (Tamulaitiene and Alekna, 2012; Lambrelli et al., 2014; Lüthje et al., 
2014; Castelli et al., 2015; Leal et al., 2016) or focus on a too short period after 
the fracture (Tamulaitiene and Alekna, 2012; Castelli et al., 2015). It has been 
estimated that the direct health care costs account for only 30–60% of the total 
hip fracture costs (Borgström et al., 2006; Lüthje et al., 2014), and other costs 
should be accounted for when evaluating the economics and the total burden on 
society (Dimai et al., 2012; Hernlund et al., 2013; Marques et al., 2015). Overall, 
country-specific cost estimates are scarce (Hernlund et al., 2013; Svedbom et 
al., 2013). 
The annual hip fracture related total cost has been estimated at 20 billion 
euros in Europe, 2/3 of that incurred in age above 80 years, and 2/3 accrued in 
the first year after fracture (Hernlund et al., 2013). For comparison, a societal 
cost of lung cancer has been estimated at 19 billion euros in Europe, dementia at 
105–160 billion, Parkinson’s disease at 14 billion, stroke at 27–64 billion, and 
coronary heart disease at 23 billion (Leal et al., 2006; Gustavsson et al., 2011; 
Wimo et al., 2011; Olesen et al., 2012; Luengo-Fernandez et al., 2013; DiLuca 
and Olesen, 2014). The highest hip fracture costs are incurred in the age group 
over 80 years (Hernlund et al., 2013). Denmark had the highest annual hip 
fracture cost (25,117 euros per hip fracture patient or 103 euros per person), 
Bulgaria the lowest cost (1826 euros per patient or 3 euros per person) 
(Hernlund et al., 2013). 
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In Estonia, the annual hip fracture cost (at 2010 prices) was estimated at 
5580 euros per patient, and the total societal cost burden at 15 million euros or 
12 euros per person (Svedbom et al., 2013) that is comparable to other common 
conditions in the elderly. For comparison, the direct healthcare cost of lung 
cancer has been estimated at 4 euros and breast cancer at 7 euros per person in 
Estonia (Luengo-Fernandez et al., 2013). The hip fracture costs were projected 
to increase by 17% by 2025 (Hernlund et al., 2013; Svedbom et al., 2013). 
However, the results were incomplete for deriving sound estimates for policy. 
Hip fracture cost was estimated using the price level adjusted cost in Finland 
(Nurmi et al., 2003; World Bank, 2008). Likewise, using Swedish data for the 
proportion of patients who transition to nursing homes after fracture may have 
overestimated the nursing home costs and underestimated the informal care cost 
for countries outside Scandinavia (Hernlund et al., 2013). For example, 30% of 
fracture cost in Austria is due to family care (Dimai et al., 2012), compared to 
only 3–20% in Sweden (Borgström et al., 2006). Indirect cost was omitted, 
underestimating the economic burden despite the relatively old age of patients 
(Hernlund et al., 2013). 
 
 
2.5. Hip fracture related excess mortality  
Patients who fracture their hip are at considerable risk of premature death 
(Abrahamsen et al., 2009; Haentjens et al., 2010). The pooled all-cause 
mortality risk of hip fracture patients from 75 cohorts and 64 300 patients (mean 
age 81 years) was as high as 13% at 1 month, 16% at 6 months, 25% at 1 year, 
and 35% at 2 years after fracture (Hu et al., 2012). For comparison, the 1-year 
mortality for heart failure is estimated at 7–17% (Maggioni et al., 2013), and for 
myocardial infarction at 6% (Smolderen et al., 2017). Mortality studies almost 
always note increased mortality soon after the fracture, within the first 3–6 
months (Johnell et al., 2004; Abrahamsen et al., 2009; Haentjens et al., 2010; 
Michaëlsson et al., 2014).  
As hip fracture is usually not recorded as an underlying cause of death 
(Calder, Anderson and Gregg, 1996), the mortality impact of hip fracture can be 
examined by comparing the observed all-cause mortality among hip fracture 
patients to the expected mortality in non-fracture controls; the absolute risk 
difference represents excess or attributable mortality (Teng, Curtis and Saag, 
2008). The pooled results of hip fracture patients aged 70 years or above from 
Western European countries, Australia, and the USA suggest that the cumulative 
excess risk of death over the first year after hip fracture varied widely from 3% 
to 43%, depending on age at the time of fracture, and sex (Haentjens et al., 
2010). The cumulative risk at 1 year was 2.9 times higher among hip fracture 
women and 3.7 times in men compared to the age-matched controls (Haentjens 
et al., 2010). Although the relative risk decreased in subsequent years, it did not 
return to that of age- and sex-matched reference groups even 10 years post-
fracture (Haentjens et al., 2010). The excess risk increased with advancing age, 
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although this differential became less pronounced over the following years due 
to increased mortality, unrelated to hip fracture, in the reference populations 
(Abrahamsen et al., 2009; Haentjens et al., 2010). The excess risk was higher 
among men than women (Abrahamsen et al., 2009; Kannegaard et al., 2010; 
Ekström et al., 2015), notably among the oldest age categories (≥80 years) 
(Haentjens et al., 2010). This leaves hip fracture men with significantly higher 
mortality than women because the risk of death in a general population is also 
higher in men (Hernlund et al., 2013).  
Estimates of hip fracture mortality in Eastern Europe are scarce (Sebestyén 
et al., 2008; Kurtinaitis et al., 2012). However, the data in this region suggests a 
sex-specific difference in the incidence of hip fractures between Eastern and 
Western Europe (Icks et al., 2013; Wilk et al., 2013), and the age and sex-
specific all-cause mortality rates in Eastern Europe differ from those in Western 
countries (Eurostat, 2017). The number of hip fracture deaths in the first year 
after fracture in Estonia has been estimated at 65 (37 women, 27 men) (Sved-
bom et al., 2013). This conservative estimation is based on assumption that only 
30% of excess deaths are attributable to hip fracture and the majority (70%) are 
related to pre-existing comorbidities (Kanis et al., 2003; Tosteson et al., 2007) 
and therefore not included in the estimate. If the impact of comorbidities was 
smaller, up to 1.5% of all deaths (up to 225) could be related to hip fracture in 
Estonia (Kanis et al., 2003; Hernlund et al., 2013), an estimate comparable to 
that for breast and stomach cancer or self-harm (Wang et al., 2016; Institute for 
Health Metrics and Evaluation University of Washington, 2017). 
 
 
2.6. The impact of comorbidities on hip fracture related 
excess mortality 
Hip fracture patients often have significant comorbidities, so that not all deaths 
associated with hip fracture are due to the fracture event (Kanis et al., 2003; 
Hernlund et al., 2013). Numerous studies have demonstrated that the presence 
of severe pre-fracture comorbidities or poor health status is a negative predictor 
of survival after hip fracture (Roche et al., 2005; Luise et al., 2008; Abraham-
sen et al., 2009; Hu et al., 2012; Hindmarsh et al., 2014; Melton et al., 2014; 
Anthony W. Ireland, Kelly and Cumming, 2015). Therefore, it is assumed that 
the excess mortality after hip fracture is a sum of two components. Some excess 
deaths are a result of the higher prevalence of pre-fracture comorbidities in that 
patient group, i.e., elevated background risk of death. Other deaths are causally 
related to the fracture, directly or indirectly by accelerating death from other 
diseases, i.e., the deaths that would not happen without sustaining a fracture 
(Kanis et al., 2003). Better understanding the impact of comorbidities on 
mortality following hip fracture is essential for identifying those patients who 
are candidates for interventions to reduce the excess risk of death (Luise et al., 
2008; Teng, Curtis and Saag, 2008; Abrahamsen et al., 2009). However, the 
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impact of comorbidities on extent and duration of excess mortality is still 
controversial (Abrahamsen et al., 2009).  
Several large cohort studies have demonstrated that the pre-fracture 
comorbidities have a leading role in excess mortality (Kanis et al., 2003; Farah-
mand et al., 2005; Tosteson et al., 2007). For example, Kanis et al, compared 
the risk of all-cause death among hip fracture patients to that in the general 
population, and suggested that the immediate elevated 6-months period risk 
(30% of all excess deaths) was associated with a fracture, whereas the following 
long term residuum (70% of deaths) accounted for comorbidity-related deaths 
(Kanis et al., 2003). However, the comorbidity data were not collected for the 
study. Tosteson et al demonstrated that much of the short-term and all of the 
long-term excess risk of death can be explained by poor health status, and not 
by fracture event (Tosteson et al., 2007). In contrast, Vestergaard et al demon-
strated that the adjustment for age, sex and comorbidities only reduced the 
excess risk a little, implying that most of the short and long-term excess risk is 
due to the fracture and its complications (Vestergaard, Rejnmark and 
Mosekilde, 2007). Similar to that, several studies have demonstrated that after 
adjustment for comorbidities the hip fracture patients were 2–3 times more 
likely to die than controls (Empana, Dargent-Molina and Bréart, 2004; Grønskag 
et al., 2012; Klop et al., 2014; Michaëlsson et al., 2014; Padrón-Monedero et al., 
2017). The controversy has also been sustained by use of different study 
methods. For example, stratification by the comorbidity status generally demon-
strated a dose-response relationship between comorbidities and excess deaths 
(Magaziner et al., 1997; Farahmand et al., 2005; Vestergaard, Rejnmark and 
Mosekilde, 2007), whereas adjustment for comorbidities derived pooled results 
(Empana, Dargent-Molina and Bréart, 2004; Tosteson et al., 2007; Vestergaard, 
Rejnmark and Mosekilde, 2007; Grønskag et al., 2012; Klop et al., 2014). 
Likewise, the studies using conditional risks account for the deaths within short 
periods over the follow-up (Kanis et al., 2003), whereas the cumulative risks 
account for all accumulating deaths (Vestergaard, Rejnmark and Mosekilde, 
2007; Kannegaard et al., 2010; Hindmarsh et al., 2014). 
 
 
2.7. Summary measures of population health 
Incidence and mortality have traditionally been the most common indicators for 
evaluation of the burden of disease in a population (Mckenna et al., 2005). 
However, large increases in life expectancy have led to the development of new 
summary measures of population health that capture both duration and quality 
of life lost (Fox-Rushby, 2002; Murray et al., 2015; Kassebaum et al., 2016). 
Disability-adjusted life year (DALY) is a composite measure that combines the 
prevalence and severity of non-fatal conditions with premature mortality and 
measures a gap between population and a normative standard of lifespan in full 
health (Murray et al., 2012). Assessment of DALYs has revealed that hip 
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fracture can lead to an average 3% loss of healthy life-years in elderly people 
and that 70% of the burden is related to disability (Papadimitriou et al., 2017).  
The use of DALYs has limitations. To derive the severity of disease DALY 
incorporates the preference based disability weights (Salomon et al., 2015), 
whereas the proposed weights are based on expert opinion rather than on patient 
or populations opinion (Sassi, 2006). Further, the severity estimates are constant 
and sometimes inconsistent (Sassi, 2006). For example, the hip fracture weights 
used in the Global Burden of Disease study were estimated at 0.26 (i.e., 26% 
health loss compared to the state of perfect health) for a short-term fracture, 
0.06 for a treated long term, and 0.40 for an untreated long-term fracture 
(Salomon et al., 2015), whereas the National Osteoporosis Foundation has 
proposed different weights, 0.47 for the first year and 0.17 for the second year 
after fracture (Kanis et al., 2001). The inconsistency might compromise the 
ability of DALY to detect change (Papadimitriou et al., 2017).  
QALY is a composite measure in which the length of life is adjusted with the 
HRQoL (Drummond et al., 2015). Unlike DALY, the severity of disease in 
QALY is elicited directly by choice methods or indirectly using pre-scored 
questionnaires (Arnold et al., 2009). QALY was developed for estimating health 
gain to inform resource allocation (Weinstein, Torrance and Mcguire, 2009); 
QALY loss is an unconventional reverse application to measure health loss 
from a disease (Lips and van Schoor, 2005) (Figure 1).  
 
 
Figure 1. Loss of quality-adjusted life years (QALY). Blue box represents the 
normative duration and quality of life, based on the highest age- and sex-specific life 
expectancy estimates worldwide, green stands for the expected health without hip 
fracture (pre-fracture QALY), and red for the observed health with fracture (post-
fracture QALY). Adapted from Fox-Rushby, et al (Fox-Rushby and Cairns, 2005) 
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The reasons for using QALY loss for estimating the hip fracture burden stems 
from its applicability for primary data collection (Fox-Rushby, 2002), higher 
responsiveness (Sassi, 2006), the use of study results in health economic 
evaluations (Weinstein, Torrance and Mcguire, 2009; Drummond et al., 2015), 
and the need to measure the loss of HRQoL against its pre-fracture levels, and 
not to the normative standard (Borgstrom et al., 2013; Hernlund et al., 2013). 
The recent study estimated the total annual hip fracture related QALY loss of 
1400 in Estonia, primarily incurred by prior fractures and patients aged over 75 
years (Svedbom et al., 2013). Mean health-related QALY loss during the first 
year after fracture was estimated at 0.23 (Svedbom et al., 2013). The estimate 
was similar to other European countries (Hernlund et al., 2013) as the HRQoL 
loss estimate was based on the pooled data (Peasgood et al., 2009). 
 
 
2.8. Health-related quality of life  
To obtain QALYs precise estimates of HRQoL are required. Direct health 
valuation methods derive HRQoL by mapping preferences for a disease status 
directly onto the HRQoL scale by means of choice (time-trade-off, TTO) or 
visual analog scale (VAS) (Arnold et al., 2009). Indirect methods derive HRQoL 
via a generic HRQoL questionnaire (e.g., EUROQoL-5D, EQ-5D), whereas the 
responses are converted onto HRQoL (utilities) using the described direct 
valuation methods (Arnold et al., 2009). The differences in EQ-5D valuation 
estimates between populations are remarkable (Szende, Oppe and Devlin, 2007). 
Therefore, the transferability of HRQoL utilities across countries is limited, and 
choosing a method, instrument, and country value set is crucial for minimizing 
measurement bias and informing health policy (Knies et al., 2009). The EQ-5D 
questionnaire has been recommended for inclusion in hip fracture trials 
(Haywood et al., 2014) but has not been validated with the Estonia’s population 
utility weights (EuroQol, 2017). The UK population-based HRQoL value set is 
considered to be the most robust and is recommended by the EUROQoL group 
in the absence of country-specific value sets (Szende, Oppe and Devlin, 2007). 
The HRQoL values that are generated range from –0.59 to 1, where 1 represents 
full health, 0 represents death, and values below 0 represent health states worse 
than death (Dolan, 1997). 
The estimates of HRQoL after hip fracture are scarce. The profound loss in 
quality of life was demonstrated among Australian hip fracture women over 75 
years (Salkeld et al., 2000). Using a TTO and EQ-5D questionnaire with UK 
utility weights, the fracture which resulted in admission to a nursing home was 
valued at 0.05 (i.e., the value of health was only 5%), and a fracture maintaining 
independent living in the community at 0.31. Of note, the respective medians 
were lower, 0 and 0.13 (IQR 0.0, 0.65), implying a large variation among 
patients. Of women surveyed, 80% would rather be dead than experience the 
loss of independence and admission to a nursing home (Salkeld et al., 2000). 
Tosteson, at al, assessed the HRQoL in fracture women over 50 years in the 
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USA using a TTO method and estimated the respective mean at 0.63 (Tosteson 
et al., 2001). However, the relatively high estimate can be explained by late 
measurement, between 1–5 years after fracture. The following systematic 
reviews revealed a wide range of empirical HRQoL estimates, mostly due to 
differences in valuation methods and instruments, health state descriptions, and 
the background and perspective of respondents (Brazier and Green, 2002; 
Peasgood et al., 2009). The pooled estimates from 12 studies were 0.76 at pre-
fracture, 0.27 at 1 week, 0.54 at 4 months, and 0.58 at 1 year; the annual HRQoL 
loss was estimated at 0.24 QALY (Peasgood et al., 2009). The HRQoL impact 
of hip fracture extended for at least 3 years (Tarride et al., 2016). 
In the meta-analysis of 14 studies the pooled pre-fracture HRQoL estimate 
of 0.76 was dependent on age (higher in younger and lower in older patients) 
and elicitation method (higher with an EQ-5D questionnaire, lower with TTO 
and VAS); recalled pre-fracture estimate was higher than that collected 
prospectively (Si et al., 2014). A country, sex and fracture history had no signi-
ficant impact on pre-fracture HRQoL. The immediate post-fracture estimate was 
rather high at 0.32, whereas those at 1 year (0.60) and subsequent years (0.66) 
came as expected. Post-fracture estimates were lower in patients with previous 
fracture, those ended in a nursing home, and in men. The estimates used in the 
meta-analysis were mostly derived from the Western European countries, the 
USA and Japan.  
With the purpose of estimating the burden and to fill parts of the data gap 
The International Costs and Utilities Related to Osteoporotic Fractures Study 
(ICUROS) was initiated to collect the comparable HRQoL estimates in 2007 in 
11 countries worldwide (Australia, Austria, Estonia, France, Italy, Lithuania, 
Mexico, Russia, Spain, the UK, and the USA), with the 4-months interim results 
published in 2013 (PAPER V) (Borgstrom et al., 2013). Based on the 1273 
patients’ data the HRQoL after hip fracture was lower than expected in most 
countries, and the recovery over 4 months was modest. For example, the 
Lithuanian EQ-5D estimates were 0.80 before, 0.01 right after, and 0.36 at 
4 months, implying that the average Lithuanian patient lost 0.21 QALY or 79% 
of the expected HRQoL over the first 4 months (PAPER V, Table 3). The final 
ICUROS results are published in PAPER VI. 
 
 
2.9. Critical review of the literature 
The marked differences in hip fracture incidence are present across Europe, 
whereas the reasons for the difference are not entirely clear; it is hypothesized 
that the socioeconomic inequalities may contribute to that. It is also known that 
the total hip fracture cost is increasing, whereas the data on costs and inequities 
in service use are insufficient for policy. The country-specific data on HRQoL 
loss are scant, and the data on the impact of comorbidities on excess mortality is 
controversial.  
21 
In conclusion, there are important gaps in the knowledge on hip fracture 
incidence, excess mortality, costs, and loss of HRQoL in Europe. Of impor-
tance, more data are available for the advanced Western European and North 
American countries, whereas the data for Eastern Europe are incomplete. We 
assume that for estimating the health and economic impact of hip fracture 
Estonia should be classified as an Eastern European country, as the risk factor 
and disease pattern in general is more characteristic to the Eastern Europe (GBD 
2013 Risk Factors Collaborators et al., 2015; Forouzanfar et al., 2016; 
Kassebaum et al., 2016) and the status of economic development is comparable 
(OECD, 2017). In general, the topic of health and economic impact of hip 
fracture has a country-specific context, whereas the impact of comorbidities on 
hip fracture mortality is a research question of a broader clinical importance.  
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3. AIMS OF THE RESEARCH 
The overarching aim of the research was to assess the health and economic 
impact of hip fracture among individuals aged over 50 years in Estonia in 2005–
2016. The specific aims were: 
1. To assess the incidence of hip fractures (PAPER I);   
2. To estimate the impact of hip fracture on health-related quality of life over 
18 months after the fracture (PAPERs II, V, VI); 
3. To estimate the impact of hip fracture on resource consumption and cost 
over 18 months after the fracture (PAPER II); 
4. To assess the impact of hip fractures on all-cause mortality over 10 years 
(PAPER III); 
5. To assess the impact of pre-fracture comorbidities on excess mortality 
(PAPER IV). 
23 
4. MATERIALS AND METHODS 
4.1. Outline of the research project 
The project was led by the Institute of Family Medicine and Public Health and 
the Institute of Clinical Medicine, University of Tartu. Research commenced in 
2010 with Estonia joining the International Costs and Utilities Related to 
Osteoporotic Fractures Study (ICUROS) for estimating the quality of life and 
costs related to osteoporotic fractures across the world (PAPERs II, V, VI). A 
series of studies were conducted to fulfill the aims set for the research project. 
The ecologic study design was chosen for assessing the incidence and time 
trends (PAPER I), a (hospital based prospective) cohort study was used to 
assess the HRQoL and societal costs (PAPERs II, V, VI), and a population-
based retrospective age- and sex-matched cohort study to assess the excess 
mortality (PAPERs III–IV). The thesis is focused on analysis and interpretation 
of Estonian data (PAPERs I–IV), and the results from PAPERs V–VI are 
presented for an international comparison. 
 
Data sources:  
(i) Face to face and phone interviews with hip fracture patients (for 
ICUROS);  
(ii) Estonian Health Insurance Fund (EHIF) administrative database (Estonian 
Health Insurance Fund, 2015) for all studies. Estonia has a universal public 
health insurance system, covering >94% of the population. Since its 
inception in the early 2000s, the EHIF has maintained a complete record of 
inpatient and outpatient health care services. The EHIF electronic database 
contains information on characteristics of the person (sex, age at health 
care service utilization), health care utilization (date of service, primary 
and other diagnoses, treatment type (in- or outpatient), a specialty of the 
provider), medication use, and the date of death; 
(iii) Statistics Estonia (data on source population age and sex distribution) for 
the incidence and mortality studies. 
 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.2. The incidence of hip fractures (PAPER I) 
4.2.1. Data and case definitions 
For this ecological time-trend study we obtained the medical claims data from 
the EHIF. We analyzed data from 2005 to 2012 to identify all individuals aged 
50 years or older who sustained hip fractures. We documented 10,704 new hip 
fracture cases among persons aged 50 years or older occurring in 2005–2012. 
The case definition of hip fracture was based on identification of the hip 
fracture specific diagnosis codes (The International Classification of Diseases, 
Tenth Revision (ICD-10), codes: S72.0 – fracture of femoral neck, S72.1 – 
pertrochanteric fracture, and S72.2 – subtrochanteric fracture) on the health care 
bill submitted to the EHIF by the health care provider. These codes must have 
been listed as the primary or secondary diagnosis on the electronic inpatient 
health care claim submitted to the EHIF. An incident case of hip fracture and 
the index date of the diagnosis was assigned to cases that had no previous 
evidence of a diagnosis of hip fracture (i.e., no health care claims related to care 
with the diagnosis of S72.0, S72.1, and S72.2) within the preceding 12 months. 
The validity and reliability of this method of a case definition to ascertain 
incident hip fracture cases from a population-based administrative database 
have been demonstrated (Lix, Azimaee and Osman, 2012). Data obtained from 
the EHIF database included the characteristics of the person receiving care due 
to hip fracture (age, gender) and an identification code which allows 




4.2.2. Statistical analysis 
The numbers of individuals with hip fractures across different age and sex 
categories were presented. Data on source population age and sex distribution 
was obtained from Statistics Estonia (Statistics Estonia, 2015c). The annual 
incidence of hip fractures (crude incidence, age-standardized incidence, and 
age- specific incidence in women and men) together with the confidence 
intervals were estimated. The age-specific incidence rates for men and women 
were calculated in 5-year age groups using the number of hip fractures in that 
specific age group, divided by the population size within that specific age 
group, and was expressed per 100 000 persons in that age group. To adjust for 
age differences in the population through the study period, standardized 
incidence rates (SIR) were estimated using direct standardization to the WHO 
world standard population (WHO, 2015). χ² test was used for categorical 
variables to explore differences in rates between men and women over the study 
period. Trends in rates over time were assessed using linear regression analysis. 
All statistical analysis was performed using Stata version 11.2.  
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The study procedures were in accordance with local data protection regulations. 
The study was based on pre-existing records containing only non-identifiable 
data about individuals, it was exempt from ethical review, and the informed 
consent was not obtained. The study was approved by the Tartu University 
Research Ethics Committee.  
 
 
We followed a cohort of hip fracture patients in Estonia for 18 months after 
fracture. The study was part of the International Costs and Utilities Related to 
Osteoporotic Fractures Study (ICUROS) with the objective of estimating the 
quality of life and costs related to osteoporotic fractures in several countries 
across the world (PAPERs V, VI). All countries participating at ICUROS 
(Austria, Australia, Estonia, Spain, France, Italy, Lithuania, Mexico, Russia, the 
UK, the USA) followed the same study protocol and data collection instru-
ments. We present the method used in Estonia (PAPER II), and highlight the 
major differences with ICUROS (PAPERs V, VI) if any. 
 
 
A convenience sample of 205 consenting patients with low-energy trauma hip 
fractures attending the departments of traumatology and orthopedics of Tartu 
University Hospital and East Tallinn Central Hospital was recruited from 
November 2010 to October 2012. Patients were followed up at 4, 12 and 18 
months after the fracture or until death. Patients aged ≥ 50 years diagnosed with 
hip fracture who were interviewed within 2 weeks after fracture were eligible 
for inclusion. Patients with fractures caused by comorbidities, e.g., cancer, 
patients with multiple fractures, patients with cognitive disabilities (judged not 
to be able to complete the questionnaire), and previously institutionalized 
patients were excluded. Out of 707 hip fracture patients hospitalized over the 
study recruitment period in the two study centers 562 patients were not included 
in the study. This includes patients not invited (patients who were admitted for 
care in periods when recruitment team was not operating; n=336), patients 
accessed but deemed to be ineligible (n=198), and patients who refused study 
participation (n=28). In the case of any new fracture during follow-up, the 
participation was discontinued and the patient excluded from further data 
collection. 
No formal statistical power calculation was conducted. Recruiting 200 
patients with hip fracture was judged to be an appropriate target sample size to 
produce stable country estimates of HRQoL and cost based on the experience of 
4.2.3. Ethical considerations 
4.3. Quality of life, resource use, and costs related to hip 
fracture (PAPERs II, V, VI) 
4.3.1. Setting and patients  
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previous similar study from Sweden (Borgström et al., 2006). The recruiting 
hospitals provided about 40% of the hip fracture inpatient care in Estonia in 
2012 (PAPER I).  
For comparison, the patients for ICUROS were recruited from 52 hospitals, 
ranging from 1–2 (the UK, the USA, Italy, Lithuania, Estonia) to 8 (Austria, 




Baseline data were collected by trained interviewers at the hospital during the 
initial inpatient stay in face to face interviews. Interviews were conducted using 
a structured questionnaire based on the ICUROS study clinical research form 
(CRF) (available in English and Russian) (PAPER V). The questionnaire was 
translated into Estonian; the team of researchers discussed the translations and 
agreed the “best fits” for items. The Estonian translation was also compared to 
the original CRF (English version) by back-translation. The CRF elicited infor-
mation on socio-demographic characteristics (date of birth, gender, education, 
working/living status, income), history of previous osteoporotic fractures, 
history of contacts with health care services for the hip fracture episode, use of 
non-prescription drugs, social care, informal care, working status, HRQoL, and 
contact information. At the first interview in addition to current (after fracture) 
HRQoL assessment, recall-based pre-fracture estimation of the HRQoL was 
obtained.  
Follow-up data were collected by study researchers during follow-up at 
months 4, 12 and 18 post-fracture via phone interviews. Data on fracture-related 
use of social care (days of living in nursing home, hours of home help by social 
worker per week, use of assistive devices, transportation) and informal care 
(hours of home help by relatives and friends per week) were collected from 
patient interviews using 4 weeks’ recall. 
 
Data from the EHIF database 
Data on fracture-related health services utilization and costs were extracted 
from the EHIF database for all recruited hip fracture patients. In addition, data 
on patients aged over 50 years treated in the same departments during the 
recruitment period but not recruited in the study (non-participants) were 
extracted. For each patient data were extracted for the index hip fracture episode 
(ICD codes S72.0 – 2 on the health care claim), and for health services/ 
medications provided 12 months before and up to 18 months after the index 
episode (dates, services provided, treatment type (in- or outpatient), specialty of 
the provider, costs), and the date of death. Data on prescription drugs con-
sidered relevant for the treatment of osteoporosis (bisphosphonates, denosumab, 
strontium ranelate, teriparatide, estrogens/receptor modulators, calcium, vitamin 
D supplements, analgesics and NSAIDs) (Borgström et al., 2006; Borgstrom et 
4.3.2. Data collection  
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al., 2013) (ATC-code, date of purchase, cost, cost-sharing (patient/EHIF)) were 
extracted. For study participants, the extracted data contained personal identi-
fication codes; for non-participants, the data contained pseudo-identification 
codes which allowed longitudinal tracking of the medical care provided to an 
individual but did not permit personal identification. For non-participants, infor-





The indirect method to measure HRQoL from the EQ-5D-3L (EuroQol, 2017) 
was used applying preference-based utility values from a UK study (Dolan, 
1997). The HRQoL loss in QALYs was calculated as the area under the curve 
using the trapezoid method (Walters, 2009). The HRQoL loss was estimated 
among surviving patients who completed the study period and whose HRQoL 
estimates were available.  
 
Disease burden  
To estimate the health burden by hip fracture patient, the mean hip fracture 
related QALY loss was calculated by adding the lost life years (until the end of 
study follow-up) of patients whose death was attributable to hip fracture to the 
HRQoL loss estimate in survivors. The lost life years attributable to fracture 
was based on a difference between observed and expected number of deaths 
(excess mortality). Expected number of deaths was calculated from the Estonian 
life tables (Shkolnikov, Barbieri and Wilmoth, 2013).  
 
Comorbidities 
Data on comorbidities was assessed using the Charlson comorbidity index 
(CCI) to measure the burden of disease and case mix (Charlson et al., 1987). 
We used the revised coding algorithm that has been validated for estimating 
comorbidity burden using ICD-10 coded administrative data (Quan et al., 
2005), and the updated disease weighting suggested by Quan (Quan et al., 
2011). The CCI assessment for all hip fracture patients (participants and non-
participants) was based on the EHIF health service claims of the index episode 
and all in- and outpatient health care claims (not only hip fracture care related) 
from the 12 months before the fracture (Toson, Harvey and Close, 2015). 
 
Resource use and cost  
We considered fracture-related resource use and costs using a societal 
perspective (Tan-Torres Edejer et al., 2003). Data on fracture-related health care 
services and prescription drug use were obtained from the EHIF database using 
ICD-10 codes. Inpatient care was categorized as specialty care (traumatology and 
orthopedics), nursing care, and rehabilitation (e.g., physiotherapy, occupational 
4.3.3. Measures 
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therapy) conducted during an overnight stay. Outpatient care comprised family 
practitioner’s / nurse’s office and home visits, visits to specialty physicians, 
home nursing, and rehabilitation. Nursing care is part of the health care system 
in Estonia and can be delivered either in licensed nursing care institutions 
(hospitals) or in patients’ homes (Estonian Health Insurance Fund, 2015). Patient 
charges for specialty care were added to each claim from the EHIF (Estonian 
Health Insurance Fund, 2015). Information on use of non-prescription drugs 
(e.g., analgesics, calcium and vitamin D supplements) was collected at each 
follow-up from patient interviews, using 4 weeks recall at each follow-up data 
collection time point, and extrapolating the reported use over the respective 
follow-up period.  
Data on fracture-related use of social and informal care (4 weeks’ recall) 
reported by patients were extrapolated over the respective follow-up period, 
excluding the days of inpatient care, if any. To obtain the cost of social care, 
unit costs of living in nursing home or costs of a home visit by a social worker 
were attributed to the self-reported service use (City of Tallinn, 2015; Ministry 
of Social Affairs, 2015). The cost of assistive devices (walking aids, hygiene, 
home modifications) was based on data provided by patients during interviews. 
To estimate the cost of informal care, a replacement cost method was used by 
assigning a cost of home help by a social worker (City of Tallinn, 2015).  
The indirect cost (the value of lost production related to sick leave and early 
retirement) was estimated using the human capital approach by assigning a self-
reported net income level and tax for the time spent in the study that patients 
would have worked had they not sustained a fracture (Drummond et al., 2015). 
Data on the number of days on fracture-related sick leave was collected using 4 
weeks’ recall and extrapolated using the assumption that the leave started from 
the beginning of the respective follow-up period. The working status was 
recorded at each follow-up interview and if retirement was reported, it was 
assumed to having commenced in the middle of the relevant follow-up period.  
All costs were presented in euros at 2014 prices, adjusted for the Estonian 
consumer price index (Statistics Estonia, 2015a).  
For ICUROS, most countries extracted the health services use data from 
administrative databases, whereas some relied on patients’ interviews only. 
However, no cost data for ICUROS (except for Estonia) have yet been published 
for details.  
 
 
We presented the number of hip fracture patients enrolled, the number of 
patients in the study at 4, 12 and 18 months, and the number of patients who 
dropped out by reason, gender (number, proportion of women), age, CCI (mean, 
proportion by score group, disease components), level of education and income, 
and working and living (living alone or with partner) status. Age-standardized 
(to the WHO world standard population) mortality rates at 12 and 18 months 
after the fracture were estimated (WHO, 2015). 
4.3.4. Statistical analysis 
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We followed a general rule to include all patients in the analysis while the 
relevant data for a specific outcome measure were available. The healthcare 
resource utilization and cost data from the health insurance database were 
available for all recruited patients (including patients who died or were lost to 
follow-up) until the end of the study or until death. The patient-reported data on 
HRQoL, social care, informal care and working status were available for all 
patients until the end of the final follow-up period for the patient. 
We presented EQ-5D estimates at 0, 4, 12 and 18 months stratified by age, 
gender, and CCI. To estimate the HRQoL loss in QALYs over 18 months, we 
estimated the difference between linearly interconnected HRQoL time-point 
estimates and pre-fracture level, using the assumption that the patient would 
have remained at the pre-fracture level of HRQoL had the fracture not occurred 
(Borgstrom et al., 2013). The follow-up periods varied in duration (from 4 to 8 
months); to increase comparability between periods, we calculated the mean 
HRQoL loss in 6-month periods by linearly interpolating the 6-month estimate. 
EQ-5D and HRQoL loss estimates were presented as means with 95% con-
fidence intervals. Acknowledging the skewed distribution of utilities and 
HRQoL loss estimates we used box plots to summarize the data (presenting the 
medians, quartiles, and range). We also presented the proportion of fully 
recovered patients (who achieved at least 100% of pre-fracture HRQoL) at 4, 12 
and 18 months.  
Health care, social care and informal care resource utilization was presented 
as the number of patients receiving care and the mean number of service units 
for patients who used the resource in question (admissions, bed days, visits, and 
hours per week) along with 95% confidence intervals, by follow-up period (0–4 
months, 5–12 months, and 13–18 months), and cumulative use over 18 months. 
Work related data were presented as the number of patients and days on sick 
leave, and the number of patients on early retirement. The average cost and cost 
structure per hip fracture patient were presented for the follow-up periods and as 
a cumulative cost over 18 months.  
To interpret generalizability of results, the case mix (gender, age, comorbidity, 
and mortality) was compared between study participants and non-participants 
aged over 50 years receiving hip fracture care at the two recruiting hospitals 
(based on data from the EHIF) during the recruitment period. We used a Mann-
Whitney non-parametric test for the differences in age, CCI score, HRQoL, and 
costs, χ² test for categorical variables (age groups, CCI score groups, and disease 
components), 95% CI-s for mortality rates. Age, CCI, and HRQoL were 
compared between patients who died or were lost to follow-up and those 
remaining in a study using a Mann-Whitney non-parametric test.   
Statistical testing was conducted at significance level 0.05. All statistical 
analysis was performed using Stata version 12.1.  
In ICUROS, the HRQoL was presented as a mean, and the comparisons were 
conducted using parametric tests (t-test, χ² test as appropriate). In the primary 
analysis for ICUROS, a complete case approach (all patients who completed the 
study) was applied. To explore the potential impact from loss of follow-up, two 
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additional approaches were implemented: an available case analysis (all patients 
with available data at a certain time point were included in the analysis for that 
time point), and a multiple imputation (a method where multiple imputations 
are made for each missing value based on a model) (Rubin, 1987). The 
imputation model comprised all available EQ-5D results, sex, and age. 
 
 
The study procedures were in accordance with local data protection regulations. 
The informed consent was obtained from all participants, and the patients could 
withdraw from the study at any time on their own request. The study was 
approved by the Tartu University Research Ethics Committee.  
 
We used a population-based retrospective cohort study to examine the excess 
all-cause mortality after hip fracture over a 10-year follow-up period. The data 
on all-cause mortality in men and women aged ≥50 years with incident hip 
fracture (cases) were compared to this of the reference group (a random sample 
of age- and sex-matched subjects with no known history of hip fracture prior to 
the index date). The excess mortality risk related to the hip fracture over a 10-
year follow-up period was estimated using Poisson regression. The impact of 
comorbidities on excess mortality was explored using an adjustment for the CCI 




For this study, the study subjects’ demographic characteristics, clinical charac-
teristics, and outcome data were ascertained from the EHIF (Estonian Health 
Insurance Fund, 2015). The sample frame included all insured individuals, 
including those with no record of health care services provided during January 
1, 2004 – December 31, 2013. Health care utilization data on all patients (aged 
≥50 years) hospitalized with incident hip fractures during the period January 1, 
2005-December 31, 2013 were identified (case group, n=8298). The case 
definition was based on the hip fracture specific diagnosis codes (see above), 
listed as the primary diagnosis on the electronic inpatient health care claim. The 
index date of diagnosis was defined as the first day of care indicated in the 
claim; patients with a diagnostic code primary for hip fracture and no known 
previous evidence of hip fracture were selected for inclusion (Lix, Azimaee and 
Osman, 2012). The hip fracture patients were matched by sex and age (year of 
4.3.5. Ethical considerations 
 
4.4. Hip fracture related excess mortality, and the impact 
of comorbidities on excess mortality (PAPERs III and IV) 
4.4.1. Setting, data source, and participants 
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birth) in a 1:4 ratio (reference group, n=33,191). Reference group subjects were 
alive and without evidence of hip fracture prior to the case patient’s index date 
of fracture. Study subjects were assigned a unique identifier decoupled from 
personal identification information to enable longitudinal tracking of care and 
mortality while maintaining patient privacy.  
 
 
Clinical characteristics and comorbidities were captured for the 365-day period 
prior to the index date for case patients and their matched controls. 
Comorbidities were defined as any secondary or other diagnoses coded at the 
index hip fracture claim and/or diagnoses of any type on hospital or outpatient 
health care claims during the year preceding the index date (Radley et al., 2008; 
Toson, Harvey and Close, 2015). We applied a restriction to outpatient claims, 
such that a comorbid condition could be flagged during the preceding period 
only if it appeared two or more times at least 7 days apart (Tosteson et al., 
2007; Radley et al., 2008).  
The comorbidity status for both groups was computed using the CCI. The 
index is based on the hazard ratios of individual life-threatening comorbidities 
for 1-year mortality presented as disease weights, and the CCI score represents 
the person’s mortality-predicting disease burden (Charlson et al., 1987; Quan et 
al., 2011). For example, a person with a score of 2 might have 2 individual 
diseases with a weight of 1 or 1 disease with a weight of 2. We used the revised 
coding algorithm described by Quan et al., and subsequently validated for 
estimating comorbidity using ICD-10 coded administrative data (Quan et al., 
2005). We also updated disease weighting to reflect advances in chronic disease 
management and treatment outcomes since the introduction of the original 
Charlson index in 1987 (Quan et al., 2011). The updated CCI consists of 12 
comorbidities (CCI components) (Table 1 in PAPER IV). Comorbidities are 
weighted from 1 to 6 for mortality risk, and then summed to form the total CCI 
score (groups ranging from 0 to ≥3). The updated CCI has demonstrated 
comparable predictive utility for mortality using ICD-10 coded administrative 
data (Quan et al., 2011) and has been validated among hip fracture patients 
(Toson, Harvey and Close, 2015).  
 
 
The primary outcome for this study was all-cause mortality. We followed all 
study subjects (belonging to the case and reference groups) until the study end 
(4th May 2016). Dates of death were obtained from the EHIF database. 
Although the EHIF database captures provision of healthcare services country-
wide, loss to follow-up upon emigration from Estonia is possible, albeit rare, 
among those 50 years or older (estimated to be less than 0.5% per year) 
(Statistics Estonia, 2015b). 
4.4.2. Identification of pre-fracture comorbidity 
4.4.3. Follow up and identification of outcome 
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The hip fracture group and the reference group were described by group size, 
mean age, age range, and 10-year groups, CCI mean score, score groups, and 
range. Age of men and women with hip fracture was compared by non-
parametric Wilcoxon rank sum test. CCI in hip fracture group was compared to 
reference group by Wilcoxon rank sum test, distribution of age groups and CCI 
groups was compared with χ² test. 95% confidence intervals for mean 
differences of age and CCI were calculated.  
Cumulative risk of death was estimated separately in 10 strata defined by sex 
and five age categories (50–59, 60–69, 70–79, 80–89, 90+ years old at index 
date), the risks were weighted by the size of respective groups to present 
generalized results (aggregated over sex and age). To capture the rapid and 
extensive changes in mortality during the first 3–6 months following a hip 
fracture [1, 5], we divided the 10-year follow-up period into graduated discrete 
intervals as follows: shorter periods proximal to the index date and wider 
intervals afterwards, with cut-points at each 0.5 months during the first three 
months, at each month during the rest of the first year; at each three months 
during the second year; and on each year from the third to the tenth year. Within 
each age and sex subset Poisson regression was used to estimate mortality rates 
for each of those intervals (to smooth the variability of data thin plate regression 
spline was used for estimating the impact of comorbidities in PAPER IV 
(Wood, 2003)) among hip fracture cases and controls. Two regression models 
were considered: crude, containing only the interaction between the group (hip 
fracture or reference/control) and follow-up time interval, and adjusted, including 
main effects of hip fracture, CCI score and groups, age, and follow-up time 
interval. Age adjustment within age groups was used to account for residual 
confounding (Sjölander and Greenland, 2013). Interval-specific mortality rates 
were transformed to calculate cumulative risks. Excess risks and risk ratios 
(RR) were calculated as differences or ratios in cumulative risks in both study 
groups. Bootstrap percentiles were used to compute 95% confidence intervals 
(CI) for cumulative and excess risks. Using bootstrapping (and splines used in 
the analysis for PAPER IV) resulted in slightly different excess mortality 
estimates in PAPERs III and IV. 
The stratification by CCI groups (0, 1–2, ≥3) was performed by comparing 
the excess risk of cases in one score group to that of reference subjects in the 
respective score group, e.g. CCI 1–2 hip fracture / CCI 1–2 reference. Strati-
fication by the individual CCI components was done in a similar fashion. In the 
CCI component-specific analysis everyone’s CCI score was reduced by the 
respective amount corresponding to the CCI component (if present). The number 
of patients in CCI groups 1–2 and ≥ 3 was relatively small in the age group of 
50–59 years. The respective age group was excluded from the CCI component-
specific risk assessment for dementia and cancer, as no patients with these 
conditions were present.  
4.4.4. Statistical analysis 
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All analyses were performed in R (versions 3.1.1 to 3.3.1) (Wickham, 2009; 
Calaway et al., 2015; Calaway, RevolutionAnalytics and Weston, 2015; R Core 
Team, 2015; Canty and Ripley, 2016; Carstensen et al., 2016; Dowle et al., 
2016; Wickham and Francois, 2016).  
 
 
The study procedures were in accordance with local data protection regulations. 
The patient privacy was maintained by assigning a personal identifier (pseudo-
identification code) to enable longitudinal tracking of diagnoses, care, and 
mortality. The study was approved by the Tartu University Research Ethics 
Committee.  
 
4.4.5. Ethical considerations 
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5. RESULTS 
5.1. The incidence of hip fracture (PAPER I) 
We documented 10 704 incident hip fracture cases among persons aged 50 
years or older occurring in 2005–2012 (Table 1 in PAPER I). Most fractures 
occurred in women (70%). Among women, we found exponential increases of 
fractures with age, with over half (58%) of all fractures in women occurring in 
the oldest age group (80+ years) and this accounted for 41% of all hip fractures 
in Estonia. Among men, 43% of all hip fractures occurred in the two youngest 
age groups of 50–69 years. The total number of fractures remained relatively 
constant over the study period in both genders, however, in the 80+ age group 
(which contributed to as much as 49% of all fractures) we observed an increase 
in both genders (p=0.012 for women, p=0.017 for men). Over the study period, 
the mean age of a fracture patient increased by 1.6 years (from 79.0 years [SD 
9.7] to 80.6 years [SD 9.4]) in women (p<0.001) and by 3.4 years (from 
69.7 years [SD 11.3] to 73.1 years [SD 11.5]) in men (p=0.001).  
The crude incidence for the entire observation period was 319.8 per 100 000 
person-years (95% CI 312.5 to 327.0 per 100 000) in women and 218.8 per 
100 000 person-years (95% CI 211.2 to 226.3 per 100 000) in men, resulting in 
a female to male incidence rate ratio (IRR) of 1.46 (95% CI 1.31 to 1.63) 
(Figure 2). Women had significantly higher crude rates over the study period 
(p<0.001). No changes in the crude incidence over the period of observation 
were observed among either gender (p=0.681 for women, 0.704 for men).  
 
 
Figure 2. Crude hip fracture incidence (per 100 000 person years) in women and men, 
2005–2012 (Figure 1, PAPER I) 
 
However, there were no significant sex differences in SIR: the SIR for the entire 
observation period was 209.2/100 000 (95% CI 204.2 to 214.2) in women and 




























IRR of 0.97 (95% CI 0.84 to 1.11) (Figure 3). Although SIR for both sexes 
decreased during the study period, the change was not statistically significant 
for neither sex (p=0.058 for women, 0.177 for men). For the period of 2009–
2012, we observed an accelerated 16% decrease in the hip fracture rate in 
women (p=0.008). 
Figure 3. Standardized hip fracture incidence rates (per 100 000 person years) in 
women and men, 2005–2012 (Figure 2, PAPER I) 
 
We observed exponential increases in hip fracture incidence with age in both 
genders: over the period of observation the incidence rate ratio (IRR) 70–79/50–
59 years was 9.1 (95% CI 8.8–9.5) in women and 3.4 (95% CI 3.2–3.5) in men, 
and 80+/50–59 years 34.3 (95% CI 33.7–35.0) in women and 9.1 (95% CI 8.9–
9.3) in men (Figure 4). We also observed marked sex differences in age-specific 
rates: over the period of observation the female to male IRR was 0.41 (95%CI 
0.38 to 0.45) in the 50–59 age group, 0.59 (95%CI 0.57 to 0.62) in the 60–69 
age group, 1.12 (95%CI 1.08 to 1.17) in the 70–79 age group, and 1.57 (95%CI 
1.54 to 1.60) in the 80+ age group. Among men, we observed a declining trend 
over the study period in the age groups of 50–59 years (p=0.030) and 60–69 
years (p=0.007). Among women, we observed a non-significant decline in 



























































































































Figure 4. Age-specific hip fracture incidence (per 100 000 person years) in women and 
men, 2005–2012 (Figure 3, PAPER I) 
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5.2. Quality of life, resource use, and costs related to hip 
fracture (PAPERs II, V, VI) 
Of the 767 patients with hip fractures who were treated at the two clinics during 
the study period, 205 (26.7%) participated in the study. Characteristics of 
participants and non-participants are presented in Table 2.  
All participants were hospitalized because of the fracture and 189 (92%) 
were admitted via an emergency department; 45 (22%) reported osteoporotic 
fracture during the last 5 years; the majority had only primary (70, 34%) or 
secondary (100, 49%) education, low net income (181, 88%; low defined as 
≤ 500 euros per month), and almost half (96, 47%) of the patients were living 
alone. 13 (6%) (mean age 61.7, range 50.1–77.7 years) were working (all full 
time) before the fracture. On average, study participants were interviewed 
within 3.9 (SD=2.5) days of the first healthcare contact for the fracture.  
The retention rate throughout the study was 60% (154 patients (75%) at 
4 months, 128 patients (62%) at 12 months and 123 patients (60%) at 18 months) 
(82% after excluding those deceased during the follow-up amongst those who 
were lost to follow-up). Among those not followed up (82 patients, 40%) 
45 (22%) died, 33 (16%) were lost, 1 patient withdrew consent, and 3 sustained 
a new fracture. Patients who died during follow-up were older (82.4 vs 
77.0 years, p=0.002) and had higher CCI score (1.7 vs 1.0, p=0.002) than those 
who remained in the study. Patients who were lost to follow-up were statisti-
cally non-significantly younger (73.6 years, p=0.13) and had similar CCI score 
(0.95, p=0.85) compared to retained patients.  
Non-participants were on average 1.7 years older (p=0.008) and had a higher 
CCI score than participants (p=0.004); predominately reflecting a higher 
prevalence of heart failure (p=0.051) and dementia (p=0.0003). Age-standar-
dized mortality at 12 and 18 months was (statistically non-significantly) higher 
among non-participants.  
For comparison, 2,406 hip fracture patients were enrolled in ICUROS from 
2007 to 2014 (PAPER VI). After excluding 184 (8%) patients who died during 
the follow-up, 246 (10%) who were not reachable, and 561 (23%) patients due 
to withdrawal, new fracture during the follow-up, or incomplete EQ-5D data, 
1415 patients (59%) were eligible for (complete case) analysis. No comparison 





Table 2. Characteristics of clinical study participants and non-participants in Estonia 







participants vs  
non-participants 
Number of hip fracture patients 205 562 
Women (%) 72 68 0.302 
Mean age, years (SD) 77.5 (9.9) 79.2 (10.5) 0.008 
Age groups (%) 
    50–59 9 6 0.005 
    60–69 11 13 
    70–79 32 23 
    80–89 42 45 
    ≥90 5 13 
Charlson index score 
    mean (SD) 1.1 (1.3) 1.5 (1.5) 0.004 
    range 0–5 0–8 
Charlson index score groups (%) 
    0 51 42 0.006 
    1–2 37 38 
    3–4 11 17 
    ≥5 2 3 
Charlson index components (%) 
    Congestive heart failure 33 41 0.051 
    Any malignancy 10 10 0.999 
    Chronic pulmonary disease 8 10 0.296 
    Rheumatologic disease 4 3 0.287 
    Diabetes mellitus with chronic 
complications 2 4 0.326 
    Renal disease 2 4 0.326 
    Hemipegia or paraplegia 2 2 0.996 
    Dementia 1 8 0.0003 
    Other 0 1 0.891 
Age-standardized mortality rate 
per 1,000 person-years (95% CI) 
    12 months 57 (35–129) 125 (78–190)
    18 months 53 (32–115) 90 (60–130) 
    
*Includes data on patients not invited (patients who were admitted for care in periods when 
recruitment team was not operating; n=336), on patients accessed but deemed to be ineligible 
(n= 198), and refused study participation (n= 28). 
39 
HRQoL  
The HRQoL estimates and loss in QALYs among survived patients are 
presented in Figure 5. The mean HRQoL was 0.67 (95% CI 0.63–0.71) before 
fracture, 0.07 (95% CI 0.01–0.12) after fracture, 0.42 (95% CI 0.36–0.47) at 
4 months, 0.54 (95% CI 0.49–0.60) at 12 months, and 0.60 (95% CI 0.54–0.65) 
at 18 months. The mean HRQoL loss was estimated at 0.16 QALYs in the first 
6 months, 0.09 in the following 6 months, and 0.06 in the last 6 months, 
resulting in a mean total of 0.31 QALYs lost during 18 months. Thirty percent 
of survived patients were fully recovered at 4 months, 41% at 12 months, and 
49% at 18 months. There was a tendency for lower HRQoL among older 
participants, those with higher CCI scores, and women (Figure 2, PAPER II).   
For comparison, the respective pooled ICUROS results were 0.77 (SD 0.27) 
(vs 0.67 in the Estonian study), –0.11 (SD 0.37) (vs 0.07, respectively), 0.49 
(SD 0.38) (vs 0.42), 0,59 (SD 0.37) (vs 0.54), and 0.66 (SD 0.34) (vs 0.60) 
(Table 2, PAPER VI). The pooled results indicated a larger 18-months HRQoL 
loss, 0.42 QALYs, mostly due to larger loss over the first 6 months. The 
HRQoL point estimates from the available case and multiple imputation 
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Figure 5. Health-related quality of life estimates before, directly after, and at 4, 12 and 
18 months after fracture (left-hand panels); and (right-hand panels) health-related 
quality of life lost in QALYs (between 0–6, 7–12, 13–18 months, and total) among 
survived hip fracture patients. Box plots present the medians, quartiles, and range 
(Figure 1, PAPER II) 
 
Patients who died during a particular follow-up period had lower HRQoL at the 
start of the period than patients who completed that period, albeit the 
differences were not statistically significant (mean HRQoL: pre-fracture 0.63 vs 
0.66 (p=0.52), after fracture –0.06, vs 0.09 (p=0.07), at 4 months 0.35 vs 0.42 
(p=0.35) and at 12 months 0.39 vs 0.54 (p=0.23)). There was no difference in 
HRQoL in patients who were lost to follow-up in a given period and patients 
who completed the period (mean HRQoL: pre-fracture 0.73 vs 0.66 (p=0.69), 
after fracture 0.01 vs 0.09 (p=0.4), at 4 months 0.42 vs 0.42 (p=0.79). 
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Disease burden 
The mean hip fracture related QALY loss that accounts for HRQoL loss of 
survivors and lost life years of patients whose death was attributable to hip 
fracture was estimated at 0.16 (95% CI 0.14–0.19) QALYs in the first 6 months, 
0.12 (95% CI 0.10–0.15) in months 7–12, and 0.11 (95% CI 0.08–0.14) in 
months 13–18. The accumulated QALY loss during 18 months was 
0.39 (95% CI 0.32–0.47). The number of observed vs expected deaths in the 
QALY calculation was 25 vs 6.5 in months 0–6, 12 vs 5.7 in months 7–12, 8 vs 
5.9 in months 13–18, and 45 vs 18.1 in the 18 months’ follow-up period.  
 
Resource use  
The average utilization of health care resources per patient utilizing a specific 
resource is presented in Table 3, and the utilization of non-medical and indirect 
resources in Table 4. In months 0–4 after fracture, all patients were admitted to 
specialty care (traumatology or orthopedics), with a mean number of admissions 
and mean length of stay of 1.6 (95% CI 1.5–1.7) and 15.2 (95% CI 13.2–17.2) 
days, respectively. Forty percent (82/205) of patients were admitted to inpatient 
nursing (on average for 32.5 days), whereas 8% (17/205) were admitted to a 
rehabilitation department. Although 58% (119/205) of patients had at least one 
outpatient care visit, only 5% of patients visited either rehabilitation or nursing 
outpatient care. Up to 65% of patients (133/205) used some type of fracture-
related medications: 53% used analgesics, 18% used calcium and vitamin D 
supplements, 8% used bisphosphonates. Alendronate accounted for over 90% of 
the bisphosphonate use. Among the 45 patients who reported previous oste-
oporotic fractures in the last five years, 2 were on bisphosphonates before the 
index fracture.  
The proportions of patients receiving medical care decreased in subsequent 
study periods. During months 5–12 and 13–18 after fracture 8% (14/185) and 
5% (9/168) were admitted to the hospital, respectively, and 27% (50/185) and 
15% (25/168) received outpatient care. Utilization of outpatient rehabilitation 
and nursing care remained low (8% of patients). The proportion of patients 
using analgesics was stable whereas the proportion of calcium and vitamin D 
users increased to 30% in months 13–18, while 13% were on bisphosphonates 
during the follow-up. No use of estrogen receptor modulators, strontium 
ranelate, and teriparatide was recorded. 
Fewer than 2% of patients were institutionalized during the follow-up, and 
the proportion receiving home help by social workers remained below 10% over 
the study despite some increase in months 5–18 post-fracture. Use of informal 
home help by relatives and friends was high (reported by 84% of patients) 
during the follow-up, with an average of 15.4 (95% CI 13.7–17.3) hours of help 
per week. Eighty-eight percent of patients used assistance devices during the 
first 4 months, but use decreased to 13% during months 12 to 18. Among the 13 
patients working before the fracture, 10 were off work due to sick leave (at least 






































































































































































































































































































































































































































































































































































































































































































































































































































































































   

























   


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The average cost and cost structure per hip fracture patient are presented in 
Table 5. The mean cumulative 18-month cost related to hip fracture was 8146 
(95% CI 6236–10717) euros per patient. Most costs were related to health care 
and informal care, 56% and 33% respectively, whereas social care and indirect 
costs accounted for less than 5% and 8%, respectively. Fifty-six percent of the 
costs (including 84% of health care costs) were incurred in the first 4 months. 
Health care costs comprised 83% of the total costs in the first 4 months, 
decreasing to 17% during months 13–18. In contrast, the proportion of informal 
care cost increased from 11% in the first period to 62% in the last period. The 
proportion of social care cost was only 1% in the first period, increasing only 
moderately thereafter. The proportion of indirect cost increased gradually from 
5% to 15%.  
 
 
5.3. Hip fracture related excess mortality (PAPER III) 
We documented 8298 incident hip fracture cases among persons aged 50 years 
and older, hospitalized in 2005–2013 in Estonia (Table 1 in PAPER III, Table 1 
in PAPER IV). 71% of fractures occurred in women. The mean patient age was 
78.0 years, and men were younger than women (72.2 vs 80.4). In total, 51% of 
fractures occurred among those 80 years and older, primarily among women. 
The mean CCI score was 0.94 (SD 1.36), whereas men were healthier (CCI 
0.88, SD 1.38) than women (CCI 0.96, SD 1.36). 39% patients had at least 1 
life-threatening pre-fracture comorbid condition, and 11% had CCI score ≥3. 
Congestive heart failure was the most prevalent comorbid condition (22%), 
followed by dementia (8%) and cancer (6%). The age- and sex-matched reference 
group subjects (n=33 191) were healthier than the hip fracture patients: the 
mean CCI score was 0.66 (SD 1.13) (p<0.0001) (men 0.59 (SD 1.11), women 
0.69 (SD 1.13)), and the prevalence of comorbidities was smaller (30%, 
p<0.0001). 
 
Absolute risk of death  
The average follow-up time was 4.3 years (3.4 years among hip fracture patients 
and 5.0 among the reference group). 5552 (67%) cases (1564 men, 3988 
women) and 14037 (42%) reference individuals (3514 men, 10523 women) died 
during the 10-year follow-up period. The crude risk of death of hip fracture 
patients was high compared to the matched reference subjects: 17.5% (95% CI 
16.8–18.1%) vs 2.0% (95% CI 1.9–2.1%) at 3 months, 28.3% (95% CI 
27.629.0%) vs 7.8% (95% CI 7.6–8.0%) after 1 year, 54.4% (53.6–55.2%) vs 
29.8% (95% CI 29.4–30.1%) in 5 years, and 78.2% (95% CI 77.2–79.2%) vs 
55.6% (95% CI 55.0–56.2%) in 10 years from fracture. The average age- and 
CCI-adjusted cumulative 10-year risk of all-cause death was 77.6% (95% CI 
76.7–78.8%) in the hip fracture group and 56.5% (95% CI 56.0–57.3%) in the 
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reference group, and women had higher risk than men in both study groups 
(Figure 6).  
 
 
Figure 6. Sex-specific cumulative 10-year risk of all-cause mortality (adjusted for age 
and Charlson index score) by study group in men and women ≥ 50 years in Estonia, 
January 1, 2005-May 4, 2016 (Figure 1, PAPER III) 
 
The mortality increased with age (Figure 7). For example, among 60–69-year-
old men the 1-year risks were 15.9% (95% CI 14.2–18.4) in hip fracture group 
and 2.5% (95% CI 2.2–3.2) in the reference group, whereas in the group of ≥90 




Figure 7. Age group-specific cumulative risk of all-cause mortality (crude, and adjusted 
for age and Charlson index score) by study group in men and women ≥ 50 years in 
Estonia, January 1, 2005–May 4, 2016 (Figure 2, PAPER III) 
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The proportion of deaths in the hip fracture group attributable to the exposure 
(attributable risk fraction) in 10 years from fracture was 27.2% (95% CI 25.9–
28.5%), i.e., one in four deaths in the case group was attributable to the fracture 
(Figure 6). The attribution was higher in younger and lower in older patients 
(Figure 7). For example, in the group of 50–59-year old patients, 2/3 of deaths 
in men and 4/5 in women were attributable to hip fracture, whereas in over 90-
year old women every 10th patient died from the fracture. 
 
Excess risk of death 
The crude excess risk of death after hip fracture compared to the reference 
subjects was pronounced, stable and persistent, reaching 22.6% (95% CI 21.4–
23.8%) after 10 years after a fracture. The CCI-adjusted cumulative excess risk 
was 18.9% (95% CI 18.3–19.5) already by month 3, 25.3% (95% CI 24.6–26.2) 
after 5 years, and as high as 21.1% (95% CI 20.0–22.5%) after 10 years from 
the fracture. The excess risk was higher in men than in women (Figure 8).  
 
 
The sex difference was present in all age groups (Figure 9). Two characteristic 
excess mortality patterns were revealed. In younger age groups (50–79 years) 
the excess risk was gradually accumulating. For example, in the 60–69-year-
olds, the 3-month excess risk was moderate (men 8.1%, 95% CI 6.5–9.9%; 
women 4.6% (95% CI 3.3–6.2%), but increased to 30% in 10 years (men 
32.8%, 95% CI 28.0–38.1%, and women 31.5%, 95% CI 26.1–37.6%). However, 
in older patients, the excess risk was immediate and high but decreased over 
time. In all age- and sex-specific groups, the excess risk was present until the 
end of follow-up. 
 
 
Figure 8. Excess cumulative 10-year risk of all-cause mortality following hip fracture 
among men and women age ≥ 50 years (adjusted for age and Charlson index score) in 




Relative risk of death 
The adjusted relative risk of all-cause death among hip fracture patients versus 
age- and sex-matched controls is presented in Table 6. At 1 year, the hip 
fracture patients were between two and 10 times more likely to die than their 
age- and gender-matched reference subjects, depending on age and sex. The 
long-term relative risk was higher in younger age groups (women greater than 
men) where the absolute risk in the respective reference groups was lower, and 
decreased with advancing age. The relative risk remained elevated over 10 years 
in all age- and sex-specific comparisons.  
 
Table 6. Age group specific and average 10-year relative risk (risk ratio (RR) 
comparing hip fracture cases to reference group) of all-cause death after hip fracture in 
men and women ≥ 50 years, adjusted for age and Charlson index score (Table 2, 
PAPER III) 
  3 months 1 year 5 years 10 years 
Sex Age 
group 
RR 95% CI RR 95% CI RR 95% CI RR 95% CI 
Men 50–59 *  5.6 3.3–10.2 4.0 3.2–4.9 3.1 2.6–3.7 
 60–69 10.6 7.3–18.1 5.9 4.8–7.5 3.2 2.9–3.6 2.1 1.9–2.4 
 70–79 10.0 7.8–13.2 3.9 3.4–4.5 2.3 2.1–2.4 1.6 1.5–1.7 
 80–89 9.9 8.2–12.4 4.0 3.6–4.6 1.7 1.6–1.8 1.2 1.2–1.3 
 90+ 8.0 6.3–11.0 3.1 2.7–3.7 1.3 1.3–1.4 1.2 1.1–1.3 
 Weighted 
average 
9.5 8.4–10.9 4.1 3.8–4.4 2.0 2.0–2.1 1.6 1.5–1.6 
             
Women 50–59 *  *  14.6 7.7–44.0 4.6 2.6–8.1 
 60–69 14.6 8.6–34.8 9.8 6.8–15.0 4.1 3.4–5.0 3.3 2.8–3.9 
 70–79 14.9 11.5–19.3 6.0 5.3–6.8 2.6 2.5–2.8 1.6 1.6–1.7 
 80–89 9.1 8.2–10.1 3.5 3.3–3.7 1.7 1.6–1.7 1.2 1.2–1.2 
 90+ 5.3 4.6–6.1 2.3 2.1–2.5 1.3 1.2–1.3 1.1 1.1–1.2 
 Weighted 
average 
8.3 7.7–9.0 3.4 3.3–3.6 1.7 1.7–1.8 1.3 1.3–1.3 
* Respective risk ratios had too high variance and were not reliable 
Figure 9. Age group-specific 10-year cumulative excess risk of death following hip 
fracture among those ≥50 years old (adjusted for age and Charlson index score), men 
and women in Estonia, January 1, 2005–May 4, 2016 (Figure 4, PAPER III) 
95% CI
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5.4. The impact of comorbidities on hip fracture  
related excess mortality (PAPER IV) 
The excess mortality, when not adjusted for CCI, was 15.1% (95% CI 14.5–
15.6) in 3 months, 21.3% (95% CI 20.6–22.0) in 1 year, 25.3% (95% CI 24.6–
26.2) in 5 years, and 21.9% (95% CI 21.0–22.9) in 10 years (Figure 10). CCI–
adjusted cumulative excess risk was 14.2% (95% CI 13.7–14.8) in 3 months, 
20.2% (95% CI 19.5–20.9) in 1 year, 24.0% (95% CI 23.2–24.8) in 5 years, and 
20.2% (95% CI 19.2–21.2) in 10 years. Therefore, after adjustment for the 
effect of CCI score, the aggregated average excess mortality decreased by 0.9% 
at 3 months, 1.1% at 1 year, 1.3% at 5 years, and 1.7% at 10 years. Thus, the 
10-year risk fraction attributable to comorbidities on the average hip-fracture 
related excess mortality was up to 8% or 1/12, and 1 out of 12 excess deaths 
was related to pre-fracture, life-threatening comorbidities. 
 
Figure 10. The excess cumulative risk of all-cause mortality following hip fracture 
among patients aged ≥ 50 years (adjusted for age and sex [solid line], and age, sex, and 
Charlson index score [dotted line]), over the 10-year follow-up (2005–2016) (Figure 1, 
PAPER IV) 
 
Stratification by CCI score groups revealed an association for CCI groups and 
excess mortality. Hip fracture patients with CCI of 0 had an excess risk of 
11.6% (95% CI 11.1–12.1) at 3 months, 17.1% (95% CI 16.5–17.8) in 1 year, 
23.2% (95% CI 22.2–24.1) in 5 years, and 21.9% (95% CI 20.7–23.1) in 
10 years from fracture compared with reference subjects with a CCI score of 0 
(Figure 11). The presence of pre-fracture comorbidities that are strongly 
associated with risk of death (i.e. having a weight of 1 or higher in CCI) was 
associated with increased excess mortality over 5–7 years. At 3 months, the 
excess risk in the CCI 1–2 group was 18.9% (95% CI 17.9–19.8%), and in the 
≥3 group 23.5% (95% CI 22.1–25.0), whereas in 1 year the respective risks 
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were as high as 25.8% (95% CI 24.6–27.0%) and 30.3% (95% CI 28.3–32.2%). 
The excess risk of patients with comorbidities declined over time below that of 
CCI 0 but did not disappear in any CCI group. 
 
 
Figure 11. The excess cumulative risk of all-cause mortality following hip fracture by 
Charlson index score group (adjusted for age and sex) among patients aged ≥ 50 years, 
over the 10-year follow-up (2005–2016) (Figure 2, PAPER IV) 
 
Overall, the stratification yielded some differences in excess mortality pattern 
across age groups and was more uniform for CCI components. In younger age 
groups the effect of comorbidities on excess mortality accumulated gradually 
and was long lasting (up to 10 years) (Figure 12). For example, among the 60–
69-year age group the excess risk in the CCI 0 group was 9.5% (95% CI 8.2–
10.8) at 1 year, 21.0% (95% CI 18.6–23.2) at 5 years, and 28.7% (95% CI 25.5–
32.4) at 10 years, whereas in the CCI 1–2 group the respective risks were 21.2% 
(95% CI 17.9–24.7), 39.8% (95% CI 35.0–45.0), and 43.3% (95% CI 37.9–
48.9). In the older groups (≥ 80 years) the impact was relatively modest and 
short (1–3 years). The effect of comorbidities was not dependent on the 
underlying comorbid condition, except for dementia (Figure 13). The 1-year 
average excess risk in dementia patients was 18.0% (95% CI 14.9–21.1) higher 
compared to those without dementia, whereas the excess risk in congestive heart 
failure patients was 6.5% (95% CI 5.1–8.0) higher than among those with no 
congestive heart failure. Patients with dementia were older than other patients 
(mean age 83.2 (SD 7.7)) and had the highest short-term excess risk of all-cause 
death. However, the excess risk in dementia patients declined fast and fall 




Figure 12. Age group-specific cumulative excess risk of death following hip fracture by 
Charlson index score group among those ≥50 years old (adjusted for sex), over the 10-




Figure 13. Excess cumulative risk of all-cause mortality following hip fracture by 
Charlson index components (adjusted for age, sex and other CCI components) among 
patients aged ≥ 50 years, over the 10-year follow-up (2005–2016) (*due to the small 
number of patients, the 50–59-year age group was excluded from analyses for dementia 




6.1. The incidence of hip fracture  
Incidence in women and men 
Compared to other countries, the SIR in Estonian women was low: it was 
comparable to that in Poland and Romania which reported the lowest rates in 
Europe (Grigorie et al., 2013; Wilk et al., 2013). The SIR in Estonian women 
was lower than those reported in the neighboring countries of Lithuania, Russia, 
and Finland (Lesnyak et al., 2012; Tamulaitiene and Alekna, 2012; Korhonen et 
al., 2013), and also lower than in many other European countries  (Ahlborg et 
al., 2010; Cooper et al., 2011; Dimai et al., 2011; Kanis, Odén and McCloskey, 
2012; Grigorie et al., 2013; Icks et al., 2013; Nilson et al., 2013; Siggeirsdottir 
et al., 2014) and in the US (Brauer and Coca-Perraillon, 2009; Ettinger et al., 
2010). The difference in incidence was predominantly attributable to the lower 
incidence among the elderly (80+ years) (Bjørgul and Reikerås, 2007; Péntek et 
al., 2008; Brauer and Coca-Perraillon, 2009; Dodds et al., 2009; Abrahamsen 
and Vestergaard, 2010; Ström et al., 2011; Dimai et al., 2011; Tamulaitiene and 
Alekna, 2012; Lesnyak et al., 2012; Støen et al., 2012; Korhonen et al., 2013; 
Nilson et al., 2013). The age-standardized incidence in women in this study was 
comparable to the previous regional estimate (Haviko, Maasalu and Seeder, 
1996; Kanis, Odén and McCloskey, 2012). 
In contrast to women, the SIR among Estonian men was higher than that 
reported in Eastern and Central European (Lesnyak et al., 2012; Tamulaitiene 
and Alekna, 2012; Grigorie et al., 2013; Wilk et al., 2013) and most Western 
European countries (Singer et al., 1998; Dodds et al., 2009; Maravic et al., 
2011; Hernlund et al., 2013; Piscitelli et al., 2013). The SIR in men was com-
parable to that in Finland, Hungary, Czech, and the US (Péntek et al., 2008; 
Brauer and Coca-Perraillon, 2009; Ettinger et al., 2010; Kanis, Odén and 
McCloskey, 2012; Stepan et al., 2012; Korhonen et al., 2013), but lower than 
that in Scandinavia and Austria, countries with the highest incidence worldwide 
(Bjørgul and Reikerås, 2007; Abrahamsen and Vestergaard, 2010; Dimai et al., 
2011; Kanis, Odén and McCloskey, 2012; Støen et al., 2012; Nilson et al., 
2013). Among men aged 50–59, Estonia had one of the highest hip fracture 
rates in Europe, comparable to that in Russia and Sweden (Singer et al., 1998; 
Kanis et al., 2000; Bjørgul and Reikerås, 2007; Péntek et al., 2008; Dodds et 
al., 2009; Ström et al., 2011; Tamulaitiene and Alekna, 2012; Lesnyak et al., 
2012; Støen et al., 2012; Grigorie et al., 2013; Korhonen et al., 2013). Clearly, 
cross-country/study comparisons are limited by methodological differences across 
studies (study design and source of data, case definition and ascertainment of 
cases, age range and stratification, study year and period of observation). 
The phenomenon of population aging has recently been observed in Estonia, 
and the population structure has become comparable to that of more stable aged 
populations in Europe (Eurostat, 2017). In line with longer survival, the mean 
52 
age of individuals sustaining hip fractures has increased. However, there are 
significant gender differences in life expectancy at age 65 (20.3 years for 
women and 15.3 in men in 2015), and the 80+ age group consists predominantly 
of women, with the female to male ratio being 3.0 in 2015 (Statistics Estonia, 
2015c). In line with this, the large difference between crude and standardized 
rates of hip fractures in women can be explained by differences in the age 
structure of the Estonian population compared with the WHO world standard 
population (Statistics Estonia, 2015c; WHO, 2015). Given the stable age-
specific hip fracture rates, the observed increase in the absolute numbers of hip 
fractures in the 80+ age group is largely attributable to the demographic changes, 
i.e., the increasing number of old people. This result corresponds to other recent 
findings (Ahlborg et al., 2010). The number of hip fractures might still increase 
in the coming decades as the number of people aged 80+ in Estonia is projected 
to increase by 50% by 2050 (UN, 2015). 
We found no sex differences in hip fracture rates in Estonia after age 
standardization. Worldwide, the standardized hip fracture rates in men are 
approximately half that noted in women, and where higher rates are observed in 
women, higher rates are found in men and vice versa (Kanis, Odén and 
McCloskey, 2012). Our observation suggests that Estonia remains an exception 
to the general pattern of sex-specific hip fracture distribution. 
It is hard to delineate the factors associated with the relatively low incidence 
of hip fractures among women. Data on health behavior for elderly Estonians 
are scant. We know that the prevalence of overweight in women aged 50+ in 
Estonia have constantly been among the highest in Europe (Eurostat, 2017) 
whereas smoking and alcohol consumption is low (Tekkel and Veideman, 
2013), and these factors could have reduced the average risk of hip fracture. In 
addition, given that older age was associated with high level of physical activity 
in everyday work in Estonia (Tekkel and Veideman, 2013), we could speculate 
that work related high physical activity (due to poor socio-economic status) 
among elderly Estonian women relatively early in the life course may have 
reduced the risk of fracture later in life (Johnell et al., 2007; Kanis et al., 2017; 
Petit et al., 2017; Rosengren et al., 2017). Interestingly, the modest vitamin D 
levels (Kull et al., 2009) and low hip fracture rates in Estonian women contrast 
with the findings of good vitamin D levels (Kuchuk et al., 2009; Wahl et al., 
2012) but high hip fracture incidence in the neighboring Scandinavian 
countries, the controversy is partly explained by the higher socio-economic 
prosperity in Scandinavia (Kuchuk et al., 2009; Rosengren et al., 2017). In 
summary, there is currently an inconsistent evidence of differences between hip 
fracture rates in Eastern and Western Europe (Kanis, Odén and McCloskey, 
2012; Icks et al., 2013) which might build to the socio-economic hypothesis, 
but our results are in line with this theory.  
The reasons for a relatively high hip fracture rate in Estonian men remain 
obscure. We hypothesize that the high incidence in the younger age groups of 
50–69 (that accounted for over 40% of hip fractures in men) could be associated 
with greater risk of alcohol-related falls. We know that heavy alcohol intake is a 
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risk factor for hip fractures (Kanis et al., 2005; Berg et al., 2008). Estonia is a 
country where heavy drinking among men is common (Popova et al., 2007); in 
the age group of 50–54 years, alcohol is the leading factor for disease burden, 
preempting dietary risks, smoking and high blood pressure (Forouzanfar et al., 
2016; Institute for Health Metrics and Evaluation University of Washington, 
2017). In this context, mortality from external causes and incidence of injuries 
are high in Estonia (Institute for Health Metrics and Evaluation University of 
Washington, 2017; National Institute for Health Development, 2017): for 
example, the rate of traumatic spinal cord injury in Estonian men is among the 
highest in Europe, and alcohol consumption precedes over 40% of cases (Sabre 
et al., 2012). However, there is conflicting evidence to this theory as the hip 
fracture rates in men differ across Eastern Europe despite a similar pattern of 
alcohol use (Lesnyak et al., 2012; Tamulaitiene and Alekna, 2012). 
 
Incidence trends 
As in several Western European countries and the US which have recently 
reported stabilizing or declining trends of hip fracture, mostly among women 
(Bjørgul and Reikerås, 2007; Brauer and Coca-Perraillon, 2009; Abrahamsen 
and Vestergaard, 2010; Cheng, Levy and Lefaivre, 2011; Cooper et al., 2011; 
Dimai et al., 2011; Maravic et al., 2011; Støen et al., 2012; Nilson et al., 2013; 
Icks et al., 2013; Korhonen et al., 2013; Siggeirsdottir et al., 2014; Lucas et al., 
2017), we too observed a 16% decrease in SIR in women since 2009, the 
change is predominantly attributable to the decline among the oldest age group. 
The period of declining incidence in our study was too short to make long term 
conclusions on trends, but the finding was confirmed in the recent study with an 
extended follow-up (Laius et al., 2017). Recent studies have suggested that 
reduction in fractures can be explained by reductions in falls-related comorbidity 
(Jørgensen et al., 2014). Data from Estonia are in line with this hypothesis: over 
the period of this study, the life expectancy at 65 in Estonian women increased 
from 18.1 to 20.3 years (2.2 years) (Statistics Estonia, 2016), indicating an 
improved general health and prevention and treatment of chronic diseases. A 
decrease in incidence corresponds temporally with an increased availability of 
BMD testing and the expanding use of bisphosphonates (Svedbom et al., 2013; 
Laius et al., 2017). We might also speculate that the impact of various socio-
economic factors during the life course feed through as a cohort effect towards 
healthier older populations (Cooper et al., 2011; Kanis et al., 2017; Rosengren 
et al., 2017).  
 
Limitations and strengths 
As the data collected for administrative purposes, we had no data on potentially 
important other risk factors. The inclusion of claims with secondary inpatient 
hip fracture diagnoses could have resulted in an overestimation of the incidence 
in the analysis (Lix, Azimaee and Osman, 2012). This clearly could not be 
driving the differences in hip fracture occurrence among men and women. Yet, 
the strength of our analysis lies in the use of a data source with nationwide 
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coverage. We had a large sample size of the representative population and 
standardized recording of health events (hip fracture contemporaneously across 
the period of observation), which avoids problems of imperfect recall and 
incomplete records.  
Further, we do not expect significant misclassification of hip fracture based 
on the incident case definition used, as the hip fracture rates were calculated 
based on the number of subjects with hip fractures and not simply on the 
number of admissions. While the used case definition adjusted for multiple 
registrations per fracture during one year, it might have slightly underestimated 
the true incidence as about 9% of patients experience a second hip fracture 
during that period (Ryg et al., 2009). We also have considered the possibility of 
sex-specific over- or under-ascertainment of incident cases leading to the 
observed uncommon female to male SIR ratio (Lix, Azimaee and Osman, 2012). 
In general, it has been demonstrated that administrative data are a valid source 
for ascertaining hip fracture cases (Lix, Azimaee and Osman, 2012), and after 
careful analysis of the diagnosis, reporting, and case ascertainment process we 
conclude that the observed results are unlikely to be a product of measurement 
bias. Finally, the study period was too short to draw conclusions on temporal 
trends in hip fracture rates in men. 
 
 
6.2. Quality of life, resource use, and  
costs related to hip fracture  
Health-related quality of life 
To start with, the pre-fracture HRQoL among hip fracture patients was low: it 
was comparable to that in Spain and Mexico which reported the lowest HRQoL 
estimates from ICUROS (Table 3, PAPER V). It was also lower than the pooled 
estimate of 0.78 (95% CI 0.75 – 0.80) reported in a recent meta-analysis (Si et 
al., 2014). For comparison, the EQ-5D Estonian population estimate for the age 
group of 55–64 years is 72.7 in men and 72.0 in women, and no estimates are 
available for the older age groups (Tekkel and Veideman, 2013). The marked 
decrease after fracture resulted in a post-fracture HRQoL of 0.07, an estimate 
close to death, that was comparable to generally low estimates from the ICUROS 
study and significantly lower than the pooled estimate of 0.31 (95% CI 0.22–
0.39) (Si et al., 2014). The mean HRQoL nearly reached the pre-fracture levels 
by the end of follow-up, however, over half of patients (51%) did not recover in 
full.  Accordingly, the HRQoL loss in QALYs after fracture was substantial 
(patients lost on average 48% of the expected HRQoL in the first 6 months). 
Our results agree with previous findings that hip fractures are associated with 
substantial reductions in HRQoL (Borgström et al., 2007; Borgstrom et al., 
2013; Si et al., 2014).  
The (non-significant) differences in HRQoL and HRQoL loss by age and 
CCI score were expected as older people with more comorbidities usually have 
lower HRQoL. It was also expected that the patients who died were older, had 
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higher CCI scores and lower HRQoL than surviving patients. Given that we did 
not see significant differences in age, CCI score and HRQoL between those 
retained and not in the study, we believe that our results are not strongly 
affected by the low retention rate.  
Comparing the Estonian results to those from ICUROS, we observed a 
slightly lower pre-fracture HRQoL and poorer recovery estimates (at 4, 12, and 
18 months) in Estonia, resulting in lower QALY loss. The post-fracture HRQoL 
(0.07) was higher in Estonia compared to ICUROS pooled estimate of –0.11. 
The severity of fractures may systematically differ between the participating 
centers. However, as the patients who died during the follow-up were not 
included in the pooled (complete case) analysis, and the institutionalized 
patients were excluded at onset (the proportion of patients who lived in a 
nursing home at a time of fracture might have been high (10 to 30%) in some 
affluent participating countries (Brennan (nee Saunders) et al., 2003; Osnes et 
al., 2004; Harris et al., 2010; Haywood et al., 2014; Anthony W Ireland, Kelly 
and Cumming, 2015)), the average hip fracture patient from ICUROS may have 
been healthier and with better recovery potential than the average Estonian 
patient in the study. Therefore, it is likely that the observed HRQoL differences 
between the Estonian and the pooled ICUROS results were related to selection 
bias. However, there is no proof to the hypothesis as the ICUROS HRQoL 
estimates from the complete case, available case, and multiple imputation 
analyses were similar, and no comparison group was available to assess bias.  
 
Resource use 
Comparing the resource use and cost to other studies is difficult as there are 
differences in socio-economic characteristics, health systems, price adjustments, 
and study methods (only a few include social and informal costs) (Borgström et 
al., 2006). However, large disparities may still be noted in the context of 
population aging. 
The utilization of fracture related specialty care services during the first 
months was comparable to that in Sweden (Borgström et al., 2006; Canto et al., 
2011) and Australia (Anthony W Ireland, Kelly and Cumming, 2015). One 
difference of note was low use of bisphosphonates, indicating a large gap 
between current use and the proportion of the population that could be 
considered eligible for treatment based on fracture risk (Ström et al., 2011). 
Compared to the similar Swedish study (Borgström et al., 2006) our results 
showed the low use of rehabilitation, nursing care and social care (particularly 
after 4 months after fracture). The use of inpatient rehabilitation (9% of patients) 
was also low compared to that in Lithuania (33%) (Tamulaitiene and Alekna, 
2012). We know that at 4 and 12 months after fracture up to 2/3 of patients (70% 
and 59% respectfully) were not fully recovered and could therefore assume that 
a substantial proportion of patients still had difficulties in mobility, self-care, 
and normal activities at that time. Hence, the use of rehabilitation, nursing care, 
and social care may potentially be insufficient to meet the needs of patients with 
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low HRQoL. We could speculate that the high excess mortality revealed in the 
study could be reduced by provision of adequate long-term care post fracture.  
 
Cost 
The hip fracture related 18-month societal cost of 8146 euros (annual cost of 
6696 euros) was higher than the previous 1-year estimate of 5580 euros (at 2010 
prices) that was equal to 40% of the EU average hip fracture cost (Hernlund et 
al., 2013). The new estimate is approximately half of the European average, 
comparable to that in Malta or Spain (Hernlund et al., 2013). For comparison, 
the 2-year direct health care cost of myocardial infarction in Estonia has been 
estimated at 8704 euros and stroke at 6937 euros per patient (Männik, Pisarev 
and Kiivet, 2015), and the annual societal cost of Parkinson’s disease at 2305 
euros per patient (Vois, 2015). The preliminary annual estimate for the total 
economic burden of incident hip fractures for Estonia is approximately 8 
million euros or 6 euros per person, comparable to the direct health care costs 
for colorectal, lung, or breast cancer (Luengo-Fernandez et al., 2013; Estonian 
Health Insurance Fund, 2017).  
Comparing the cost structure to that in Sweden (Borgström et al., 2006), 
significant differences were revealed. In our study the proportion of social cost 
was below 5%, compared with almost 30% in Sweden. The proportion of 
informal care cost exceeded that in Sweden. A remarkably high use of informal 
care in Estonia may partly be explained by the shortage of social care. In line 
with our findings, a large proportion of informal care cost was also noted in a 
recent study from Austria (Dimai et al., 2012). Another important finding was 
an increasing proportion of indirect cost, confirming the understanding that 
despite the advanced age of hip fracture patients, the cost of productivity should 
not be omitted from hip fracture economic evaluations (Hernlund et al., 2013). 
In this context, it may be noted that the human capital approach may 
overestimate costs of productivity losses (Larg and John R Moss, 2011).  
 
Limitations and strengths 
A cautious approach should be applied in generalizing results to the total hip 
fracture population in Estonia as we collected data in two hospitals. However, 
these hospitals provide 40% of hip fracture inpatient care in Estonia, and we 
assume that the patients admitted and quality of care do not significantly differ 
from the other clinics (The World Bank Group, 2015). Further, the modest 
sample size increases the likelihood of type II error (for example the statistically 
non-significant differences in HRQoL by age, gender and CCI).  
Our results are prone to selection bias – both in relation to recruitment (our 
sample comprised only 27% of all hospitalized patients with hip fracture at the 
recruiting hospitals) and retention (60%). We acknowledge that low recruitment 
rate cannot be explained solely by excluding the previously institutionalized and 
cognitively impaired patients. Non-participants were significantly older, had 
higher comorbidity burden and a higher risk of death. One might speculate that 
this would lead to moderately overestimating HRQoL loss (since recruitment of 
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younger and milder cases might have resulted in higher HRQoL before fracture) 
and underestimating costs. However, the cost consequences of fracture might be 
lower among previously institutionalized patients who already incur the cost of 
nursing care before fracture. 22% of patients died and 16% were lost during the 
follow-up, thus the data on social and informal care use for these patients were 
not available for the non-completed periods. As the respective costs for the 
patients who died in each period might have been higher than for patients who 
remained in the study, exclusion of those costs from analysis probably resulted 
in a slight underestimation of average hip fracture cost.  
Methodological issues in HRQoL measurement could also contribute to a 
possible overestimation of HRQoL loss. First, the initial interview took place 
right after fracture and patients might have recalled their pre-fracture health 
better than it was. Second, the assumption that the HRQoL pre-fracture level 
remained constant during the follow-up had the fracture not occurred may not 
hold in life, because in older age health might deteriorate over time, reducing 
the difference between pre-fracture and follow-up estimates. Third, it is possible 
that most of the HRQoL improvement after fracture happened not in a linear 
fashion over 4 months, but faster, and therefore the HRQoL loss during the first 
4 months was overestimated. Furthermore, we used the EQ-5D UK population 
values (Dolan, 1997) to determine HRQoL. The country comparisons of EQ-5D 
value sets have shown that there are considerable differences in HRQoL 
estimations (Knies et al., 2009). Thus, from an Estonian perspective, the use of 
a UK value set increased the uncertainty of HRQoL estimations in our study.  
It is worth noting that as costs and QALYs were censored after 18 months 
the true disease burden might be underestimated. Furthermore, we need to 
acknowledge the uncertainty related to the proportion of deaths attributable to 
hip fracture in the calculation of total hip fracture related QALYs lost.  
The strength of our analysis lies in a study design that enabled prospective 
collection of cost data from a societal perspective. Simultaneous collection of 
HRQoL and resource use permitted inferences to unmet needs of care in some 
patient subgroups. Another strength is the use of EHIF data for assessing 
fracture related health resources and costs.   
 
 
6.3. Hip fracture related excess mortality 
Excess mortality 
Previous studies have demonstrated an immediate elevated risk of mortality 
after hip fracture (Kanis et al., 2003; Johnell et al., 2004; Vestergaard, Rejnmark 
and Mosekilde, 2007; Abrahamsen et al., 2009; Haentjens et al., 2010; 
Kannegaard et al., 2010; Klop et al., 2014, 2017; Omsland et al., 2014), however, 
the evidence of persistence is not universal (Tosteson et al., 2007; Rapp et al., 
2008; Abrahamsen et al., 2009; LeBlanc et al., 2011; Michaëlsson et al., 2014). 
Our results are in line with the meta-analysis suggesting that the excess 
mortality is extensive already in the first months after fracture and persists for at 
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least 10 years (Haentjens et al., 2010). After adjustment for age and pre-fracture 
comorbidities, hip fracture was associated with a 21% 10-year cumulative 
excess risk of death (RR 1.4), i.e., more than 1 in 4 deaths among hip fracture 
patients was attributable to the fracture. To describe the magnitude of a public 
health problem, the 1-year average relative risk of all-cause death after hip 
fracture (4.1 in men, 3.4 in women) was comparable to that of diseases with the 
highest mortality, such as dementia, cancer, heart failure (Quan et al., 2011), 
and mental disorders (Nordentoft et al., 2013).  
It is a common knowledge that the hip fracture excess mortality increases with 
age (Haentjens et al., 2010). In younger age groups (50–79 years) the excess 
was mild at the onset but increased in a linear fashion over the follow-up. For 
example, in the 60–69-year-old patients, the excess risk increased over 10 years 
gradually to as high as 30% and became 2–3 times higher than in the reference 
group. This mortality pattern has been described before, suggesting that in 
younger and healthier patients a hip fracture can trigger a chain of events leading 
to frailty, disability, and death (Teng, Curtis and Saag, 2008). In contrast, in older 
age groups (≥80 years) hip fracture had an immediate marked impact on excess 
mortality. For example, in the group of men ≥90 years old, the excess risk at 3 
months was as high as 45%, 8 times higher than in men without fracture. Over 
half of patients died already within 3 months, and by 12 months over two-thirds 
of the men had died. This mortality pattern suggests that a hip fracture 
accelerates the chain of lethal events among older subjects and brings deaths from 
other pre-existing conditions forward (Magaziner et al., 1997; Empana, Dargent-
Molina and Bréart, 2004). It is important to note that the excess risk persisted 
throughout the 10-year period and did not disappear in any age- or sex-specific 
group. Our results are in line with the collective evidence confirming that 
excess mortality increases with age, and is higher in men than in women 
(Abrahamsen et al., 2009; Haentjens et al., 2010). 
Compared to the pooled estimates (Haentjens et al., 2010) the excess risk of 
death in younger (50–79 years) age groups was rather high, particularly in the 
first months and years after fracture. For example, in the 70–79-year-old men 
the excess risk in our study reached as high as 18% within 1 year, and 30% 
within 5 years, whereas in the meta-analysis the respective estimates were lower 
(11% and 20%). Likewise, in women of the same age, we found the excess risk to 
be 14% in 1 year and 24% in 5 years, versus 5% and 13% in the meta-analysis. It 
is difficult to explain the reasons for increased mortality in these groups, but 
insufficient case management upon discharge and low utilization of rehabi-
litation, nursing care, and social care could be potential contributors. However, 
excess mortality study results are difficult to compare due to differences in 
study design and sources of data, ascertainment of cases and controls, determi-
nation of death, differences in follow-up time, adjustment for confounding, and 
presentation of results (Abrahamsen et al., 2009; Haentjens et al., 2010).  
The average excess risk among men in our study did not exceed that among 
women during 3 years following the fracture; this can be explained by the 
different age distribution of fractures in men and women. We know that most 
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hip fractures in Estonian men occur at a younger age (50–79 years), whereas 
over half of fractures in women occur among those ≥80 years. Due to the 
considerable age difference between sexes (8.2 years) women experienced an 
elevated risk of death in both study groups (see Figure 6), and the weighted 
average excess risk in both groups was influenced by the higher-weighted age 
groups, with younger groups in men and older groups in women.  
The possible reasons for the greater mortality in men than in women 
following hip fracture are still poorly understood (Abrahamsen et al., 2009). 
Previously described risk factors in older men include multi-morbidity, smoking, 
lower dietary protein, greater height combined with the use of antidepressants 
leading to a greater impact upon falling, whereas the traditional risk factors in 
women (rheumatoid arthritis, use of benzodiazepines and corticosteroids) were 
not related to hip fractures in men (Cauley et al., 2016). It has also been 
suggested that men have higher rates of pneumonia and septicemia than women 
(Wehren et al., 2003), or more severe medical comorbidities prior to the hip 
fracture (Endo, Yoshimi; Aharonoff, Gina; Zuckerman, Joseph; Egol, Kenneth; 
Koval, 2005; Holt et al., 2008). However, in our study the CCI score was lower 
in men than in women in both study groups, suggesting that men were healthier 
than women. It is possible that the lower CCI score in men was related to their 
younger age compared to women. Our study adjusted for CCI, yet the excess 
risk was higher in men than in women. 
 
The impact of comorbidities on excess mortality 
We also analyzed the impact of comorbidities on excess mortality in detail. 
Most subjects, in both the hip fracture and reference groups, had no comorbid 
conditions contributing to the CCI, therefore adjusting for the CCI had little 
impact on the overall average excess risk either short or long-term (maximum 
difference between adjusted and unadjusted excess risks was 1.7% at 10 years 
of follow-up). A low comorbidity effect upon adjustment has also been shown 
in some other studies where CCI-related comorbidity was not highly prevalent 
(Farahmand et al., 2005; Vestergaard, Rejnmark and Mosekilde, 2007; 
Michaëlsson et al., 2014). Our results imply that only 1 out of 12 excess deaths 
was related to pre-fracture, life-threatening comorbidities, suggesting that 
comorbidities may not be the primary target for improving survival after hip 
fracture. The results are in line with a Danish study which found that the major 
causes of excess mortality in hip fracture patients were linked to the fracture 
event and not to pre-existing comorbidity (Vestergaard, Rejnmark and 
Mosekilde, 2007).  
We also show that the mortality effect of fracture varies across CCI groups. 
Among the people without the concomitant disease(s) (CCI 0 group), the 
average excess risk was profound and durable, implying that hip fracture is an 
independent risk factor for short and long-term all-cause mortality. The average 
excess risk of patients with up to two or three co-morbid conditions (CCI 
groups 1–2 and ≥ 3) exceeded that in the CCI 0 group over 5–7 years, and a 
clear dose-response for the association of CCI score and short-term excess 
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mortality was observed. It is likely that the comorbidities modify the effect of 
hip fracture on all-cause mortality. 
The effect of comorbidity was age-dependent. In younger patients (50–79 
years) without comorbid conditions (CCI of 0) the excess risk gradually 
accumulated over the 10-year follow-up period, adding up to 20–30% to the 
patient’s background risk of death without fracture. The presence of pre-fracture 
comorbidities (CCI groups 1–2 and ≥ 3) almost doubled that excess risk, both 
short- and long-term. This inflating impact of comorbidities on hip-fracture 
related excess mortality has been described before (Luise et al., 2008; 
Abrahamsen et al., 2009; Hu et al., 2012; Anthony W. Ireland, Kelly and 
Cumming, 2015; Cauley et al., 2016). In older patients (≥ 80 years) the dose–
response relationship between CCI score and risk of death was immediate but 
shorter than in younger patients. Over time, the excess risk in CCI groups 1–2 
and ≥ 3 groups decreased below that of CCI 0 as the risk of death, unrelated to 
hip fracture, increased in the respective reference groups. It is likely that age is 
an effect modifier for an association for comorbidity and hip-fracture related 
excess mortality, suggesting that the interaction of comorbidity and hip fracture 
depends on age-related factors (Knol and VanderWeele, 2012). 
We also assessed the effect of specific comorbid conditions (diseases; indi-
vidual CCI components) on excess mortality. The excess mortality attributable 
to the most prevalent diseases (malignancy, chronic pulmonary disease, 
congestive heart failure, diabetes with complications) exceeded the excess 
mortality of those without that specific disease by 5–10% over the first 4–5 
years after a fracture, being essentially similar to that in a CCI score-specific 
analysis. The only exception was dementia which had the highest and shortest 
excess risk (up to 20% over 2–3 years) among all conditions. The prevalence of 
dementia was higher among fracture patients (8%, vs 2% among reference 
subjects), the patients were older and probably frailer than those without 
dementia. A higher prevalence of dementia among hip fracture patients than in 
the general population has been noted before (Yiannopoulou et al., 2012) and 
the survival of such patients is lower (Scandol, Toson and Close, 2013). We 
expect this patient group will increase with population aging, and further 
research is required to alleviate the post-fracture implications of dementia 
(Chaudhry, Devereaux and Bhandari, 2013).  
The conclusions derived from our research are three-fold. First, hip fracture 
is a strong independent risk factor for death. This result is of clinical importance 
implying that a substantial proportion of hip-fracture related deaths can be 
avoided by preventing a fracture and its complications and improving post-
fracture rehabilitation and social care. Second, the impact of life-threatening 
comorbidities on aggregated hip-fracture related excess mortality is likely to be 
modest, depending on the (low) prevalence of the comorbid conditions. Third, 
the mortality impact of comorbidities in CCI groups is age and time-dependent: 
in younger patients, the comorbidities almost doubled the excess risk of death 
from fracture for over 10 years, in older patients the increment was shorter and 
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modest. It is likely that age modifies the effect of comorbidities and hip fracture 
on excess mortality.  
 
Limitations and strengths 
We acknowledge the limitations of our study. It is possible that the excess risk 
of death in our analysis was slightly overestimated due to measurement bias. 
Our data collection started from 2004, and some subjects with unascertained 
fractures before 2004 might have been misclassified as incident cases (fracture 
group) or non-fracture patients (reference group). This misclassification might 
have resulted in slightly overestimating mortality in both groups. However, as 
the risk for further hip fracture after previous hip fracture is over 2-fold 
(Klotzbuecher et al., 2010; Hernlund et al., 2013) and a subsequent fracture is 
associated with increased mortality risk (Bliuc et al., 2009), the overestimation 
would have been higher in the fracture group, resulting in a slightly overes-
timated excess mortality. 
We did not assess the impact of hip fracture complications and post-fracture 
care (such as anesthesia, surgery, or inadequate rehabilitation) on excess 
mortality, or the causes of death. Thus, we cannot discriminate between hip 
fracture and its complications. Neither did we assess the impact of other 
confounding factors such as frailty, social deprivation, behavioral factors (low 
BMI, smoking, alcohol consumption), previous fragility fracture, and the type 
of fracture (Ensrud et al., 2007; Hu et al., 2012; Hernlund et al., 2013; Cenzer 
et al., 2016; Ray et al., 2016; Thorne et al., 2016). Nursing home or facility 
residence, poor preoperative walking capacity, poor activities of daily living and 
poor mental state have been identified as strongly predictive factors for the 
excess mortality (Hu et al., 2012) suggesting that frail and disabled elderly are 
at higher immediate risk of death after hip fracture (Tosteson et al., 2007; 
Cenzer et al., 2016). It is possible that additional adjustment for these factors 
could reduce the hip fracture related excess mortality (Magaziner et al., 1997; 
Tosteson et al., 2007; Vestergaard, Rejnmark and Mosekilde, 2007; Solbakken 
et al., 2017), while the impact of CCI-related comorbidities on the excess 
mortality remains unchanged. We used data from the (administrative) health 
insurance database that covers the overwhelming majority of the Estonia’s 
population. However, we are not aware of any data documenting the comple-
teness of the database. Finally, we did not account for changes in hip fracture 
mortality in the population over time. 
CCI as a measure of co-morbid conditions has its strengths but also limi-
tations. We used the CCI as a well-accepted comorbidity burden index for 
adjustment of concomitant diseases (Luise et al., 2008; Radley et al., 2008; 
Neuhaus et al., 2013; Hindmarsh et al., 2014; Smith et al., 2014; Toson, Harvey 
and Close, 2015). We chose the CCI because of its adaptability to large 
population databases using diagnostic codes from the ICD-10 (Hindmarsh et al., 
2014). It has also been documented that excess deaths among hip fracture 
patients can mainly be explained by the conditions predominantly responsible 
for mortality in the general population, i.e. those represented in the CCI (Melton 
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et al., 2014). However, the CCI does not allow to account for disease severity 
(Hindmarsh et al., 2014; Toson, Harvey and Close, 2015). In addition, we know 
that as a composite index it does not discriminate well between diseases, i.e. it 
equates the entities. Models incorporating comorbidities as individual variables 
have performed better in predicting mortality than the weighted index (Toson, 
Harvey and Close, 2015), and clinicians are more likely to identify and respond 
to a medical diagnosis than (even a validated) calculated index (Anthony W. 
Ireland, Kelly and Cumming, 2015). In our analysis, the CCI disease-specific 
excess mortality patterns were comparable to those of CCI 1–2 and ≥ 3 group 
specific mortality, with the exception of dementia.  
Two potential limitations are related to differential misclassification of 
comorbidity diagnoses. First, the comorbidity data for both groups were 
collected at the time of, and for 1 year before, the index date of a hip fracture 
case. It is possible that some reference subjects did not visit a physician over 
that period (for example, 81% of publicly insured individuals had a visit to a 
family physician, and 65% to a specialist in 2015) (Estonian Health Insurance 
Fund, 2015), whereas all cases were hospitalized for the incident fracture. That 
might have resulted in underascertainment of comorbidities in the reference 
group. However, we believe that people with severe life-threatening conditions 
would have received health care, and including data from hospitalization 
episodes (including primary and secondary diagnoses) within the 12-months 
recall period into CCI for individuals in the reference group might mitigate 
some of this bias. Further, we speculate that potential differential misclassi-
fication described above might lead to overestimating the effect of comorbid 
conditions on mortality and thus support our main finding of hip fracture as a 
major independent risk factor for death.  
Second, the fact that we used an updated version of the CCI could have 
resulted in measurement bias. Quan et al found that five of the original Charlson 
conditions were not associated with increased mortality in the general 
population, and they were removed from the updated score (Quan et al., 2011). 
Inline with that, Toson et al showed that the updated version was comparable to 
the older version for predicting 1-year mortality in hip fracture patients (Toson, 
Harvey and Close, 2015). However, it was recently found that some of the 
omitted conditions (myocardial infarction, cerebrovascular disease, and 
peripheral vascular disease) were associated with increased mortality in the hip 
fracture population (Toson, Harvey and Close, 2015). If this were true, it is 
possible that using an older version of CCI could have given larger effects on 
risk adjustment, and we might have potentially underestimated the effect of life-
threatening comorbidities on excess risk of death. Further research is needed to 
identify specific diseases most responsible for the hip-fracture excess mortality. 
To our knowledge, this is the first population-based study to estimate the 
impact of comorbidities on hip-fracture related excess mortality in Eastern 
Europe. The strength of our analysis lies in the use of a data source with 
nationwide coverage and complete follow-up (EHIF data). We had a large 
sample size of a representative population (given the >94% population coverage 
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of the EHIF), long follow-up, and standardized recording of health events 
across the period of observation, which avoids problems related to imperfect 
recall and incomplete records. The large sample size provided a high number of 
events (deaths) over the long follow-up period even in older age groups to 
increase the precision of estimates, and the high frequency of observations 
allowed for assessment of rapid and extensive changes during the first months 
after fracture. We believe that our results allowing inferences to other hip 
fracture populations ≥50 years of age. 
 
 
6.4. Summary of the discussion 
To finalize, the study series demonstrates a marked health and economic impact 
of hip fracture on patients and society. The results serve as a platform for 
prioritization of hip fracture in health and social policy agenda, draw attention 
to gaps and inequalities in care, and imply that implementation of fracture 
prevention programs and optimal post fracture rehabilitation and social care are 
warranted. The results will also be used in economic evaluations for selecting 
cost-effective interventions for hip fracture prevention and care. To estimate a 
societal burden of hip fractures in Estonia, further research is required to 
estimate the number of prevalent hip fractures, the number of QALYs lost in the 
population and the total societal cost. This will enable to compare the burden 
across countries and other conditions and determine future predictions in the 
light of population aging.  
In the light of results, a suggestion was derived for improving a methodology 
for comorbidity research. Despite a high all-cause mortality, a hip fracture is not 
included in any common comorbidity index (Charlson et al., 1987; Elixhauser 
et al., 1998; Klabunde et al., 2000; de Groot et al., 2003). The reasons for non-
inclusion remain obscure, but low disease awareness and lack of mortality data 
at the time of index development could be among the potential reasons. The 
inclusion of a hip fracture in the indices containing the severest life-threatening 






1. The age-standardized hip fracture incidence in Estonian women ≥ 50 years 
was among the lowest, and the rate in men among the highest in Europe. The 
increasing number of fractures was a result of population aging.  
2. The impact of hip fracture on the quality of life was substantial. After a 
fracture, the HRQoL was only 7%, i.e., the estimate close to death. The 
HRQoL before fracture and during the recovery was low in Estonia, and less 
than half of patients recovered in full.   
3. Fracture-related specialty and primary care use was comparable to that in 
Sweden, but the use of rehabilitation, home nursing, and social care after 
discharge was low. The shortfall may explain the high use of informal care. 
The hip fracture related societal cost was >8000 euros per patient, 
comparable to that for myocardial infarction and stroke. 
4. Hip fracture is a strong independent risk factor for death. The aggregated 
risk of all-cause death at 1 year after fracture was 28%, being 20% or 3–4 
times higher than that without fracture. This excess mortality is comparable 
to that for dementia and cancer. In younger patients (50–79 years), the 
excess mortality gradually increased over 10 years, suggesting that a fracture 
may induce a long-term progressive decline in health leading to death. In 
older patients (≥80 years) the excess risk was immediate, as a fracture may 
have accelerated the chain of lethal events and bring the death from other 
conditions forward. The excess mortality in younger patients in Estonia was 
higher than in the Western countries. A substantial proportion of hip-fracture 
related deaths could be avoided by preventing a fracture and its compli-
cations and improving post-fracture care. 
5. In patients with comorbidities, a fracture may accelerate the chain of lethal 
events and bring the death from other conditions forward. A clear dose 
response for the association of co-morbid conditions’ quantity and excess 
mortality was observed. Patients with dementia had the highest excess risk of 
death from hip fracture, probably because of older age (83.2 years) and 
frailty. However, the impact of comorbidities on aggregated excess mortality 
was modest, depending on their low prevalence. Therefore, comorbidities 
may not be the primary target for improving survival after hip fracture.  
65 
8. REFERENCES 
Abrahamsen, B. et al. (2009) ‘Excess mortality following hip fracture: a systematic 
epidemiological review.’, Osteoporosis international : a journal established as 
result of cooperation between the European Foundation for Osteoporosis and the 
National Osteoporosis Foundation of the USA, 20(10), pp. 1633–50.   
doi: 10.1007/s00198-009-0920-3. 
Abrahamsen, B. and Vestergaard, P. (2010) ‘Declining incidence of hip fractures and 
the extent of use of anti-osteoporotic therapy in Denmark 1997–2006’, Osteoporosis 
international, 21(3), pp. 373–380. doi: 10.1007/s00198-009-0957-3. 
Ahlborg, H. G. et al. (2010) ‘Prevalence of osteoporosis and incidence of hip fracture in 
women – secular trends over 30 years.’, BMC musculoskeletal disorders, 11, p. 48. 
Arnold, D. et al. (2009) ‘Comparison of direct and indirect methods of estimating health 
state utilities for resource allocation: review and empirical analysis’, Bmj, 339, p. 
b2688. doi: 10.1136/bmj.b2688. 
Ballane, G. et al. (2014) ‘Secular trends in hip fractures worldwide: Opposing trends 
east versus west’, Journal of Bone and Mineral Research, 29(8), pp. 1745–1755. 
doi: 10.1002/jbmr.2218. 
Berg, K. M. et al. (2008) ‘Association between alcohol consumption and both 
osteoporotic fracture and bone density.’, The American journal of medicine. NIH 
Public Access, 121(5), pp. 406–18. doi: 10.1016/j.amjmed.2007.12.012. 
Berry, J. D. et al. (2012) ‘Lifetime Risks of Cardiovascular Disease’, New England 
Journal of Medicine.  Massachusetts Medical Society , 366(4), pp. 321–329. doi: 
10.1056/NEJMoa1012848. 
Bjørgul, K. and Reikerås, O. (2007) ‘Incidence of hip fracture in southeastern Norway: 
a study of 1,730 cervical and trochanteric fractures.’, International orthopaedics, 
31(5), pp. 665–9. doi: 10.1007/s00264-006-0251-3. 
Bliuc, D. et al. (2009) ‘Mortality risk associated with low-trauma osteoporotic fracture 
and subsequent fracture in men and women.’, JAMA, 301(5), pp. 513–21. doi: 
10.1001/jama.2009.50. 
Borgstrom, F. et al. (2013) ‘The International Costs and Utilities Related to 
Osteoporotic Fractures Study (ICUROS) – quality of life during the first 4 months 
after fracture.’, Osteoporosis International 24(3), pp. 811–23. doi: 10.1007/s00198-
012-2240-2. 
Borgström, F. et al. (2006) ‘Costs and quality of life associated with osteoporosis-
related fractures in Sweden’, Osteoporosis International, 17(5), pp. 637–650. doi: 
10.1007/s00198-005-0015-8. 
Borgström, F. et al. (2007) ‘The societal burden of osteoporosis in Sweden’, Bone, 
40(6), pp. 1602–1609. doi: 10.1016/j.bone.2007.02.027. 
Brazier, J. E. and Green, C. (2002) ‘A Systematic Review of Health State Utility Values 
for Osteoporosis-Related Conditions’, Osteoporosis International. Springer-Verlag 
London Limited, 13(10), pp. 768–776. doi: 10.1007/s001980200107. 
Brauer, C. and Coca-Perraillon, M. (2009) ‘Incidence and mortality of hip fractures in 
the United States’, JAMA : the journal of the American Medical Association, 
302(14), pp. 1573–1579. (Accessed: 23 February 2014). 
Brennan (nee Saunders), J. et al. (2003) ‘Place of residence and risk of fracture in older 
people: a population-based study of over 65-year-olds in Cardiff’, Osteoporosis 
International. Springer-Verlag, 14(6), pp. 515–519. doi: 10.1007/s00198-003-1404-5. 
66 
Calaway, R. et al. (2015) doParallel: Foreach Parallel Adaptor for the ‘parallel’ 
Package. R package version 1.0.10. Comprehensive R Archive Network (CRAN). 
Available at: https://cran.r-project.org/package=doParallel (Accessed: 9 March 
2017). 
Calaway, R., RevolutionAnalytics and Weston, S. (2015) foreach: Provides Foreach 
Looping Construct for R. R package version 1.4.3. Comprehensive R Archive 
Network (CRAN). Available at: https://cran.r-project.org/package=foreach 
(Accessed: 9 March 2017). 
Calder, S. J., Anderson, G. H. and Gregg, P. J. (1996) ‘Certification of cause of death in 
patients dying soon after proximal femoral fracture’, BMJ, 312(7045). 
Canto, J. G. et al. (2011) ‘Number of Coronary Heart Disease Risk Factors and 
Mortality in Patients With First Myocardial Infarction’, JAMA 306(19), pp. 822–
823. doi: 10.1001/jama.2011.1654. 
Canty, A. and Ripley, B. (2016) boot: Bootstrap R (S-Plus) Functions. R package 
version 1.3–18. Available at: https://cran.r-project.org/web/packages/boot  
(Accessed: 9 March 2017). 
Carstensen, B. et al. (2016) Epi: A Package for Statistical Analysis in Epidemiology. R 
package version 2.7. Available at: http://cran.r-project.org/package=Epi (Accessed: 
9 March 2017). 
Castelli, A. et al. (2015) ‘The determinants of costs and length of stay for hip fracture 
patients’, PLoS ONE. Edited by A. Icks, 10(7), p. e0133545.   
doi: 10.1371/journal.pone.0133545. 
Cauley, J. A. et al. (2016) ‘Risk Factors for Hip Fracture in Older Men: The 
Osteoporotic Fractures in Men Study (MrOS)’, Journal of Bone and Mineral 
Research, 31(10), pp. 1810–1819. doi: 10.1002/jbmr.2836. 
Cenzer, I. S. et al. (2016) ‘One-Year Mortality After Hip Fracture: Development and 
Validation of a Prognostic Index’, Journal of the American Geriatrics Society. doi: 
10.1111/jgs.14237. 
Charlson, M. E. et al. (1987) ‘A new method of classifying prognostic comorbidity in 
longitudinal studies: Development and validation’, Journal of Chronic Diseases, 
40(5), pp. 373–383. doi: 10.1016/0021-9681(87)90171-8. 
Chaudhry, H., Devereaux, P. J. and Bhandari, M. (2013) ‘Cognitive Dysfunction in Hip 
Fracture Patients’, Orthopedic Clinics of North America. Elsevier Inc, 44(2), pp. 
153–162. doi: 10.1016/j.ocl.2013.01.003. 
Cheng, S., Levy, A. and Lefaivre, K. (2011) ‘Geographic trends in incidence of hip 
fractures: a comprehensive literature review’, Osteoporosis International, 22(10), 
pp. 2575–2586. doi: 10.1007/s00198-011-1596-z. 
City of Tallinn (2015) Social welfare services. Available at: http://www.tallinn.ee/eng/ 
(Accessed: 23 July 2015). 
Cooper, C. et al. (2011) ‘Secular trends in the incidence of hip and other osteoporotic 
fractures.’, Osteoporosis international : a journal established as result of 
cooperation between the European Foundation for Osteoporosis and the National 
Osteoporosis Foundation of the USA, 22(5), pp. 1277–88.   
doi: 10.1007/s00198-011-1601-6. 
DiLuca, M. and Olesen, J. (2014) ‘The cost of brain diseases: A burden or a 
challenge?’, Neuron. Elsevier Inc., 82(6), pp. 1205–1208.  
doi: 10.1016/j.neuron.2014.05.044. 
Dimai, H. P. et al. (2011) ‘Epidemiology of hip fractures in Austria: evidence for a 
change in the secular trend.’, Osteoporosis international : a journal established as 
67 
result of cooperation between the European Foundation for Osteoporosis and the 
National Osteoporosis Foundation of the USA, 22(2), pp. 685–92.   
doi: 10.1007/s00198-010-1271-9. 
Dimai, H. P. et al. (2012) ‘Economic burden of osteoporotic fractures in Austria.’, 
Health economics review, 2(1), p. 12. doi: 10.1186/2191-1991-2-12. 
Dodds, M. K. et al. (2009) ‘Incidence of hip fracture in the Republic of Ireland and 
future projections: a population-based study.’, Osteoporosis international : a journal 
established as result of cooperation between the European Foundation for 
Osteoporosis and the National Osteoporosis Foundation of the USA, 20(12), pp. 
2105–10. doi: 10.1007/s00198-009-0922-1. 
Dolan, P. (1997) ‘Modeling Valuations for EuroQol Health States’, Medical Care, 
35(11), pp. 1095–1108. 
Dowle, M. et al. (2016) ‘data.table: Extension of data.frame. R package version 1.9.8.’ 
Comprehensive R Archive Network (CRAN). Available at: https://cran.r-
project.org/package=data.table (Accessed: 9 March 2017). 
Drummond, M. F. et al. (2015) Methods for the Economic Evaluation of Health Care 
Programmes. 4th edn. Oxford University Press. Available at:  
https://books.google.com/books?id=xyPLJIiEn7cC&pgis=1  
(Accessed: 8 January 2017). 
Ekström, W. et al. (2015) ‘Sex effects on short-term complications after hip fracture: a 
prospective cohort study.’, Clinical interventions in aging. Dove Press, 10, pp. 
1259–66. doi: 10.2147/CIA.S80100. 
Elixhauser, A. et al. (1998) ‘Comorbidity measures for use with administrative data’, 
Medical care, 36(1), pp. 8–27. doi: 10.1097/00005650-199801000-00004. 
Empana, J.-P. J., Dargent-Molina, P. and Bréart, G. (2004) ‘Effect of hip fracture on 
mortality in elderly women: the EPIDOS prospective study’, Journal of the 
American Geriatrics Society, 52(5), pp. 685–690.   
doi: 10.1111/j.1532-5415.2004.52203.x. 
Endo, Yoshimi; Aharonoff, Gina; Zuckerman, Joseph; Egol, Kenneth; Koval, K. (2005) 
‘Gender Differences in Patients With Hip Fracture: A Greater Risk of Morbidity and 
Mortality in Men’, Journal of Orthopaedic Trauma, 19(1), pp. 29–35. (Accessed: 10 
March 2016). 
Ensrud, K. E. et al. (2007) ‘Frailty and risk of falls, fracture, and mortality in older 
women: the study of osteoporotic fractures.’, The journals of gerontology. Series A, 
Biological sciences and medical sciences. Oxford University Press, 62(7), pp. 744–
51. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17634322 (Accessed: 7 July 
2016). 
Estonian Health Insurance Fund (2015) Annual report. Available at:  
https://www.haigekassa.ee/ (Accessed: 29 June 2017). 
Estonian Health Insurance Fund (2017) Overview of the Estonian specialized medical 
care spending and patient counts by age and diagnosis. Available at:  
http://haigekassa.ee/et/ulevaade-eriarsti-kuludest (Accessed: 29 April 2016). 
Ettinger, B. et al. (2010) ‘Updated fracture incidence rates for the US version of 
FRAX.’, Osteoporosis international : a journal established as result of cooperation 
between the European Foundation for Osteoporosis and the National Osteoporosis 
Foundation of the USA, 21(1), pp. 25–33. doi: 10.1007/s00198-009-1032-9. 
EuroQol (2017) EQ-5D: a standardized instrument for use as a measure of health 
outcome. Available at: https://euroqol.org/. 
68 
Eurostat (2017) Population change – Demographic balance and crude rates at national 
level. Available at: http://epp.eurostat.ec.europa.eu/portal/page/portal/eurostat/home/ 
(Accessed: 24 January 2017). 
Farahmand, B. Y. et al. (2005) ‘Survival after hip fracture.’, Osteoporosis inter-
national : a journal established as result of cooperation between the European 
Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 
16(12), pp. 1583–90. doi: 10.1007/s00198-005-2024-z. 
Forouzanfar, M. M. H. et al. (2016) ‘Global, regional, and national comparative risk 
assessment of 79 behavioural, environmental and occupational, and metabolic risks 
or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of 
Disease Study 2015’, The Lancet. Elsevier, 388(10053), pp. 1659–1724. doi: 
10.1016/S0140-6736(16)31679-8. 
Fox-Rushby, J. A. (2002) Disability Adjusted Life Years (DAILY) For Decision-
Making? An overview of the literature. Office of Health Economics 12 Whitehall 
London: Office of Health Economics, London, UK. 
Fox-Rushby, J. A. and Cairns, J. (2005) Economic evaluation. Edited by J. A. Fox-
Rushby and J. Cairns. Maidenhead, New York: Open University Press. 
Fried, L. P. et al. (2001) ‘Frailty in older adults: evidence for a phenotype.’, The 
journals of gerontology. Series A, Biological sciences and medical sciences. Oxford 
University Press, 56(3), pp. M146–56. doi: 10.1093/GERONA/56.3.M146. 
GBD 2013 Risk Factors Collaborators et al. (2015) ‘Global, regional, and national 
comparative risk assessment of 79 behavioural, environmental and occupational, and 
metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic 
analysis for the Global Burden of Disease Study 2013.’, Lancet (London, England). 
Elsevier, 386(10010), pp. 1990–2013. doi: 10.1016/S0140-6736(15)00128-2. 
Grigorie, D. et al. (2013) ‘Incidence of hip fracture in Romania and the development of 
a Romanian FRAX model.’, Calcified tissue international, 92(5), pp. 429–36. doi: 
10.1007/s00223-013-9697-7. 
Grønskag, A. B. et al. (2012) ‘Excess mortality after hip fracture among elderly women 
in Norway. The HUNT study.’, Osteoporosis international: a journal established as 
result of cooperation between the European Foundation for Osteoporosis and the 
National Osteoporosis Foundation of the USA. Springer-Verlag, 23(6), pp. 1807–11. 
doi: 10.1007/s00198-011-1811-y. 
de Groot, V. et al. (2003) ‘How to measure comorbidity: a critical review of available 
methods’, Journal of Clinical Epidemiology, 56(3), pp. 221–229.   
doi: 10.1016/S0895-4356(02)00585-1. 
Gustavsson, A. et al. (2011) ‘Cost of disorders of the brain in Europe 2010.’, European 
neuropsychopharmacology. Elsevier, 21(10), pp. 718–79.  
doi: 10.1016/j.euroneuro.2011.08.008. 
Haentjens, P. et al. (2010) ‘Meta-analysis: excess mortality after hip fracture among 
older women and men’, Annals of internal medicine. American College of 
Physicians, 152(6), pp. 380–390. doi: 10.1059/0003-4819-152-6-201003160-
00008.Meta-analysis. 
Harris, I. A. et al. (2010) ‘A prospective study of the effect of nursing home residency 
on mortality following hip fracture’, ANZ Journal of Surgery. Blackwell Publishing 
Asia, 80(6), pp. 447–450. doi: 10.1111/j.1445-2197.2010.05313.x. 
Harvey, N. C. W. et al. (2017) ‘Mind the (treatment) gap: a global perspective on 
current and future strategies for prevention of fragility fractures’, Osteoporosis 
69 
International. Osteoporosis International, pp. 1507–1529. doi: 10.1007/s00198-016-
3894-y. 
Haviko, T., Maasalu, K. and Seeder, J. (1996) ‘The Incidence of Osteoporotic Fractures 
at the University Hospital of Tartu, Estonia’, Scandinavian Journal of Rheumatology 
25(sup103), pp. 13–15.   
doi: 10.3109/03009749609103738. 
Haywood, K. L. et al. (2014) ‘Developing a core outcome set for hip fracture trials’, 
Bone & Joint Journal, 96–B(8). (Accessed: 28 December 2016). 
Hernlund, E. et al. (2013) ‘Osteoporosis in the European Union: medical management, 
epidemiology and economic burden. A report prepared in collaboration with the 
International Osteoporosis Foundation (IOF) and the European Federation of 
Pharmaceutical Industry Associations (EFPIA).’, Archives of osteoporosis, 8(1–2), 
p. 136. doi: 10.1007/s11657-013-0136-1. 
Hindmarsh, D. et al. (2014) ‘Effect of comorbidity on relative survival following 
hospitalisation for fall-related hip fracture in older people.’, Australasian journal on 
ageing, 33(3), pp. E1–7. doi: 10.1111/j.1741-6612.2012.00638.x. 
Hodgson, T. A. (1994) ‘Costs of Illness in Cost-Effectiveness Analysis’, Phar-
macoEconomics. Springer International Publishing, 6(6), pp. 536–552.   
doi: 10.2165/00019053-199406060-00007. 
Holt, G. et al. (2008) ‘Gender differences in epidemiology and outcome after hip 
fracture: evidence from the Scottish Hip Fracture Audit.’, The Journal of bone and 
joint surgery. British volume, 90(4), pp. 480–483.   
doi: 10.1302/0301-620X.90B4.20264. 
Hu, F. et al. (2012) ‘Preoperative predictors for mortality following hip fracture 
surgery: a systematic review and meta-analysis.’, Injury. Elsevier Ltd, 43(6), pp. 
676–85. doi: 10.1016/j.injury.2011.05.017. 
Icks, A. et al. (2013) ‘Incidence of hip fractures in Germany, 1995–2010.’, Archives of 
osteoporosis, 8(1–2), p. 140. doi: 10.1007/s11657-013-0140-5. 
Institute for Health Metrics and Evaluation University of Washington (2017) Global 
Burden of Disease Visualizations. Available at: https://vizhub.healthdata.org/gbd-
compare/ (Accessed: 11 April 2017). 
Ireland, A. W. and Kelly, P. J. (2013) ‘Total length of stay, costs and outcomes at final 
discharge for admitted patients with hip fracture: linked episode data for Australian 
veterans and war widows’, Internal Medicine Journal, 43(12), pp. 1280–1286.   
doi: 10.1111/imj.12071. 
Ireland, A. W., Kelly, P. J. and Cumming, R. G. (2015) ‘Risk factor profiles for early 
and delayed mortality after hip fracture: Analyses of linked Australian Department 
of Veterans’ Affairs databases’, Injury, 46(6), pp. 1028–1035.   
doi: 10.1016/j.injury.2015.03.006. 
Ireland, A. W., Kelly, P. J. and Cumming, R. G. (2015) ‘Total hospital stay for hip 
fracture: measuring the variations due to pre-fracture residence, rehabilitation, 
complications and comorbidities’, BMC Health Services Research, 15(1), p. 17.   
doi: 10.1186/s12913-015-0697-3. 
Johnell, O. et al. (2004) ‘Mortality after osteoporotic fractures.’, Osteoporosis 
international : a journal established as result of cooperation between the European 
Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 
15(1), pp. 38–42. doi: 10.1007/s00198-003-1490-4. 
70 
Johnell, O. et al. (2005) ‘Predictive value of BMD for hip and other fractures.’, Journal 
of bone and mineral research : the official journal of the American Society for Bone 
and Mineral Research, 20(7), pp. 1185–94. doi: 10.1359/JBMR.050304. 
Johnell, O. et al. (2007) ‘Latitude, socioeconomic prosperity, mobile phones and hip 
fracture risk.’, Osteoporosis international : a journal established as result of 
cooperation between the European Foundation for Osteoporosis and the National 
Osteoporosis Foundation of the USA, 18(3), pp. 333–7.   
doi: 10.1007/s00198-006-0245-4. 
Johnell, O. and Kanis, J. A. (2006) ‘An estimate of the worldwide prevalence and 
disability associated with osteoporotic fractures.’, Osteoporosis international : a 
journal established as result of cooperation between the European Foundation for 
Osteoporosis and the National Osteoporosis Foundation of the USA, 17(12), pp. 
1726–33. doi: 10.1007/s00198-006-0172-4. 
Jørgensen, T. S. H. et al. (2014) ‘Falls and comorbidity: The pathway to fractures.’, 
Scandinavian journal of public health 42(3).   
doi: 10.1177/1403494813516831. 
Kanis, J. A. et al. (2000) ‘Long-Term Risk of Osteoporotic Fracture in Malmö’, Osteo-
porosis International, 11(8), pp. 669–674. doi: 10.1007/s001980070064. 
Kanis, J. A. et al. (2001) ‘The burden of osteoporotic fractures: A method for setting 
intervention thresholds’, Osteoporosis International, 12(5), pp. 417–427.   
doi: 10.1007/s001980170112. 
Kanis, J. A. et al. (2002) ‘Diagnosis of osteoporosis and assessment of fracture risk.’, 
Lancet (London, England). Elsevier, 359(9321), pp. 1929–36.   
doi: 10.1016/S0140-6736(02)08761-5. 
Kanis, J. A. et al. (2003) ‘The components of excess mortality after hip fracture’, Bone. 
Elsevier, 32(5), pp. 468–473. doi: 10.1016/S8756-3282(03)00061-9. 
Kanis, J. A. et al. (2005) ‘Alcohol intake as a risk factor for fracture.’, Osteoporosis 
international: a journal established as result of cooperation between the European 
Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 
16(7), pp. 737–42. doi: 10.1007/s00198-004-1734-y. 
Kanis, J. A. et al. (2013) ‘SCOPE: a scorecard for osteoporosis in Europe.’, Archives of 
osteoporosis, 8(1–2), p. 144. doi: 10.1007/s11657-013-0144-1. 
Kanis, J. A. et al. (2017) ‘Identification and management of patients at increased risk of 
osteoporotic fracture: outcomes of an ESCEO expert consensus meeting’, 
Osteoporosis International. Springer London, pp. 2023–2034.   
doi: 10.1007/s00198-017-4009-0. 
Kanis, J. A., Odén, A. and McCloskey, E. (2012) ‘A systematic review of hip fracture 
incidence and probability of fracture worldwide’, Osteoporosis International, 23(9), 
pp. 2239–56. doi: 10.1007/s00198-012-1964-3. 
Kannegaard, P. N. et al. (2010) ‘Excess mortality in men compared with women fol-
lowing a hip fracture. National analysis of comedications, comorbidity and 
survival.’, Age and ageing, 39(2), pp. 203–9. doi: 10.1093/ageing/afp221. 
Kassebaum, N. J. et al. (2016) ‘Global, regional, and national disability-adjusted life-
years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 
1990–2015: a systematic analysis for the Global Burden of Disease Study 2015’, 
The Lancet. Elsevier, 388(10053), pp. 1603–1658.   
doi: 10.1016/S0140-6736(16)31460-X. 
71 
Kerr, C. et al. (2017) ‘The importance of physical function to people with osteoporosis’, 
Osteoporosis International 28(5), pp.1597–1607  
doi: 10.1007/s00198-017-3911-9. 
Klabunde, C. N. et al. (2000) ‘Development of a comorbidity index using physician 
claims data’, Journal of Clinical Epidemiology, 53(12), pp. 1258–1267.   
doi: 10.1016/S0895-4356(00)00256-0. 
Klop, C. et al. (2014) ‘Mortality in British hip fracture patients, 2000–2010: A 
population-based retrospective cohort study’, Bone, 66, pp. 171–177.   
doi: 10.1016/j.bone.2014.06.011. 
Klop, C. et al. (2017) ‘The epidemiology of mortality after fracture in England: 
variation by age, sex, time, geographic location, and ethnicity’, Osteoporosis 
International. Springer London, 28(1), pp. 161–168. doi: 10.1007/s00198-016-3787-0. 
Klotzbuecher, C. M. et al. (2010) ‘Patients with Prior Fractures Have an Increased Risk 
of Future Fractures: A Summary of the Literature and Statistical Synthesis’, Journal 
of Bone and Mineral Research, 15(4), pp. 721–739.   
doi: 10.1359/jbmr.2000.15.4.721. 
Knies, S. et al. (2009) ‘Utilities of the EQ-5D: transferable or not?’, PharmacoEco-
nomics, 27(9), pp. 767–79. doi: 10.2165/11314120. 
Knol, M. J. and VanderWeele, T. J. (2012) ‘Recommendations for presenting analyses 
of effect modification and interaction’, International Journal of Epidemiology, 
41(2), pp. 514–520. doi: 10.1093/ije/dyr218. 
Korhonen, N. et al. (2013) ‘Continuous decline in incidence of hip fracture: nationwide 
statistics from Finland between 1970 and 2010.’, Osteoporosis international : a 
journal established as result of cooperation between the European Foundation for 
Osteoporosis and the National Osteoporosis Foundation of the USA, 24(5), pp. 
1599–603. doi: 10.1007/s00198-012-2190-8. 
Kuchuk, N. O. et al. (2009) ‘Vitamin D status, parathyroid function, bone turnover, and 
BMD in postmenopausal women with osteoporosis: global perspective.’, Journal of 
bone and mineral research : the official journal of the American Society for Bone 
and Mineral Research, 24(4), pp. 693–701. doi: 10.1359/jbmr.081209. 
Kull, M. et al. (2009) ‘Seasonal variance of 25-(OH) vitamin D in the general popu-
lation of Estonia, a Northern European country.’, BMC public health, 9(1), p. 22. 
doi: 10.1186/1471-2458-9-22. 
Kurtinaitis, J. et al. (2012) ‘Mortality after femoral neck fractures: a two-year follow-
up.’, Medicina (Kaunas, Lithuania), 48(3), pp. 145–9. (Accessed: 6 March 2015). 
Laius, O. et al. (2017) ‘Trends in and relation between hip fracture incidence and 
osteoporosis medication utilization and prices in Estonia in 2004–2015’, Archives of 
Osteoporosis. Archives of Osteoporosis, 12(1), p. 48.   
doi: 10.1007/s11657-017-0341-4. 
Lambrelli, D. et al. (2014) ‘Retrospective database study to assess the economic impact 
of hip fracture in the United Kingdom’, Journal of Medical Economics, 17(11), pp. 
817–825. doi: 10.3111/13696998.2014.959588. 
Larg, A. and Moss, J. R. (2011) ‘Cost-of-Illness Studies’, PharmacoEconomics. 
Springer International Publishing, 29(8), pp. 653–671. doi: 10.2165/11588380. 
Larg, A. and Moss, J. R. (2011) ‘Cost-of-illness studies: a guide to critical evaluation.’, 
PharmacoEconomics, 29(8), pp. 653–71. doi: 10.2165/11588380. 
Leal, J. et al. (2006) ‘Economic burden of cardiovascular diseases in the enlarged 
European Union’, European Heart Journal, 27(13), pp. 1610–1619.   
doi: 10.1093/eurheartj/ehi733. 
72 
Leal, J. et al. (2016) ‘Impact of hip fracture on hospital care costs: a population-based 
study’, Osteoporosis International, 27(2), pp. 549–558.   
doi: 10.1007/s00198-015-3277-9. 
LeBlanc, E. S. et al. (2011) ‘Hip Fracture and Increased Short-term but Not Long-term 
Mortality in Healthy Older Women’, Archives of Internal Medicine. American 
Medical Association, 171(20), p. 1831. doi: 10.1001/archinternmed.2011.447. 
Lesnyak, O. et al. (2012) ‘Epidemiology of fracture in the Russian Federation and the 
development of a FRAX model.’, Archives of osteoporosis, 7(1–2), pp. 67–73.   
doi: 10.1007/s11657-012-0082-3. 
Lips, P. and van Schoor, N. M. (2005) ‘Quality of life in patients with osteoporosis’, 
Osteoporosis International. Springer-Verlag, 16(5), pp. 447–455.   
doi: 10.1007/s00198-004-1762-7. 
Lix, L., Azimaee, M. and Osman, B. (2012) ‘Osteoporosis-related fracture case 
definitions for population-based administrative data’, BMC Public Health, 12(1), 
p. 301. (Accessed: 5 February 2014). 
Lucas, R. et al. (2017) ‘Quantitative modelling of hip fracture trends in 14 European 
countries: testing variations of a shared reversal over time’, Scientific reports. 
Nature Publishing Group, 7(1), p. 3754. doi: 10.1038/s41598-017-03847-x. 
Luengo-Fernandez, R. et al. (2013) ‘Economic burden of cancer across the European 
Union: a population-based cost analysis’, The Lancet Oncology, 14(12), pp. 1165–
1174. doi: 10.1016/S1470-2045(13)70442-X. 
Luise, C. et al. (2008) ‘Comorbidity and mortality following hip fracture: a population-
based cohort study.’, Aging clinical and experimental research, 20(5), pp. 412–8. 
doi: 10.1007/BF03325146. 
Lüthje, P. et al. (2014) ‘An 8-year follow-up study of 221 consecutive hip fracture 
patients in Finland: analysis of reoperations and their direct medical costs’, 
Scandinavian Journal of Surgery, 103(1), pp. 46–53.   
doi: 10.1177/1457496913494726. 
Magaziner, J. et al. (1997) ‘Excess mortality attributable to hip fracture in white women 
aged 70 years and older’, American Journal of Public Health. American Public 
Health Association, 87(10), pp. 1630–6. Available at:  
http://ajph.aphapublications.org/doi/abs/10.2105/AJPH.87.10.1630 (Accessed: 27 
February 2014). 
Maggioni, A. P. et al. (2013) ‘EUR Observational Research Programme: regional 
differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF 
Pilot)’, European Journal of Heart Failure, 15(7), pp. 808–817.   
doi: 10.1093/eurjhf/hft050. 
Maravic, M. et al. (2011) ‘Change in hip fracture incidence over the last 6 years in 
France.’, Osteoporosis international : a journal established as result of cooperation 
between the European Foundation for Osteoporosis and the National Osteoporosis 
Foundation of the USA, 22(3), pp. 797–801. doi: 10.1007/s00198-010-1255-9. 
Marques, A. et al. (2015) ‘The burden of osteoporotic hip fractures in Portugal: costs, 
health related quality of life and mortality.’, Osteoporosis International. Springer 
London, 26(11), pp. 2623–2630. doi: 10.1007/s00198-015-3171-5. 
Martinez-Laguna, D. et al. (2017) ‘Excess of all-cause mortality after a fracture in type 
2 diabetic patients: a population-based cohort study’, Osteoporosis International  
28(9), pp. 2573–2581. doi: 10.1007/s00198-017-4096-y. 
73 
Mckenna, M. T. et al. (2005) ‘Assessing the Burden of Disease in the United States 
Using Disability-Adjusted Life Years’, Am J Prev Med, 28(5), pp. 415–423.   
doi: 10.1016/j.amepre.2005.02.009. 
Melton, L. J. et al. (1997) ‘Fractures attributable to osteoporosis: report from the 
National Osteoporosis Foundation.’, J. Bone Miner. Res., 12(1), pp. 16–23.   
doi: 10.1359/jbmr.1997.12.1.16. 
Melton, L. J. (2003) ‘Adverse outcomes of osteoporotic fractures in the general popu-
lation.’, Journal of bone and mineral research: the official journal of the American 
Society for Bone and Mineral Research, 18(6), pp. 1139–41.   
doi: 10.1359/jbmr.2003.18.6.1139. 
Melton, L. J. et al. (2014) ‘Predictors of excess mortality after fracture: A population-
based cohort study’, Journal of Bone and Mineral Research, 29(7), pp. 1681–1690. 
doi: 10.1002/jbmr.2193. 
Michaëlsson, K. et al. (2014) ‘Impact of hip fracture on mortality: a cohort study in hip 
fracture discordant identical twins.’, Journal of bone and mineral research : the 
official journal of the American Society for Bone and Mineral Research, 29(2), pp. 
424–31. doi: 10.1002/jbmr.2029. 
Ministry of Social Affairs (2015) Social services. Available at: http://www.sm.ee/en 
(Accessed: 11 March 2016). 
Murray, C. J. L. et al. (2012) ‘GBD 2010: design, definitions, and metrics.’, Lancet 
(London, England). Elsevier, 380(9859), pp. 2063–6.   
doi: 10.1016/S0140-6736(12)61899-6. 
Murray, C. J. L. et al. (2015) ‘Global, regional, and national disability-adjusted life 
years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 
188 countries, 1990–2013: quantifying the epidemiological transition’, The Lancet. 
Elsevier, 386(10009), pp. 2145–2191. doi: 10.1016/S0140-6736(15)61340-X. 
Männik, A., Pisarev, H. and Kiivet, R.-A. (2015) ‘Type II Diabetes Complications’ Cost 
in Estonia’, Value in Health, 18, p. A603. doi: 10.1016/j.jval.2015.09.2076. 
National Institute for Health Development (2017) Health statistics. Available at: 
http://www.tai.ee/en/r-and-d/health-statistics (Accessed: 20 June 2017). 
Neuhaus, V. et al. (2013) ‘Charlson comorbidity indices and in-hospital deaths in 
patients with hip fractures.’, Clinical orthopaedics and related research, 471(5), pp. 
1712–9. doi: 10.1007/s11999-012-2705-9. 
Nieves, J. W. et al. (2010) ‘Fragility fractures of the hip and femur: incidence and 
patient characteristics.’, Osteoporosis international : a journal established as result 
of cooperation between the European Foundation for Osteoporosis and the National 
Osteoporosis Foundation of the USA, 21(3), pp. 399–408. doi: 10.1007/s00198-009-
0962-6. 
Nilson, F. et al. (2013) ‘Trends in hip fracture incidence rates among the elderly in 
Sweden 1987–2009.’, Journal of public health (Oxford, England), 35(1), pp. 125–
31. doi: 10.1093/pubmed/fds053. 
Nordentoft, M. et al. (2013) ‘Excess Mortality, Causes of Death and Life Expectancy in 
270,770 Patients with Recent Onset of Mental Disorders in Denmark, Finland and 
Sweden’, PLoS ONE, 8(1), p. e55176. doi: 10.1371/journal.pone.0055176. 
Nurmi, I. et al. (2003) ‘Cost analysis of hip fracture treatment among the elderly for the 
public health services: a 1-year prospective study in 106 consecutive patients.’, 
Archives of orthopaedic and trauma surgery, 123(10), pp. 551–4.   
doi: 10.1007/s00402-003-0583-z. 
74 
OECD (2017) ‘National Accounts of OECD Countries, Volume 2016 Issue 2’. OECD 
Publishing (National Accounts of OECD Countries), p. 340.   
doi: 10.1787/na_ma_dt-v2016-2-en. 
Olesen, J. et al. (2012) ‘The economic cost of brain disorders in Europe’, European 
Journal of Neurology, 19(1), pp. 155–162. doi: 10.1111/j.1468-1331.2011.03590.x. 
Omsland, T. K. et al. (2014) ‘Mortality following the first hip fracture in Norwegian 
women and men (1999–2008). A NOREPOS study.’, Bone, 63C, pp. 81–86.   
doi: 10.1016/j.bone.2014.02.016. 
Osnes, E. K. K. et al. (2004) ‘Consequences of hip fracture on activities of daily life and 
residential needs.’, Osteoporosis international : a journal established as result of 
cooperation between the European Foundation for Osteoporosis and the National 
Osteoporosis Foundation of the USA. Springer-Verlag, 15(7), pp. 567–574.  
doi: 10.1007/s00198-003-1583-0. 
Padrón-Monedero, A. et al. (2017) ‘Effect of comorbidities on the association between 
age and hospital mortality after fall-related hip fracture in elderly patients’, 
Osteoporosis International 28(5),  pp. 1–10.   
doi: 10.1007/s00198-017-3926-2. 
Papadimitriou, N. et al. (2017) ‘Burden of hip fracture using disability-adjusted life-
years: a pooled analysis of prospective cohorts in the CHANCES consortium’, The 
Lancet Public Health. doi: 10.1016/S2468-2667(17)30046-4. 
Peasgood, T. et al. (2009) ‘An updated systematic review of Health State Utility Values 
for osteoporosis related conditions.’, Osteoporosis international : a journal estab-
lished as result of cooperation between the European Foundation for Osteoporosis 
and the National Osteoporosis Foundation of the USA, 20(6), pp. 853–68.   
doi: 10.1007/s00198-009-0844-y. 
Péntek, M. et al. (2008) ‘Epidemiology of osteoporosis related fractures in Hungary 
from the nationwide health insurance database, 1999–2003.’, Osteoporosis 
international : a journal established as result of cooperation between the European 
Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 
19(2), pp. 243–9. doi: 10.1007/s00198-007-0453-6. 
Petit, M.-P. et al. (2017) ‘Hip fracture incidence and social deprivation: results from a 
French ecological study’, Osteoporosis International. Springer London, 28(7), pp. 
2045–2051. doi: 10.1007/s00198-017-3998-z. 
Piscitelli, P. et al. (2013) ‘Updated fracture incidence rates for the Italian version of 
FRAX®.’, Osteoporosis international : a journal established as result of coope-
ration between the European Foundation for Osteoporosis and the National 
Osteoporosis Foundation of the USA, 24(3), pp. 859–66.   
doi: 10.1007/s00198-012-2021-y. 
Popova, S. et al. (2007) ‘Comparing alcohol consumption in central and eastern Europe 
to other European countries.’, Alcohol and alcoholism (Oxford, Oxfordshire), 42(5), 
pp. 465–73. doi: 10.1093/alcalc/agl124. 
Quan, H. et al. (2005) ‘Coding algorithms for defining comorbidities in ICD-9-CM and 
ICD-10 Administrative Data’, Medical care, 43(11), pp. 1130–1139. (Accessed: 4 
July 2014). 
Quan, H. et al. (2011) ‘Updating and validating the Charlson comorbidity index and 
score for risk adjustment in hospital discharge abstracts using data from 6 
countries.’, American journal of epidemiology, 173(6), pp. 676–82.   
doi: 10.1093/aje/kwq433. 
75 
R Core Team (2015) ‘R: The R Project for Statistical Computing’, R Foundation for 
Statistical Computing, Vienna, Austria. Available at: https://www.r-project.org/ 
(Accessed: 22 March 2016). 
Radley, D. C. et al. (2008) ‘Comorbidity risk-adjustment strategies are comparable 
among persons with hip fracture.’, Journal of clinical epidemiology, 61(6), pp. 580–
7. doi: 10.1016/j.jclinepi.2007.08.001. 
Rapp, K. et al. (2008) ‘Hip Fractures in Institutionalized Elderly People: Incidence 
Rates and Excess Mortality’, Journal of Bone and Mineral Research. John Wiley 
and Sons and The American Society for Bone and Mineral Research (ASBMR), 
23(11), pp. 1825–1831. doi: 10.1359/jbmr.080702. 
Ray, R. et al. (2016) ‘High mortality in younger patients with major osteoporotic 
fractures’, Osteoporosis International 28(3),pp. 1047–1052. doi: 10.1007/s00198-
016-3827-9. 
Roche, J. J. W. et al. (2005) ‘Effect of comorbidities and postoperative complications 
on mortality after hip fracture in elderly people: prospective observational cohort 
study.’, BMJ (Clinical research ed.), 331(7529), p. 1374.   
doi: 10.1136/bmj.38643.663843.55. 
Romero-Ortuno, R. and Kenny, R. A. (2012) ‘The frailty index in Europeans: asso-
ciation with age and mortality.’, Age and ageing. Oxford University Press, 41(5), pp. 
684–9. doi: 10.1093/ageing/afs051. 
Rosengren, B. E. et al. (2017) ‘Recent hip fracture trends in Sweden and Denmark with 
age-period-cohort effects’, Osteoporosis International 28(1),pp. 139–149. doi: 
10.1007/s00198-016-3768-3. 
Roux, C. and Briot, K. (2017) ‘Imminent fracture risk’, Osteoporosis International 
28(6), pp.1765-1769.. doi: 10.1007/s00198-017-3976-5. 
Rubin, D. B. (1987) Multiple Imputation for Nonresponse in Surveys. Wiley-Inter-
science. doi: 10.1002/9780470316696. 
Ryg, J. et al. (2009) ‘Hip fracture patients at risk of second hip fracture: a nationwide 
population-based cohort study of 169,145 cases during 1977–2001.’, Journal of 
bone and mineral research : the official journal of the American Society for Bone 
and Mineral Research, 24(7), pp. 1299–307. doi: 10.1359/jbmr.090207. 
Sabre, L. et al. (2012) ‘High incidence of traumatic spinal cord injury in Estonia.’, 
Spinal cord. International Spinal Cord Society, 50(10), pp. 755–9.   
doi: 10.1038/sc.2012.54. 
Salkeld, G. et al. (2000) ‘Quality of life related to fear of falling and hip fracture in 
older women: a time trade off studyCommentary: Older people’s perspectives on life 
after hip fractures’, BMJ, 320(7231). 
Salomon, J. A. et al. (2015) ‘Disability weights for the Global Burden of Disease 2013 
study.’, The Lancet. Global health. Elsevier, 3(11), pp. e712–23.   
doi: 10.1016/S2214-109X(15)00069-8. 
Sassi, F. (2006) ‘Calculating QALYs, comparing QALY and DALY calculations.’, 
Health policy and planning, 21(5), pp. 402–8. doi: 10.1093/heapol/czl018. 
Scandol, J. P., Toson, B. and Close, J. C. T. (2013) ‘Fall-related hip fracture hospi-
talisations and the prevalence of dementia within older people in New South Wales, 
Australia: An analysis of linked data’, Injury. Elsevier Ltd, 44(6), pp. 776–783.   
doi: 10.1016/j.injury.2012.11.023. 
Sebestyén, A. et al. (2008) ‘[Correlation between risk factors and mortality in elderly 
patients with femoral neck fracture with 5-year follow-up].’, Orvosi hetilap, 
149(11), pp. 493–503. doi: 10.1556/OH.2008.28228. 
76 
Shkolnikov, V., Barbieri, M. and Wilmoth, J. (2013) The Human Mortality Database. 
Available at: http://www.mortality.org/ (Accessed: 22 May 2017). 
Si, L. et al. (2014) ‘A systematic review and meta-analysis of utility-based quality of 
life for osteoporosis-related conditions.’, Osteoporosis international: a journal 
established as result of cooperation between the European Foundation for Osteo-
porosis and the National Osteoporosis Foundation of the USA. doi: 10.1007/s00198-
014-2636-2. 
Siggeirsdottir, K. et al. (2014) ‘Epidemiology of fractures in Iceland and secular trends 
in major osteoporotic fractures 1989–2008.’, Osteoporosis international : a journal 
established as result of cooperation between the European Foundation for 
Osteoporosis and the National Osteoporosis Foundation of the USA, 25(1), pp. 211–
9. doi: 10.1007/s00198-013-2422-6. 
Singer, A. et al. (2015) ‘Burden of illness for osteoporotic fractures compared with 
other serious diseases among postmenopausal women in the United States’, Mayo 
Clinic Proceedings. Elsevier Inc, 90(1), pp. 53–62.   
doi: 10.1016/j.mayocp.2014.09.011. 
Singer, B. R. et al. (1998) ‘Epidemiology of fractures in 15 000 adults: The influence of 
age and gender, J Bone Joint Surg Br, 80–B(2), pp. 243–248. (Accessed: 22 
February 2014). 
Sjölander, A. and Greenland, S. (2013) ‘Ignoring the matching variables in cohort 
studies – When is it valid and why?’, Statistics in Medicine, 32(27), pp. 4696–4708. 
doi: 10.1002/sim.5879. 
Smith, T. et al. (2014) ‘Pre-operative indicators for mortality following hip fracture 
surgery: A systematic review and meta-analysis’, Age and Ageing, 43(4), pp. 464–
71. doi: 10.1093/ageing/afu065. 
Smolderen, K. G. et al. (2017) ‘Depression Treatment and 1-Year Mortality Following 
Acute Myocardial Infarction: Insights from the TRIUMPH Registry’, Circulation. 
Available at: http://circ.ahajournals.org/content/early/2017/02/16/  
CIRCULATIONAHA.116.025140.short (Accessed: 16 June 2017). 
Solbakken, S. M. et al. (2017) ‘Excess mortality following hip fracture: impact of self-
perceived health, smoking, and body mass index. A NOREPOS study’, Osteoporosis 
International28(3), pp. 881–887. doi: 10.1007/s00198-016-3795-0. 
Szende, A., Oppe, M. and Devlin, N. (2007) EQ-5D Value Sets. Dordrecht: Springer 
Netherlands (EuroQol Group Monographs). doi: 10.1007/1-4020-5511-0. 
Statistics Estonia (2015a) Estonian consumer price index. Available at:  
https://www.stat.ee/stat-consumer-price-index-change (Accessed: 20 June 2017). 
Statistics Estonia (2015b) Migration. Available at: https://www.stat.ee/database 
(Accessed: 20 June 2017). 
Statistics Estonia (2015c) Population by sex and age group. Available at:  
https://www.stat.ee/database (Accessed: 17 May 2017). 
Statistics Estonia (2016) Main demographic indicators. Available at:  
https://www.stat.ee/database (Accessed: 20 June 2017). 
Stepan, J. J. et al. (2012) ‘Hip fracture incidence from 1981 to 2009 in the Czech 
Republic as a basis of the country-specific FRAX model.’, Calcified tissue 
international. Springer-Verlag, 90(5), pp. 365–72. doi: 10.1007/s00223-012-9582-9. 
Støen, R. O. et al. (2012) ‘Hip fracture incidence is decreasing in the high incidence 
area of Oslo, Norway.’, Osteoporosis international : a journal established as result 
of cooperation between the European Foundation for Osteoporosis and the National 
77 
Osteoporosis Foundation of the USA, 23(10), pp. 2527–34.   
doi: 10.1007/s00198-011-1888-3. 
Ström, O. et al. (2011) ‘Osteoporosis: burden, health care provision and opportunities in 
the EU: a report prepared in collaboration with the International Osteoporosis 
Foundation (IOF) and the European Federation of Pharmaceutical Industry 
Associations (EFPIA).’, Archives of osteoporosis, 6(1–2), pp. 59–155.   
doi: 10.1007/s11657-011-0060-1. 
Svedbom, A. et al. (2013) ‘Osteoporosis in the European Union: a compendium of 
country-specific reports.’, Archives of osteoporosis. Springer London, 8(1–2), p. 
137. doi: 10.1007/s11657-013-0137-0. 
Tamulaitiene, M. and Alekna, V. (2012) ‘Incidence and direct hospitalisation costs of 
hip fractures in Vilnius, capital of Lithuania, in 2010.’, BMC public health, 12(1), p. 
495. doi: 10.1186/1471-2458-12-495. 
Tan-Torres Edejer, T. et al. (2003) ‘Making choices in health: WHO guide to cost-
effectivess analysis’. Edited by T. Tan-Torres Edejer, R. Baltussen, and T. Adam. 
World Health Organization. Available at: http://www.who.int/choice/book/en/ 
(Accessed: 9 April 2017). 
Tarride, J.-E. et al. (2016) ‘Loss of health related quality of life following low-trauma 
fractures in the elderly.’, BMC geriatrics. BMC Geriatrics, 16(1), p. 84. doi: 
10.1186/s12877-016-0259-5. 
Tekkel, M. and Veideman, T. (2013) Health Behaviour among Estonian Adult 
Population, Health Behaviour among Estonian Adult Population. Available at: 
https://intra.tai.ee/images/prints/documents/136479842690_TKU_2012.pdf 
(Accessed: 9 March 2014). 
Teng, G. G., Curtis, J. R. and Saag, K. G. (2008) ‘Mortality and osteoporotic fractures: 
is the link causal, and is it modifiable?’, Clinical and experimental rheumatology. 
NIH Public Access, 26(5 Suppl 51), pp. S125–37. (Accessed: 21 November 2016). 
The World Bank Group (2015) The State of Health Care Integration in Estonia. 
Available at: http://rahvatervis.ut.ee/bitstream/1/6047/1/EHK2015_ik.pdf (Accessed: 
30 July 2015). 
Thorne, K. et al. (2016) ‘The impact of social deprivation on mortality following hip 
fracture in England and Wales: a record linkage study’, Osteoporosis International 
27(9), pp. 2727–2737. doi: 10.1007/s00198-016-3608-5. 
Todd, S. et al. (2013) ‘Survival in dementia and predictors of mortality: A review’, 
International Journal of Geriatric Psychiatry, pp. 1109–1124.   
doi: 10.1002/gps.3946. 
Toson, B., Harvey, L. A. and Close, J. C. T. (2015) ‘The ICD-10 Charlson Comorbidity 
Index predicted mortality but not resource utilization following hip fracture.’, 
Journal of clinical epidemiology. Elsevier, 68(1), pp. 44–51.   
doi: 10.1016/j.jclinepi.2014.09.017. 
Tosteson, A. N. A. et al. (2001) ‘Impact of hip and vertebral fractures on quality-
adjusted life years’, Osteoporosis International, 12(12), pp. 1042–1049.   
doi: 10.1007/s001980170015. 
Tosteson, A. N. A. et al. (2007) ‘Excess mortality following hip fracture: the role of 
underlying health status.’, Osteoporosis international : a journal established as 
result of cooperation between the European Foundation for Osteoporosis and the 
National Osteoporosis Foundation of the USA, 18(11), pp. 1463–72.   
doi: 10.1007/s00198-007-0429-6. 
78 
UN (2015) United Nations Department of Economic and Social Affairs Population 
Division. World Population Prospects: The 2015 Revision, custom data acquired via 
website. Available at: https://esa.un.org/unpd/wpp/DataQuery/ (Accessed: 30 
December 2016). 
Wahl, D. A. et al. (2012) ‘A global representation of vitamin D status in healthy 
populations.’, Archives of osteoporosis, 7(1–2), pp. 155–72.   
doi: 10.1007/s11657-012-0093-0. 
Walters, S. J. (2009) Quality of Life Outcomes in Clinical Trials and Health-Care 
Evaluation: A Practical Guide to analysis and interpretation. University of 
Sheffield: John Wiley & Sons, Ltd. 
Wang, H. et al. (2016) ‘Global, regional, and national life expectancy, all-cause 
mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a 
systematic analysis for the Global Burden of Disease Study 2015’, The Lancet. 
Elsevier, 388(10053), pp. 1459–1544. doi: 10.1016/S0140-6736(16)31012-1. 
Wehren, L. E. et al. (2003) ‘Gender Differences in Mortality After Hip Fracture: The 
Role of Infection’, Journal of Bone and Mineral Research. John Wiley and Sons and 
The American Society for Bone and Mineral Research (ASBMR), 18(12), pp. 2231–
2237. doi: 10.1359/jbmr.2003.18.12.2231. 
Weinstein, M. C., Torrance, G. and Mcguire, A. (2009) ‘QALYs: The Basics’, Value in 
Health, 12(s1), pp. S5–S9. doi: 10.1111/j.1524-4733.2009.00515.x. 
Vestergaard, P., Rejnmark, L. and Mosekilde, L. (2007) ‘Increased mortality in patients 
with a hip fracture-effect of pre-morbid conditions and post-fracture complications.’, 
Osteoporosis International, 18(12), pp. 1583–93. doi: 10.1007/s00198-007-0403-3. 
WHO (2015) World (WHO 2000–2025) Standard Populations – SEER Datasets. 
Available at: http://seer.cancer.gov/stdpopulations/world.who.html (Accessed: 17 
May 2017). 
Wickham, H. (2009) ggplot2: Elegant Graphics for Data Analysis. Springer. 
Wickham, H. and Francois, R. (2016) ‘A Grammar of Data Manipulation. R package 
dplyr version 0.5.0.’ Comprehensive R Archive Network (CRAN). Available at: 
https://cran.r-project.org/package=dplyr (Accessed: 9 March 2017). 
Wilk, R. et al. (2013) ‘Standardized incidence and trend of osteoporotic hip fracture in 
Polish women and men: A nine year observation.’, Maturitas. Elsevier, 77(1), pp. 
59–63. doi: 10.1016/j.maturitas.2013.09.004. 
Wimo, A. et al. (2011) ‘The economic impact of dementia in Europe in 2008-cost 
estimates from the Eurocode project’, International Journal of Geriatric Psychiatry, 
26(8), pp. 825–832. doi: 10.1002/gps.2610. 
Vois, K. (2015) Parkinsoni tõve haiguskulusid Eesti ühiskonnale. Tartu Ülikool. 
Available at: http://rahvatervis.ut.ee/handle/1/6224 (Accessed: 28 May 2017). 
Wood, S. N. (2003) ‘Thin plate regression splines’, Journal of the Royal Statistical 
Society: Series B (Statistical Methodology), 65(1), pp. 95–114.   
doi: 10.1111/1467-9868.00374. 
World Bank (2008) Global Purchasing Power Parities and Real Expenditures, 2005 
International Comparison Program. doi: 10.1787/9789264022171-ja. 
Xue, Q.-L. (2011) ‘The frailty syndrome: definition and natural history.’, Clinics in 
geriatric medicine. NIH Public Access, 27(1), pp. 1–15.   
doi: 10.1016/j.cger.2010.08.009. 
Yiannopoulou, K. G. et al. (2012) ‘Prevalence of dementia in elderly patients with hip 
fracture.’, Hip international : the journal of clinical and experimental research on 
hip pathology and therapy, 22(2), pp. 209–13. doi: 10.5301/HIP.2012.9229. 
79 
8. SUMMARY IN ESTONIAN 
Reieluukaela murru tervise- ja majandusmõju Eestis 
Reieluukaela murd kui rahvatervise probleem 
Reieluukaela murd vanemas eas on üks olulistest rahvatervise probleemidest 
(Kanis et al., 2013). Reieluukaela murd on enamasti luuhõrenemisest tingitud 
haprusmurd, mis tekib kukkumisel seisvast asendist ilma olulise traumata 
(Hernlund et al., 2013). Reieluukaela murruga kaasnevad lühi- ja pikaajalised 
vaevused, tegevuspiirangud, elukvaliteedi langus ja suur suremus (Teng, Curtis 
and Saag, 2008). Arenenud maades saab iga kuues üle 50-aastane naine eluea 
jooksul reieluukaela murru (Kanis et al., 2013) ning sellega seotud haiglaravi 
kulud on võrreldavad müokardi infarkti või insuldi vastavate ravikuludega 
(Singer et al., 2015). Kuni 20% haigetest sureb aasta jooksul peale murdu 
(Abrahamsen and Vestergaard, 2010; Haentjens et al., 2010). Seega ületab 
reieluukaela murruga haigete ühe aasta suremus üldsuremuse 3–4-kordselt 
(Abrahamsen et al., 2009; Haentjens et al., 2010) ja on võrreldav suremusega 
metastaatilise vähi või dementsuse korral (Quan et al., 2011; Todd et al., 2013). 
Murrueelne elukvaliteet taastub vähem kui pooltel haigetest (Melton, 2003). 
Reieluukaela murruga seotud tervisekaotust ≥50-aastastel on hinnatud mo-
delleerimise teel (Ström et al., 2011; Hernlund et al., 2013; Svedbom et al., 
2013). Reieluukaela murru esmasjuhtude arvuks Euroopas on hinnatud 615 000 
aastas ja murruga haigete koguarvuks 3,3 miljonit. Murruga seotud kogukulu on 
hinnanguliselt 20 miljardit eurot aastas. Seega on reieluukaela murru kogukulu 
võrreldav kopsuvähi (19 miljardit), rinnavähi (15 miljardit) (Luengo-Fernandez 
et al., 2013) ja insuldi (27–64 miljardit) kogukuluga (Gustavsson et al., 2011; 
DiLuca and Olesen, 2014).  
Reieluukaela murru alane haigusteadlikkus on seni piiratud ning riski-
gruppide määratlemine keeruline (Harvey et al., 2017), samuti on tervisekaotuse 
hinnangutes palju ebaselget. Esmashaigestumus Euroopa riikides varieerub, 
kuid erinevuse põhjused ei ole lõpuni selged. Reieluukaela murruga seotud 
kulud suurenevad, kuid andmed kulude ja tervishoiu- ja sotsiaalteenuste kasu-
tuse kohta on puudulikud (Hernlund et al., 2013). Lisaks esineb Euroopas olu-
lisi erinevusi tervishoiuteenuste ja sotsiaalabi kättesaadavuses ja kasutuses 
(Hernlund et al., 2013; Svedbom et al., 2013). Kaasuvate haiguste mõju 
reieluukaela murruga seotud liigsuremusele ei ole lõpuni selge (Abrahamsen et 
al., 2009). 
Eestis esineb hinnanguliselt 1600 reieluukaela esmasmurdu aastas ja murruga 
haigete üldarv on 7300 (Hernlund et al., 2013; Svedbom et al., 2013). Esimese 
murrujärgse aasta kogukuluks on hinnanguliselt 5580 eurot haige kohta ja ühis-
kondlik kogukulu ulatub 15 miljoni euroni (12 eurot inimese kohta) aastas. 
Eeldatakse kulude 17%-list tõusu järgneva kümnendi jooksul (Hernlund et al., 
2013; Svedbom et al., 2013). Samas ei ole olemasolevad epidemioloogilised ja 
kuluandmed piisavad tervisepoliitilisteks otsusteks. Näiteks esmashaigestumust 
on hinnatud piirkondliku uuringu (Haviko, Maasalu and Seeder, 1996) ja 
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Soome vastavate andmete põhjal (Svedbom et al., 2013), suremuse hindamisel 
on lähtutud Rootsi andmetest (Kanis et al., 2003; Johnell et al., 2004; 
Borgström et al., 2007), elukvaliteedi hinnangud põhinevad teaduskirjanduse 
süstemaatilisel ülevaatel (Peasgood et al., 2009). Tervishoiuteenuste kasutus ja 
kulud on ekstrapoleeritud Soome ja Rootsi uuringutest (Nurmi et al., 2003; 
Borgström et al., 2006; World Bank, 2008).  
Käesolev uurimistöö käsitleb reieluukaela murru tervise- ja majandusmõju 
Eestis, et võimaldada reieluukaela murruga seotud summaarse tervisekaotuse 
hindamist ühiskonnas ja prognoosida selle muutusi ajas. Tervisekaotuse hinda-
mine aitab parandada haigusteadlikkust (Kanis et al., 2013; Harvey et al., 
2017). Uuringu tulemuste põhjal saab täpsemalt määratleda sihtrühmad reie-
luukaela murru ja murruga seotud suremuse vähendamiseks, kirjeldada ravi- ja 
sotsiaalteenuste kasutust ja teha informeeritud tervise- ja sotsiaalpoliitilised 
otsused. Tulemusi saab kasutada ka reieluukaela murru ennetus- ja ravimeet-
mete kulutõhususe hindamisel. Teadaolevalt on tegemist esimese tervikliku 
reieluukaela murru tervise- ja majandusmõju hindamisega Kesk- ja Ida-Euroopas.  
 
Uurimistöö eesmärgid 
Doktoritöö üldeesmärk oli reieluukaela murruga seotud tervise- ja majandus-
mõju hindamine ≥50-aastastel inimestel Eestis 2005–2016 aastal. Alaeesmärki-
deks oli: 
1. Hinnata reieluukaela murru avaldumust (I publikatsioon);   
2. Hinnata reieluukaela murruga seotud elukvaliteedi kaotust 18 kuu jooksul 
pärast murdu (II, V ja VI publikatsioon); 
3. Hinnata reieluukaela murruga seotud ressursikasutust ja kogukulu 18 kuu 
jooksul pärast murdu (II publikatsioon); 
4. Hinnata reieluukaela murruga seotud liigsuremust 10 aasta jooksul pärast 
murdu (III publikatsioon); 





(i) Eesti Haigekassa andmebaas soo, vanuse, diagnooside, tervishoiuteenuste 
kasutuse ja kulude, ravimikasutuse, surma kohta (kõik alaeesmärgid);  
(ii) Reieluukaela murruga haigete standardiseeritud intervjuud sotsiaaldemo-
graafiliste näitajate, elukvaliteedi ja kulude hindamiseks (2. ja 3. alaeees-
märk);  
(iii) Statistika andmebaas rahvastiku vanuselise ja soolise jaotuse kohta (1., 4. 
ja 5. alaeesmärk).  
Reieluukaela murru avaldumuse hindamiseks kasutati ökoloogilise uuringu 
meetodit (I publikatsioon). Teostati andmepäring Haigekassa andmebaasist kõigi 
≥50-aastaste reieluukaela murruga hospitaliseeritud haigete kohta aastatel 
2005–2012. Juhu definitsioon põhines reieluukaela murru diagnoosi koodidel 
(S72.0-S72.2 põhi- või kaasuva haigusena) Haigekassale esitatud raviarvetel. 
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Vaadeldava kaheksa aasta (2005–2012) jooksul dokumenteeriti 10704 reieluu-
kaela murru esmasjuhtu. Hinnati tooravaldumust, vanusespetsiifilist ja vanusele 
standarditud avaldumust, samuti avaldumuse muutust uuringu perioodil.  
Reieluukaela murruga seotud elukvaliteedi kaotust ja kogukulu hinnati 
prospektiivses kohortuuringus kahes Eesti haiglas ravitud patsientidel (II, V ja 
VI publikatsioon). Mugavusvalimi moodustasid 205 ≥ 50-aastast reieluukaela 
murruga haiget Tartu Ülikooli Kliinikumi (TÜK) ja Ida-Tallinna Keskhaigla 
(ITK) traumatoloogia ja ortopeedia osakondadest aastatel 2010–2012. Uuringus 
hinnati haigete elukvaliteeti, murruga seotud ressursikasutust ja kulu (tervis-
hoiuteenused, sotsiaalabi, lähedaste abi, kaudsed kulud) uuringusse kaasamisel 
ning kolmel korral 18 kuu jooksul pärast murdu. Nimetatud uuring viidi läbi 
rahvusvahelise uuringu International Costs and Utilities Related to Osteoporotic 
Fractures Study (ICUROS) osana, milles osales 52 haiglat 11-st riigist. 
Liigsuremust hinnati rahvastikupõhises retrospektiivses kohortuuringus (III 
publikatsioon). Võrdlusrühmadeks olid murruga patsiendid (juhud) ning viite-
rahvastikuks juhtudele vanuse ja soo järgi sobitatud (reieluu murruta) isikud. 
Kõik andmed pärinesid Haigekassa andmebaasist perioodist 2005–2013. Uuri-
misgrupi moodustas 8298 esmase reieluukaela murruga haiget ja viiterahvastiku 
33191 isikut. Murruhaigete üldsuremust võrreldi viiterahvastiku suremusega 
kuni 10 aasta jooksul. Kumulatiivset liigsuremust hinnati kohandatuna vanusele 
ja Charlsoni kaasuvate haiguste uuendatud indeksile (CCI) (Quan et al., 2011) 
ning kihitatuna soo ja vanuse lõikes. CCI on komposiitindeks, mis koondab 
suure suremusriskiga haigused. Kaasuvate haiguste mõju liigsuremusele hinnati 
ka eraldiseisva analüüsiga kihitamise ja kohandamise abil (IV publikatsioon).  
Uuringutel oli Tartu Ülikooli inimuuringute eetika komitee luba.  
 
Peamised tulemused ja arutelu 
Avaldumus 
Vaadeldava kaheksa uuringuaasta (2005–2012) jooksul dokumenteeriti 10704 
reieluukaela murru esmasjuhtu, millest 70% esines naistel. Valdav osa naiste 
murdudest (58%) esines üle 80-aastastel, kuid ligi pooled (43%) meeste murdu-
dest esinesid nooremates vanusrühmades (50–69 aastat). Naiste keskmine vanus 
murru tekkel oli 79,8 aastat, meestel 71,2 aastat. Murdude koguarv püsis aastate 
lõikes stabiilsena ja suurenes vaid üle 80-aastaste vanusrühmas.  
Avaldumuse toorkordaja naistel (320/100 000/aastas) oli 1,46 korda kõrgem 
kui meestel (219/100 000/aastas), kuid vanusele standardimisel avaldumuse 
sooline erinevus kadus (naistel 209, meestel 216/100 000/aastas, riskide suhe 
0,97). Alates 2009. aastast oli täheldatav avaldumuse langus naistel. Seega oli 
murdude arvu suurenemine eakatel ja toorkordajate sooline erinevus tingitud 
rahvastiku vanuselisest struktuurist ja mitte haigestumuse tõusust. Võrreldes 
teiste Euroopa riikidega oli avaldumus Eesti naistel madal (võrreldav mada-
laima avaldumusega Poola ja Rumeeniaga), kuid meestel üks kõrgematest, 
võrreldav Skandinaavia ja Venemaaga. Naiste madal avaldumus tulenes eeskätt 
eakate (80+) suhteliselt madalast haigestumusest. Võimalike kaitsvate tegu-
ritena eakatel võib välja tuua ülekaalu ja madala suitsetamise levimuse, samuti 
82 
madala sotsiaalmajandusliku staatusega seostuva intensiivse füüsilise töö elu 
jooksul. Avaldumuse languse, mida on viimasel kümnendil täheldatud ena-
muses arenenud riikides, võimalike põhjustena võib välja tuua kukkumisriski 
vähenemise seoses terviseseisundi üldise paranemise ja linnastumisega, samuti 
kehakaalu tõusu ning paranenud diagnostika ja ravi võimalused. Meeste kõrge 
avaldumuse põhjuseks nooremates vanusrühmades (50–69 aastat) võivad 
sarnaselt Venemaaga olla alkoholi liigtarbimisega seotud traumad.  
 
Tervisega seotud elukvaliteet, ressursikasutus ja kulud 
Uuringu valimi moodustas 205 haiget (27% kõigist uuringuperioodil TÜK-i ja 
ITK-sse hospitaliseeritud reieluukaela murruga haigetest). Elukvaliteedi hin-
nang enne murdu oli 0,67, mis oli võrreldes kõigi osalevate riikide keskmisega 
(0,77) suhteliselt madal. Murrujärgne elukvaliteet oli ülimadal (0,07) ehk lähe-
dane surmale. Taastumine oli Eestis aeglasem kui võrdlusriikides ning murru-
eelse elukvaliteedi saavutas vaid alla poolte uuritavatest. Uuringus leidis kinni-
tust, et reieluukaela murru mõju elukvaliteedile on suur.  
Arvestades võimalikku selektsiooninihet võib tegelik elukvaliteet reieluu-
kaela murru korral olla veelgi madalam. Võrdlusel uuringusse mittekaasatud 
haigetega selgus, et uuritavad olid 1,7 aastat nooremad ja tervemad (CCI uurita-
vatel 1,1, uuringusse mittekaasatuil 1,5; 18 kuu suremusmäär vastavalt 53/1000 
(95% CI 32–115) ja 90/1000 (95% CI 60–130)). Seega olid uuringusse kaasatud 
haiged keskmisest nooremad ja tervemad, kelle elukvaliteet võis olla parem kui 
keskmisel haiglates ravitud reieluukaela murruga patsiendil. 
Tervishoiu- ja sotsiaalabi teenuste analüüsil selgus, et haiged viibisid aktiiv-
ravil traumatoloogia ja ortopeedia osakonnas keskmiselt 15 päeva ning ligi poo-
led suunati edasi õendusabi osakonda. Eriarsti- ja perearsti teenuse kasutus peale 
murdu oli võrreldav Rootsiga. Aktiivravile järgnenud taastusravi, koduõenduse 
ja sotsiaalabi kasutus oli aga väga vähene ning sellega kooskõlas elukvaliteedi 
aeglane taastumine ja piiratud toimetulek. Esimese nelja murrujärgse kuu 
jooksul sai vaid 8% haigetest statsionaarset ja 1% ambulatoorset taastusravi, 4% 
kasutas koduõendusteenust ning sotsiaaltöötaja külastas vaid kolme haiget. 
Hooldekodusse suunati 2 haiget. Üle poole (53%) haigetest kasutas analgeeti-
kume ja mittesteroidseid põletikuvastaseid aineid ning vaid 8% bisfosfonaate. 
Järgnevate kuude jooksul raviteenuste kasutus vähenes ja sotsiaalteenuste kasu-
tus oluliselt ei muutunud. Minimaalset taastusravi, õendus- ja sotsiaalabi kom-
penseeris lähedaste abi sage kasutus: 83% kasutas lähedaste abi keskmiselt 
2 tundi päevas kuni 18 kuu jooksul. Kulude hindamisel selgus, et 18 kuu kumu-
latiivne kogukulu oli 8146 eurot haige kohta, kusjuures poole (56%) moodustas 
aktiivravi ja 33% lähedaste abi, sotsiaalabi osakaal oli vaid 5%. Võimalik, et 
uuringusse mittekaasatud haigete murrujärgne ressursikasutus oli suurem. 
Uuringust selgus ka suhteliselt suur (8%) kaudse kulu osakaal, seda vaatamata 






Uurimisgrupi moodustas 8298 esmase reieluukaela murruga haiget ja viite-
rahvastiku 33191 vanusele ja soole sobitatud ilma eelneva murruta isikut. 
Reieluukaela murruga patsientidel oli rohkem kaasuvaid haigusi, kuigi erinevus 
ei olnud suur: 39%-l uuritavatest esines vähemalt üks eelnev raske haigus ja 
grupi keskmine CCI oli 0,94. Võrdlusgrupi vastavad näitajad olid 30% ja 0,66. 
Vanusele ja CCI-le kohandatud 10 aasta üldsuremus oli uurimisgrupis 77.6% 
(95% CI 76.7–78.8%) ja viiterahvastikus 56.5% (95% CI 56.0–57.3%), liigsure-
mus seega 21.1% (95% CI 20.0–22.5%). 27% ehk iga neljas surm murruhaigete 
grupis oli tingitud murrust. Liigsuremus ilmnes koheselt pärast murdu, olles 
18.9% (95% CI 18.3–19.5) juba kolm kuud pärast murdu ning püsis stabiilsena 
järgneva 10 aasta jooksul. Kuigi naised olid vanemad kui mehed (80,4 vs 72,2 
aastat) ja nende üldsuremus oli suurem, oli liigsuremus suurem meestel. Meeste 
suurema liigriski põhjused ei ole seni täiesti selged. Noorematel haigetel (50–69 
aastat) suurenes liigsuremus järk-järgult 10 aasta jooksul, seega võib reieluu-
kaela murd põhjustada pikaajalise progresseeruva surmaga lõppeva tervise-
kaotuse. Vanematel haigetel (≥ 80 aastat) esines liigsuremus aga vahetult murru 
järgselt näidates, et murd kiirendab oluliselt surma saabumist. Liigsuremus 
nooremates vanusrühmades oli Eestis ligikaudu 10% suurem kui lääneriikides, 
millel võib olla seos ebapiisava õendus- ja sotsiaalabiga. Uuringutulemused 
näitavad, et reieluukaela murd on oluline iseseisev suremuse riskifaktor ning 
suur osa murruga seotud liigsuremusest võiks olla välditav ennetuse, tüsistuste 
vältimise ja piisava murrujärgse hooldusega. 
 
Kaasuvate haiguste mõju liigsuremusele 
Sarnaselt kõrge vanusega patsientidele kiirendas murd surma saabumist ka 
raskete kaasuvate haigustega patsientidel. Kaasuvate haiguste ja liigsuremuse 
vahel esines selge annus-vastuse seos: ilma kaasuvate haigusteta (CCI 0 grupp) 
murruga seotud ühe aasta liigsuremus oli 17.1% (95% CI 16.5–17.8), CCI 1–2 
grupis 25.8% (95% CI 24.6–27.0%) ja CCI ≥3 grupis 30.3% (95% CI 28.3–
32.2%). Enamuse enamlevinud haiguste (kasvaja, kroonilise kopsuhaiguse, 
südamepuudulikkuse) korral oli liigsuremus 5–10% kõrgem kui ilma vastava 
haiguseta, kuid dementsusega haigetel oli erinevus 18%, tõenäoliselt haigete 
kõrgema vanuse (83,2 aastat) ja hapruse (kaalukaotus, nõrkus, aeglane kõnd, 
madal energiatase ja füüsiline tegevus) tõttu. Samas oli kaasuvate haiguste 
levimus suhteliselt madal ja gruppidevaheline erinevus väike, mistõttu CCI 
kohandamisel selgus, et vaid 8% reieluukaela murruga seotud liigsurmadest oli 
tingitud murrueelsetest kaasuvatest haigustest. Seega on võimalik, et kaasuvate 
haiguste mõju reieluukaela murru liigsuremusele on väike ja ei oma liigsure-




1. Vanusele standarditud reieluukaela murru avaldumus ≥ 50-aastastel Eesti 
naistel oli suhteliselt madal, kuid meestel üks Euroopa kõrgematest. Murdude 
arvu suurenemine oli tingitud rahvastiku vananemisest. Sarnaselt paljudele 
Euroopa riikidele esines ka Eestis avaldumuse langus naistel.  
2. Reieluukaela murru mõju patsiendi elukvaliteedile oli suur. Tervisega seotud 
elukvaliteet vahetult peale murdu oli vaid 7% ehk lähedane surmale. Elu-
kvaliteedi taastumine oli aeglasem kui võrdlusriikides ja vähem kui pooled 
patsiendid taastusid täielikult.  
3. Reieluukaela murru järgse eriarstiabi ja perearsti teenuse kasutus oli võrrel-
dav Rootsiga, kuid taastusravi, koduõenduse ja sotsiaalabi kasutus oli madal. 
Lähedaste abi, mida kasutas üle 80% haigetest, võis osaliselt kompenseerida 
ebapiisavat õendus- ja sotsiaalabi.  Reieluukaela murru kogukulu oli >8000 
eurot haige kohta, mis on teaduskirjanduse andmetel võrreldav infarkti ja 
insuldi kogukuluga.   
4. Reieluukaela murd on oluline iseseisev suremuse riskifaktor. Keskmine 
murrujärgne üldsuremus ühe aasta jooksul oli 28% ehk 20% võrra (3–4 
korda) kõrgem kui ilma murruta isikuil. Selline liigsuremus on võrreldav 
dementsuse või metastaatilise vähi korral esinevaga. Liigsuremus noore-
mates vanusrühmades (50–69 aastat) oli Eestis suurem kui lääneriikides. 
Liigsuremuse vähendamine saab olla võimalik murru ja selle tüsistuste 
vältimise ning piisava murrujärgse abiga.  
5. Kaasuvate haiguste ja liigsuremuse vahel esines selge annus-vastuse seos. 
Murd kiirendas surma saabumist kaasuvate haigustega patsientidel. Dement-
susega haigetel esines suurim murruga seotud liigsuremus, ilmselt kõrgema 
vanuse ja hapruse tõttu. Samas oli kaasuvate haiguste levimus suhteliselt 
väike ja nende mõju üldsuremusele mõõdukas: ainult 8% liigsuremusest oli 
tingitud kaasuvatest haigustest. Seega on kaasuvate haiguste mõju reielu-




The studies presented in the thesis were carried out at the Institute of Family 
Medicine and Public Health, University of Tartu, and were a teamwork with the 
contribution of many persons whom I am grateful to. 
I wish to express my sincere gratitude to Professor Anneli Uusküla for 
continuously guiding and coaching me throughout the years of my studies and 
research. I am very grateful to Professor Riina Kallikorm and Professor Margus 
Lember for the introduction to the research topic and continuous guidance 
throughout the studies. I am also grateful that I was given a latitude to work and 
decide within a practical domain. 
I am thankful to my colleagues and co-authors Sigrid Vorobjov, Heti 
Pisarev, and Mait Raag for the invaluable methodological guidance and 
contribution to the studies conducted for this thesis. I would also like to 
acknowledge the research team members in studies conducted for this thesis: 
Fredrik Borgström and Axel Svedbom from Karolinska Institute, and Professor 
John Kanis from the WHO Collaborating Centre for Metabolic Bone Diseases, 
University of Sheffield. I would also like to thank Liz Wager and Allison Krug 
for editing my English. 
 
The studies included in this thesis were financially supported by the Estonian 
Science Foundation [grant number 9368], the Estonian Ministry of Education 
and Research [grant numbers SF0180060s09], and the institutional research 













Name:   Mikk Jürisson 
Date of birth: July 22, 1963 
Citizenship: Estonian 
Address: Institute of Family medicine and Public Health 
  University of Tartu 
  Ravila st 19, Tartu 50411, Estonia 




2011–  University of Tartu, Faculty of Medicine, PhD studies 
2005–2008 University of London / London School of Hygiene and Tropical 
Medicine, Postgraduate Diploma in Public Health 
1988–1990 University of Tartu, Pediatric Neurologist 
1981–1988 University of Tartu, Pediatrician 
1970–1981 Tallinn School No 22 
 
Professional employment 
2014– University of Tartu, Institute of Family Medicine and Public 
Health, Lecturer of Public Health, Health Technology Assess-
ment analyst 
2011–2014 East Tallinn Central Hospital, Director of Research and 
Development 
1994–2011 Merck Sharp & Dohme Europe, Managing Director Baltics, 
Marketing Director Scandinavia and Ireland 
1990–1994 Tallinn Children’s Hospital, Pediatric Neurologist 
 
Scientific work 
Main field of research: 
‒ Osteoporosis, hip fracture burden in Estonia 
‒ Health technology assessment and economic evaluation 
Author and coauthor of 16 scientific papers in peer-reviewed journals, 3 
conference presentations (abstracts), 3 health technology assessment reports, 
and 2 other scientific publications 
155 
ELULOOKIRJELDUS 
Nimi:  Mikk Jürisson 
Sünniaeg: 22. juuli 1963 
Kodakondsus: Eesti 
Aadress: Tartu Ülikooli Peremeditsiini ja rahvatervishoiu instituut 
 Ravila tänav 19  
 Tartu 50411, Eesti 




2011– Tartu Ülikool, meditsiiniteaduste valdkond, doktoriõpe (arsti-
teadus) 
2005–2008 University of London / London School of Hygiene and Tropical 
Medicine, rahvatervise diplomiõpe 
1988–1990 Tartu Ülikool, kliiniline ordinatuur lasteneuroloogias 
1981–1988 Tartu Ülikool, arstiteaduskond, pediaatria eriala 
1970–1981 Tallinna 22. keskkool 
 
Teenistuskäik 
2014– Tartu Ülikool, Peremeditsiini ja rahvatervishoiu instituut, 
rahvatervishoiu lektor, tervisetehnoloogiate hindamise grupi 
analüütik 
2011–2014 Ida-Tallinna Keskhaigla, arendusjuht 
1994–2011 Merck Sharp & Dohme Europe, Balti piirkonna juht, 
Skandinaavia ja Iirimaa piirkonna turundusjuht 




‒ Osteoporoosi ja reieluukaela murruga seotud haiguskoormus 
‒ Tervisetehnoloogiate hindamine ja majandusanalüüs 
16 eelretsenseeritud ajakirjas avaldatud teaduspublikatsiooni, 3 konverentsi-
ettekande (lühikokkuvõtte), 3 tervisetehnoloogiate hindamise raporti ja 2 muu 






DISSERTATIONES MEDICINAE  
UNIVERSITATIS TARTUENSIS 
 
 1. Heidi-Ingrid Maaroos. The natural course of gastric ulcer in connection 
with chronic gastritis and Helicobacter pylori. Tartu, 1991. 
 2. Mihkel Zilmer. Na-pump in normal and tumorous brain tissues: Structu-
ral, functional and tumorigenesis aspects. Tartu, 1991. 
 3. Eero Vasar. Role of cholecystokinin receptors in the regulation of beha-
viour and in the action of haloperidol and diazepam. Tartu, 1992. 
 4. Tiina Talvik. Hypoxic-ischaemic brain damage in neonates (clinical, 
biochemical and brain computed tomographical investigation). Tartu, 1992. 
 5. Ants Peetsalu. Vagotomy in duodenal ulcer disease: A study of gastric 
acidity, serum pepsinogen I, gastric mucosal histology and Helicobacter 
pylori. Tartu, 1992. 
 6. Marika Mikelsaar. Evaluation of the gastrointestinal microbial ecosystem 
in health and disease. Tartu, 1992. 
 7. Hele Everaus. Immuno-hormonal interactions in chronic lymphocytic leu-
kaemia and multiple myeloma. Tartu, 1993. 
 8. Ruth Mikelsaar. Etiological factors of diseases in genetically consulted 
children and newborn screening: dissertation for the commencement of the 
degree of doctor of medical sciences. Tartu, 1993. 
 9. Agu Tamm. On metabolic action of intestinal microflora: clinical aspects. 
Tartu, 1993. 
 10. Katrin Gross. Multiple sclerosis in South-Estonia (epidemiological and 
computed tomographical investigations). Tartu, 1993. 
 11. Oivi Uibo. Childhood coeliac disease in Estonia: occurrence, screening, 
diagnosis and clinical characterization. Tartu, 1994. 
 12. Viiu Tuulik. The functional disorders of central nervous system of che-
mistry workers. Tartu, 1994. 
 13. Margus Viigimaa. Primary haemostasis, antiaggregative and anticoagulant 
treatment of acute myocardial infarction. Tartu, 1994. 
 14. Rein Kolk. Atrial versus ventricular pacing in patients with sick sinus 
syndrome. Tartu, 1994. 
 15. Toomas Podar. Incidence of childhood onset type 1 diabetes mellitus in 
Estonia. Tartu, 1994. 
 16. Kiira Subi. The laboratory surveillance of the acute respiratory viral 
infections in Estonia. Tartu, 1995. 
17. Irja Lutsar. Infections of the central nervous system in children (epidemi-
ologic, diagnostic and therapeutic aspects, long term outcome). Tartu, 1995. 
18. Aavo Lang. The role of dopamine, 5-hydroxytryptamine, sigma and 
NMDA receptors in the action of antipsychotic drugs. Tartu, 1995. 
19.  Andrus Arak. Factors influencing the survival of patients after radical 
surgery for gastric cancer. Tartu, 1996. 
157 
20.  Tõnis Karki. Quantitative composition of the human lactoflora and 
method for its examination. Tartu, 1996. 
21. Reet Mändar. Vaginal microflora during pregnancy and its transmission 
to newborn. Tartu, 1996.  
22. Triin Remmel. Primary biliary cirrhosis in Estonia: epidemiology, clinical 
characterization and prognostication of the course of the disease. Tartu, 
1996. 
23. Toomas Kivastik. Mechanisms of drug addiction: focus on positive rein-
forcing properties of morphine. Tartu, 1996.  
24.  Paavo Pokk. Stress due to sleep deprivation: focus on GABAA receptor-
chloride ionophore complex. Tartu, 1996. 
25. Kristina Allikmets. Renin system activity in essential hypertension. As-
sociations with atherothrombogenic cardiovascular risk factors and with 
the efficacy of calcium antagonist treatment. Tartu, 1996. 
26. Triin Parik. Oxidative stress in essential hypertension: Associations with 
metabolic disturbances and the effects of calcium antagonist treatment. 
Tartu, 1996. 
27.  Svetlana Päi. Factors promoting heterogeneity of the course of rheumatoid 
arthritis. Tartu, 1997.  
28. Maarike Sallo. Studies on habitual physical activity and aerobic fitness in 
4 to 10 years old children. Tartu, 1997. 
29. Paul Naaber. Clostridium difficile infection and intestinal microbial eco-
logy. Tartu, 1997. 
30. Rein Pähkla. Studies in pinoline pharmacology. Tartu, 1997. 
31. Andrus Juhan Voitk. Outpatient laparoscopic cholecystectomy. Tartu, 1997. 
32. Joel Starkopf. Oxidative stress and ischaemia-reperfusion of the heart. 
Tartu, 1997. 
33.  Janika Kõrv. Incidence, case-fatality and outcome of stroke. Tartu, 1998. 
34. Ülla Linnamägi. Changes in local cerebral blood flow and lipid peroxida-
tion following lead exposure in experiment. Tartu, 1998. 
35. Ave Minajeva. Sarcoplasmic reticulum function: comparison of atrial and 
ventricular myocardium. Tartu, 1998. 
36. Oleg Milenin. Reconstruction of cervical part of esophagus by revascular-
ised ileal autografts in dogs. A new complex multistage method. Tartu, 
1998. 
37. Sergei Pakriev. Prevalence of depression, harmful use of alcohol and 
alcohol dependence among rural population in Udmurtia. Tartu, 1998. 
38. Allen Kaasik. Thyroid hormone control over β-adrenergic signalling 
system in rat atria. Tartu, 1998. 
39. Vallo Matto. Pharmacological studies on anxiogenic and antiaggressive 
properties of antidepressants. Tartu, 1998. 
40. Maire Vasar. Allergic diseases and bronchial hyperreactivity in Estonian 
children in relation to environmental influences. Tartu, 1998. 
41. Kaja Julge. Humoral immune responses to allergens in early childhood. 
Tartu, 1998. 
158 
42. Heli Grünberg. The cardiovascular risk of Estonian schoolchildren. 
A cross-sectional study of 9-, 12- and 15-year-old children. Tartu, 1998. 
43. Epp Sepp. Formation of intestinal microbial ecosystem in children. Tartu, 
1998. 
44. Mai Ots. Characteristics of the progression of human and experimental 
glomerulopathies. Tartu, 1998. 
45. Tiina Ristimäe. Heart rate variability in patients with coronary artery 
disease. Tartu, 1998. 
46. Leho Kõiv. Reaction of the sympatho-adrenal and hypothalamo-pituitary-
adrenocortical system in the acute stage of head injury. Tartu, 1998. 
47. Bela Adojaan. Immune and genetic factors of childhood onset IDDM in 
Estonia. An epidemiological study. Tartu, 1999. 
48. Jakov Shlik. Psychophysiological effects of cholecystokinin in humans. 
Tartu, 1999. 
49. Kai Kisand. Autoantibodies against dehydrogenases of α-ketoacids. Tartu, 
1999. 
50. Toomas Marandi. Drug treatment of depression in Estonia. Tartu, 1999. 
51. Ants Kask. Behavioural studies on neuropeptide Y. Tartu, 1999. 
52. Ello-Rahel Karelson. Modulation of adenylate cyclase activity in the rat 
hippocampus by neuropeptide galanin and its chimeric analogs. Tartu, 1999. 
53. Tanel Laisaar. Treatment of pleural empyema — special reference to 
intrapleural therapy with streptokinase and surgical treatment modalities. 
Tartu, 1999. 
54. Eve Pihl. Cardiovascular risk factors in middle-aged former athletes. 
Tartu, 1999. 
55.  Katrin Õunap. Phenylketonuria in Estonia: incidence, newborn screening, 
diagnosis, clinical characterization and genotype/phenotype correlation. 
Tartu, 1999. 
56. Siiri Kõljalg. Acinetobacter – an important nosocomial pathogen. Tartu, 
1999. 
57. Helle Karro. Reproductive health and pregnancy outcome in Estonia: 
association with different factors. Tartu, 1999. 
58. Heili Varendi. Behavioral effects observed in human newborns during 
exposure to naturally occurring odors. Tartu, 1999.  
59. Anneli Beilmann. Epidemiology of epilepsy in children and adolescents in 
Estonia. Prevalence, incidence, and clinical characteristics. Tartu, 1999. 
60. Vallo Volke. Pharmacological and biochemical studies on nitric oxide in 
the regulation of behaviour. Tartu, 1999. 
61.  Pilvi Ilves. Hypoxic-ischaemic encephalopathy in asphyxiated term infants. 
A prospective clinical, biochemical, ultrasonographical study. Tartu, 1999. 
62. Anti Kalda. Oxygen-glucose deprivation-induced neuronal death and its 
pharmacological prevention in cerebellar granule cells. Tartu, 1999. 
63.  Eve-Irene Lepist. Oral peptide prodrugs – studies on stability and 
absorption. Tartu, 2000. 
159 
64. Jana Kivastik. Lung function in Estonian schoolchildren: relationship 
with anthropometric indices and respiratory symptomas, reference values 
for dynamic spirometry. Tartu, 2000. 
65. Karin Kull. Inflammatory bowel disease: an immunogenetic study. Tartu, 
2000. 
66. Kaire Innos. Epidemiological resources in Estonia: data sources, their 
quality and feasibility of cohort studies. Tartu, 2000. 
67. Tamara Vorobjova. Immune response to Helicobacter pylori and its 
association with dynamics of chronic gastritis and epithelial cell turnover 
in antrum and corpus. Tartu, 2001. 
68. Ruth Kalda. Structure and outcome of family practice quality in the 
changing health care system of Estonia. Tartu, 2001. 
69. Annika Krüüner. Mycobacterium tuberculosis – spread and drug 
resistance in Estonia. Tartu, 2001. 
70. Marlit Veldi. Obstructive Sleep Apnoea: Computerized Endopharyngeal 
Myotonometry of the Soft Palate and Lingual Musculature. Tartu, 2001. 
71. Anneli Uusküla. Epidemiology of sexually transmitted diseases in Estonia 
in 1990–2000. Tartu, 2001. 
72. Ade Kallas. Characterization of antibodies to coagulation factor VIII. 
Tartu, 2002. 
73. Heidi Annuk. Selection of medicinal plants and intestinal lactobacilli as 
antimicrobil components for functional foods. Tartu, 2002.  
74. Aet Lukmann. Early rehabilitation of patients with ischaemic heart 
disease after surgical revascularization of the myocardium:  assessment of 
health-related quality of life, cardiopulmonary reserve and oxidative stress. 
A clinical study. Tartu, 2002. 
75. Maigi Eisen. Pathogenesis of Contact Dermatitis: participation of Oxida-
tive Stress. A clinical – biochemical study. Tartu, 2002. 
76. Piret Hussar. Histology of the post-traumatic bone repair in rats. Elabora-
tion and use of a new standardized experimental model – bicortical perfora-
tion of tibia compared to internal fracture and resection osteotomy. Tartu, 
2002. 
77. Tõnu Rätsep. Aneurysmal subarachnoid haemorrhage: Noninvasive moni-
toring of cerebral haemodynamics. Tartu, 2002. 
78. Marju Herodes. Quality of life of people with epilepsy in Estonia. Tartu, 
2003. 
79. Katre Maasalu. Changes in bone quality due to age and genetic disorders 
and their clinical expressions in Estonia. Tartu, 2003. 
80. Toomas Sillakivi. Perforated peptic ulcer in Estonia: epidemiology, risk 
factors and relations with Helicobacter pylori. Tartu, 2003. 
81. Leena Puksa. Late responses in motor nerve conduction studies. F and A 
waves in normal subjects and patients with neuropathies. Tartu, 2003. 
82. Krista Lõivukene. Helicobacter pylori in gastric microbial ecology and  
its antimicrobial susceptibility pattern. Tartu, 2003. 
160 
83. Helgi Kolk. Dyspepsia and Helicobacter pylori infection: the diagnostic 
value of symptoms, treatment and follow-up of patients referred for upper 
gastrointestinal endoscopy by family physicians. Tartu, 2003. 
84. Helena Soomer. Validation of identification and age estimation methods 
in forensic odontology. Tartu, 2003. 
85. Kersti Oselin. Studies on the human MDR1, MRP1, and MRP2 ABC 
transporters: functional relevance of the genetic polymorphisms in the 
MDR1 and MRP1 gene. Tartu, 2003. 
86. Jaan Soplepmann. Peptic ulcer haemorrhage in Estonia: epidemiology, 
prognostic factors, treatment and outcome. Tartu, 2003. 
87. Margot Peetsalu. Long-term follow-up after vagotomy in duodenal ulcer 
disease: recurrent ulcer, changes in the function, morphology and Helico-
bacter pylori colonisation of the gastric mucosa. Tartu, 2003. 
88. Kersti Klaamas. Humoral immune response to Helicobacter pylori a study 
of host-dependent and microbial factors. Tartu, 2003. 
89. Pille Taba. Epidemiology of Parkinson’s disease in Tartu, Estonia. Pre-
valence, incidence, clinical characteristics, and pharmacoepidemiology. 
Tartu, 2003.  
90. Alar Veraksitš. Characterization of behavioural and biochemical pheno-
type of cholecystokinin-2 receptor deficient mice: changes in the function 
of the dopamine and endopioidergic system. Tartu, 2003. 
91. Ingrid Kalev. CC-chemokine receptor 5 (CCR5) gene polymorphism in 
Estonians and in patients with Type I and Type II diabetes mellitus. Tartu, 
2003. 
92. Lumme Kadaja. Molecular approach to the regulation of mitochondrial 
function in oxidative muscle cells. Tartu, 2003. 
93. Aive Liigant. Epidemiology of primary central nervous system tumours in 
Estonia from 1986 to 1996. Clinical characteristics, incidence, survival and 
prognostic factors. Tartu, 2004. 
94. Andres, Kulla. Molecular characteristics of mesenchymal stroma in 
human astrocytic gliomas. Tartu, 2004. 
95. Mari Järvelaid. Health damaging risk behaviours in adolescence. Tartu, 
2004. 
96. Ülle Pechter. Progression prevention strategies in chronic renal failure and 
hypertension. An experimental and clinical study. Tartu, 2004. 
97. Gunnar Tasa. Polymorphic glutathione S-transferases – biology and role 
in modifying genetic susceptibility to senile cataract and primary open 
angle glaucoma. Tartu, 2004. 
98. Tuuli Käämbre. Intracellular energetic unit: structural and functional 
aspects. Tartu, 2004. 
99.  Vitali Vassiljev. Influence of nitric oxide syntase inhibitors on the effects  
of ethanol after acute and chronic ethanol administration and withdrawal. 
Tartu, 2004. 
161 
100. Aune Rehema. Assessment of nonhaem ferrous iron and glutathione 
redox ratio as markers of pathogeneticity of oxidative stress in different 
clinical groups. Tartu, 2004. 
101.   Evelin Seppet. Interaction of mitochondria and ATPases in oxidative 
muscle cells in normal and pathological conditions. Tartu, 2004. 
102. Eduard Maron. Serotonin function in panic disorder: from clinical expe-
riments to brain imaging and genetics. Tartu, 2004.  
103. Marje Oona. Helicobacter pylori infection in children: epidemiological 
and therapeutic aspects. Tartu, 2004. 
104. Kersti Kokk. Regulation of active and passive molecular transport in the 
testis. Tartu, 2005.  
105. Vladimir Järv. Cross-sectional imaging for pretreatment evaluation and 
follow-up of pelvic malignant tumours. Tartu, 2005. 
106. Andre Õun. Epidemiology of adult epilepsy in Tartu, Estonia. Incidence, 
prevalence and medical treatment. Tartu, 2005. 
107. Piibe Muda. Homocysteine and hypertension: associations between 
homocysteine and essential hypertension in treated and untreated hyper-
tensive patients with and without coronary artery disease. Tartu, 2005. 
108. Külli Kingo. The interleukin-10 family cytokines gene polymorphisms in 
plaque psoriasis. Tartu, 2005.  
109. Mati Merila. Anatomy and clinical relevance of the glenohumeral joint  
capsule and ligaments. Tartu, 2005. 
110. Epp Songisepp. Evaluation of technological and functional properties of 
the new probiotic Lactobacillus fermentum ME-3. Tartu, 2005. 
111. Tiia Ainla. Acute myocardial infarction in Estonia: clinical characte-
ristics, management and outcome. Tartu, 2005. 
112. Andres Sell. Determining the minimum local anaesthetic requirements for 
hip replacement surgery under spinal anaesthesia – a study employing a 
spinal catheter. Tartu, 2005. 
113. Tiia Tamme. Epidemiology of odontogenic tumours in Estonia. Patho-
genesis and clinical behaviour of ameloblastoma. Tartu, 2005. 
114. Triine Annus. Allergy in Estonian schoolchildren: time trends and 
characteristics. Tartu, 2005. 
115. Tiia Voor. Microorganisms in infancy and development of allergy: com-
parison  of  Estonian  and Swedish  children. Tartu, 2005. 
116. Priit Kasenõmm. Indicators for tonsillectomy in adults with recurrent 
tonsillitis – clinical, microbiological and pathomorphological investi-
gations. Tartu, 2005. 
117. Eva Zusinaite. Hepatitis C virus: genotype identification and interactions 
between viral proteases. Tartu, 2005. 
118. Piret Kõll. Oral lactoflora in chronic periodontitis and periodontal health. 
Tartu, 2006. 
119. Tiina Stelmach. Epidemiology of cerebral palsy and unfavourable neuro-
developmental outcome in child population of Tartu city and county, 
Estonia Prevalence, clinical features and risk factors. Tartu, 2006. 
162 
120. Katrin Pudersell. Tropane alkaloid production and riboflavine excretion 
in the field and tissue cultures of henbane (Hyoscyamus niger L.). Tartu, 
2006.  
121. Külli Jaako. Studies on the role of neurogenesis in brain plasticity. Tartu, 
2006.  
122. Aare Märtson. Lower limb lengthening: experimental studies of bone 
regeneration and long-term clinical results. Tartu, 2006. 
123.  Heli Tähepõld. Patient consultation in family medicine. Tartu, 2006. 
124. Stanislav Liskmann. Peri-implant disease: pathogenesis, diagnosis and 
treatment in view of both inflammation and oxidative stress profiling. 
Tartu, 2006. 
125. Ruth Rudissaar. Neuropharmacology of atypical antipsychotics and an 
animal model of psychosis. Tartu, 2006. 
126. Helena Andreson. Diversity of Helicobacter pylori genotypes in 
Estonian patients with chronic inflammatory gastric diseases. Tartu, 2006. 
127. Katrin Pruus. Mechanism of action of antidepressants: aspects of sero-
toninergic system and its interaction with glutamate. Tartu, 2006. 
128. Priit Põder. Clinical and experimental investigation: relationship of 
ischaemia/reperfusion injury with oxidative stress in abdominal aortic 
aneurysm repair and in extracranial brain artery endarterectomy and possi-
bilities of protection against ischaemia using a glutathione analogue in a 
rat model of global brain ischaemia. Tartu, 2006.   
129. Marika Tammaru. Patient-reported outcome measurement in rheumatoid 
arthritis. Tartu, 2006. 
130.   Tiia Reimand. Down syndrome in Estonia. Tartu, 2006. 
131. Diva Eensoo. Risk-taking in traffic and Markers of Risk-Taking Beha-
viour in Schoolchildren and Car Drivers. Tartu, 2007. 
132. Riina Vibo. The third stroke registry in Tartu, Estonia from 2001 to 2003: 
incidence, case-fatality, risk factors and long-term outcome. Tartu, 2007.  
133. Chris Pruunsild. Juvenile idiopathic arthritis in children in Estonia. 
Tartu, 2007. 
134. Eve Õiglane-Šlik. Angelman and Prader-Willi syndromes in Estonia. 
Tartu, 2007. 
135. Kadri Haller. Antibodies to follicle stimulating hormone. Significance in 
female infertility. Tartu, 2007. 
136.  Pille Ööpik. Management of depression in family medicine. Tartu, 2007. 
137. Jaak Kals. Endothelial function and arterial stiffness in patients with 
atherosclerosis and in healthy subjects. Tartu, 2007. 
138.  Priit Kampus. Impact of inflammation, oxidative stress and age on 
arterial stiffness and carotid artery intima-media thickness. Tartu, 2007. 
139.  Margus Punab. Male fertility and its risk factors in Estonia. Tartu, 2007. 
140. Alar Toom. Heterotopic ossification after total hip arthroplasty: clinical 
and pathogenetic investigation. Tartu, 2007. 
163 
141. Lea Pehme. Epidemiology of tuberculosis in Estonia 1991–2003 with 
special regard to extrapulmonary tuberculosis and delay in diagnosis of 
pulmonary tuberculosis. Tartu, 2007. 
142.  Juri Karjagin. The pharmacokinetics of metronidazole and meropenem 
in septic shock. Tartu, 2007. 
143. Inga Talvik. Inflicted traumatic brain injury shaken baby syndrome in 
Estonia – epidemiology and outcome. Tartu, 2007. 
144.  Tarvo Rajasalu. Autoimmune diabetes: an immunological study of type 
1 diabetes in humans and in a model of experimental diabetes (in RIP-
B7.1 mice). Tartu, 2007. 
145. Inga Karu. Ischaemia-reperfusion injury of the heart during coronary 
surgery: a clinical study investigating the effect of hyperoxia. Tartu, 2007. 
146. Peeter Padrik. Renal cell carcinoma: Changes in natural history and 
treatment of metastatic disease. Tartu, 2007.  
147.  Neve Vendt. Iron deficiency and iron deficiency anaemia in infants aged 
9 to 12 months in Estonia. Tartu, 2008.  
148. Lenne-Triin Heidmets. The effects of neurotoxins on brain plasticity: 
focus on neural Cell Adhesion Molecule. Tartu, 2008. 
149.  Paul Korrovits. Asymptomatic inflammatory prostatitis: prevalence, etio-
logical factors, diagnostic tools. Tartu, 2008. 
150.   Annika Reintam. Gastrointestinal failure in intensive care patients. Tartu, 
2008. 
151.   Kristiina Roots. Cationic regulation of Na-pump in the normal, Alzhei-
mer’s and CCK2 receptor-deficient brain. Tartu, 2008. 
152. Helen Puusepp. The genetic causes of mental retardation in Estonia: 
fragile X syndrome and creatine transporter defect. Tartu, 2009. 
153. Kristiina Rull. Human chorionic gonadotropin beta genes and recurrent 
miscarriage: expression and variation study. Tartu, 2009. 
154.  Margus Eimre. Organization of energy transfer and feedback regulation 
in oxidative muscle cells. Tartu, 2009. 
155. Maire Link. Transcription factors FoxP3 and AIRE: autoantibody 
associations. Tartu, 2009. 
156.  Kai Haldre. Sexual health and behaviour of young women in Estonia. 
Tartu, 2009. 
157. Kaur Liivak. Classical form of congenital adrenal hyperplasia due to  
21-hydroxylase deficiency in Estonia: incidence, genotype and phenotype 
with special attention to short-term growth and 24-hour blood pressure. 
Tartu, 2009. 
158. Kersti Ehrlich. Antioxidative glutathione analogues (UPF peptides) – 
molecular design, structure-activity relationships and testing the protec-
tive properties. Tartu, 2009. 
159. Anneli Rätsep. Type 2 diabetes care in family medicine. Tartu, 2009. 
160. Silver Türk. Etiopathogenetic aspects of chronic prostatitis: role of 
mycoplasmas, coryneform bacteria and oxidative stress. Tartu, 2009. 
164 
161. Kaire Heilman. Risk markers for cardiovascular disease and low bone 
mineral density in children with type 1 diabetes. Tartu, 2009. 
162.  Kristi Rüütel. HIV-epidemic in Estonia: injecting drug use and quality of 
life of people living with HIV. Tartu, 2009. 
163. Triin Eller. Immune markers in major depression and in antidepressive 
treatment. Tartu, 2009. 
164.  Siim Suutre. The role of TGF-β isoforms and osteoprogenitor cells in the 
pathogenesis of heterotopic ossification. An experimental and clinical 
study of hip arthroplasty. Tartu, 2010. 
165.  Kai Kliiman. Highly drug-resistant tuberculosis in Estonia: Risk factors 
and predictors of poor treatment outcome. Tartu, 2010.  
166.  Inga Villa. Cardiovascular health-related nutrition, physical activity and 
fitness in Estonia. Tartu, 2010. 
167. Tõnis Org. Molecular function of the first PHD finger domain of Auto-
immune Regulator protein. Tartu, 2010.  
168. Tuuli Metsvaht. Optimal antibacterial therapy of neonates at risk of early 
onset sepsis. Tartu, 2010. 
169.  Jaanus Kahu. Kidney transplantation: Studies on donor risk factors and 
mycophenolate mofetil. Tartu, 2010.  
170.  Koit Reimand. Autoimmunity in reproductive failure: A study on as-
sociated autoantibodies and autoantigens. Tartu, 2010. 
171. Mart Kull. Impact of vitamin D and hypolactasia on bone mineral 
density: a population based study in Estonia. Tartu, 2010. 
172. Rael Laugesaar. Stroke in children – epidemiology and risk factors. 
Tartu, 2010.  
173.  Mark Braschinsky. Epidemiology and quality of life issues of hereditary 
spastic paraplegia in Estonia and implemention of genetic analysis in 
everyday neurologic practice. Tartu, 2010. 
174. Kadri Suija. Major depression in family medicine: associated factors, 
recurrence and possible intervention. Tartu, 2010. 
175. Jarno Habicht. Health care utilisation in Estonia: socioeconomic determi-
nants and financial burden of out-of-pocket payments. Tartu, 2010. 
176. Kristi Abram. The prevalence and risk factors of rosacea. Subjective 
disease perception of rosacea patients. Tartu, 2010. 
177. Malle Kuum. Mitochondrial and endoplasmic reticulum cation fluxes: 
Novel roles in cellular physiology. Tartu, 2010. 
178. Rita Teek. The genetic causes of early onset hearing loss in Estonian 
children. Tartu, 2010. 
179. Daisy Volmer. The development of community pharmacy services in 
Estonia – public and professional perceptions 1993–2006. Tartu, 2010. 
180. Jelena Lissitsina. Cytogenetic causes in male infertility. Tartu, 2011. 
181.  Delia Lepik. Comparison of gunshot injuries caused from Tokarev, 
Makarov and Glock 19 pistols at different firing distances. Tartu, 2011. 
182.  Ene-Renate Pähkla. Factors related to the efficiency of treatment of 
advanced periodontitis. Tartu, 2011.  
165 
183. Maarja Krass. L-Arginine pathways and antidepressant action. Tartu, 
2011.  
184.  Taavi Lai. Population health measures to support evidence-based  
health policy in Estonia. Tartu, 2011.  
185. Tiit Salum. Similarity and difference of temperature-dependence of the 
brain sodium pump in normal, different neuropathological, and aberrant 
conditions and its possible reasons. Tartu, 2011.  
186.  Tõnu Vooder. Molecular differences and similarities between histo-
logical subtypes of non-small cell lung cancer. Tartu, 2011.  
187.  Jelena Štšepetova. The characterisation of intestinal lactic acid bacteria 
using bacteriological, biochemical and molecular approaches. Tartu, 2011.  
188. Radko Avi. Natural polymorphisms and transmitted drug resistance in 
Estonian HIV-1 CRF06_cpx and its recombinant viruses. Tartu, 2011, 116 p. 
189.  Edward Laane. Multiparameter flow cytometry in haematological malig-
nancies. Tartu, 2011, 152 p. 
190.  Triin Jagomägi. A study of the genetic etiology of nonsyndromic cleft lip 
and palate. Tartu, 2011, 158 p. 
191.  Ivo Laidmäe. Fibrin glue of fish (Salmo salar) origin: immunological 
study and development of new pharmaceutical preparation. Tartu, 2012, 
150 p. 
192.  Ülle Parm. Early mucosal colonisation and its role in prediction of inva-
sive infection in neonates at risk of early onset sepsis. Tartu, 2012, 168 p. 
193.  Kaupo Teesalu. Autoantibodies against desmin and transglutaminase 2 in 
celiac disease: diagnostic and functional significance. Tartu, 2012, 142 p. 
194. Maksim Zagura. Biochemical, functional and structural profiling of 
arterial damage in atherosclerosis. Tartu, 2012, 162 p. 
195. Vivian Kont. Autoimmune regulator: characterization of thymic gene 
regulation and promoter methylation. Tartu, 2012, 134 p. 
196. Pirje Hütt. Functional properties, persistence, safety and efficacy of 
potential probiotic lactobacilli. Tartu, 2012, 246 p. 
197.  Innar Tõru. Serotonergic modulation of CCK-4- induced panic. Tartu, 
2012, 132 p. 
198.  Sigrid Vorobjov. Drug use, related risk behaviour and harm reduction 
interventions utilization among injecting drug users in Estonia: impli-
cations for drug policy. Tartu, 2012, 120 p. 
199.  Martin Serg. Therapeutic aspects of central haemodynamics, arterial 
stiffness and oxidative stress in hypertension. Tartu, 2012, 156 p.  
200. Jaanika Kumm. Molecular markers of articular tissues in early knee 
osteoarthritis: a population-based longitudinal study in middle-aged sub-
jects. Tartu, 2012, 159 p. 
201. Kertu Rünkorg. Functional changes of dopamine, endopioid and endo-
cannabinoid systems in CCK2 receptor deficient mice. Tartu, 2012, 125 p. 
202. Mai Blöndal. Changes in the baseline characteristics, management and 
outcomes of acute myocardial infarction in Estonia. Tartu, 2012, 127 p.        
166 
203. Jana Lass. Epidemiological and clinical aspects of medicines use in 
children in Estonia. Tartu, 2012, 170 p. 
204. Kai Truusalu. Probiotic lactobacilli in experimental persistent Salmo-
nella infection. Tartu, 2013, 139 p.  
205. Oksana Jagur.  Temporomandibular joint diagnostic imaging in relation 
to pain and bone characteristics. Long-term results of arthroscopic treat-
ment. Tartu, 2013, 126 p. 
206. Katrin Sikk. Manganese-ephedrone intoxication – pathogenesis of neuro-
logical damage and clinical symptomatology. Tartu, 2013, 125 p. 
207. Kai Blöndal. Tuberculosis in Estonia with special emphasis on drug-
resistant tuberculosis: Notification rate, disease recurrence and mortality. 
Tartu, 2013, 151 p. 
208. Marju Puurand. Oxidative phosphorylation in different diseases of 
gastric mucosa. Tartu, 2013, 123 p.  
209. Aili Tagoma. Immune activation in female infertility: Significance of 
autoantibodies and inflammatory mediators. Tartu, 2013, 135 p. 
210.  Liis Sabre. Epidemiology of traumatic spinal cord injury in Estonia. 
Brain activation in the acute phase of traumatic spinal cord injury. Tartu, 
2013, 135 p. 
211. Merit Lamp. Genetic susceptibility factors in endometriosis. Tartu, 2013, 
125 p. 
212.  Erik Salum. Beneficial effects of vitamin D and angiotensin II receptor 
blocker on arterial damage. Tartu, 2013, 167 p.   
213.  Maire Karelson. Vitiligo: clinical aspects, quality of life and the role of 
melanocortin system in pathogenesis. Tartu, 2013, 153 p.  
214. Kuldar Kaljurand. Prevalence of exfoliation syndrome in Estonia and its 
clinical significance. Tartu, 2013, 113 p.  
215.  Raido Paasma. Clinical study of methanol poisoning: handling large out-
breaks, treatment with antidotes, and long-term outcomes. Tartu, 2013,  
96 p. 
216.  Anne Kleinberg. Major depression in Estonia: prevalence, associated 
factors, and use of health services. Tartu, 2013, 129 p. 
217.  Triin Eglit. Obesity, impaired glucose regulation, metabolic syndrome 
and their associations with high-molecular-weight adiponectin levels. 
Tartu, 2014, 115 p. 
218.  Kristo Ausmees. Reproductive function in middle-aged males: Asso-
ciations with prostate, lifestyle and couple infertility status. Tartu, 2014, 
125 p.  
219.  Kristi Huik. The influence of host genetic factors on the susceptibility to 
HIV and HCV infections among intravenous drug users. Tartu, 2014, 
144 p.  
220. Liina Tserel. Epigenetic profiles of monocytes, monocyte-derived macro-
phages and dendritic cells. Tartu, 2014, 143 p. 
221. Irina Kerna. The contribution of ADAM12 and CILP genes to the 
development of knee osteoarthritis. Tartu, 2014, 152 p. 
167 
222. Ingrid Liiv. Autoimmune regulator protein interaction with DNA-depen-
dent protein kinase and its role in apoptosis. Tartu, 2014, 143 p. 
223.  Liivi Maddison. Tissue perfusion and metabolism during intra-abdominal 
hypertension. Tartu, 2014, 103 p. 
224.  Krista Ress. Childhood coeliac disease in Estonia, prevalence in atopic 
dermatitis and immunological characterisation of coexistence. Tartu, 
2014, 124 p. 
225.  Kai Muru. Prenatal screening strategies, long-term outcome of children 
with marked changes in maternal screening tests and the most common 
syndromic heart anomalies in Estonia. Tartu, 2014, 189 p. 
226. Kaja Rahu. Morbidity and mortality among Baltic Chernobyl cleanup 
workers: a register-based cohort study. Tartu, 2014, 155 p.  
227.  Klari Noormets. The development of diabetes mellitus, fertility and ener-
gy metabolism disturbances in a Wfs1-deficient mouse model of Wolfram 
syndrome. Tartu, 2014, 132 p. 
228. Liis Toome. Very low gestational age infants in Estonia. Tartu, 2014,  
183 p. 
229.  Ceith Nikkolo. Impact of different mesh parameters on chronic pain and 
foreign body feeling after open inguinal hernia repair. Tartu, 2014, 132 p. 
230.  Vadim Brjalin. Chronic hepatitis C: predictors of treatment response in 
Estonian patients. Tartu, 2014, 122 p. 
231.  Vahur Metsna. Anterior knee pain in patients following total knee arthro-
plasty: the prevalence, correlation with patellar cartilage impairment and 
aspects of patellofemoral congruence. Tartu, 2014, 130 p. 
232.  Marju Kase. Glioblastoma multiforme: possibilities to improve treatment 
efficacy. Tartu, 2015, 137 p.  
233. Riina Runnel. Oral health among elementary school children and the 
effects of polyol candies on the prevention of dental caries. Tartu, 2015, 
112 p. 
234. Made Laanpere. Factors influencing women’s sexual health and re-
productive choices in Estonia. Tartu, 2015, 176 p. 
235.  Andres Lust. Water mediated solid state transformations of a polymorphic 
drug – effect on pharmaceutical product performance. Tartu, 2015, 134 p.  
236. Anna Klugman. Functionality related characterization of pretreated wood 
lignin, cellulose and polyvinylpyrrolidone for pharmaceutical applications. 
Tartu, 2015, 156 p. 
237. Triin Laisk-Podar. Genetic variation as a modulator of susceptibility to 
female infertility and a source for potential biomarkers. Tartu, 2015, 155 p. 
238. Mailis Tõnisson. Clinical picture and biochemical changes in blood in 
children with acute alcohol intoxication. Tartu, 2015, 100 p. 
239. Kadri Tamme. High volume haemodiafiltration in treatment of severe 
sepsis – impact on pharmacokinetics of antibiotics and inflammatory 




240. Kai Part. Sexual health of young people in Estonia in a social context: the 
role of school-based sexuality education and youth-friendly counseling 
services. Tartu, 2015, 203 p. 
241. Urve Paaver. New perspectives for the amorphization and physical 
stabilization of poorly water-soluble drugs and understanding their 
dissolution behavior. Tartu, 2015, 139 p. 
242. Aleksandr Peet. Intrauterine and postnatal growth in children with HLA-
conferred susceptibility to type 1 diabetes. Tartu. 2015, 146 p. 
243. Piret Mitt. Healthcare-associated infections in Estonia – epidemiology 
and surveillance of bloodstream and surgical site infections. Tartu, 2015, 
145 p. 
244.  Merli Saare. Molecular Profiling of Endometriotic Lesions and Endo-
metria of Endometriosis Patients. Tartu, 2016, 129 p. 
245.  Kaja-Triin Laisaar. People living with HIV in Estonia: Engagement in 
medical care and methods of increasing adherence to antiretroviral therapy 
and safe sexual behavior. Tartu, 2016, 132 p. 
246. Eero Merilind. Primary health care performance: impact of payment and 
practice-based characteristics. Tartu, 2016, 120 p. 
247. Jaanika Kärner. Cytokine-specific autoantibodies in AIRE deficiency. 
Tartu, 2016, 182 p. 
248. Kaido Paapstel. Metabolomic profile of arterial stiffness and early bio-
markers of renal damage in atherosclerosis. Tartu, 2016, 173 p. 
249.  Liidia Kiisk. Long-term nutritional study: anthropometrical and clinico-
laboratory assessments in renal replacement therapy patients after inten-
sive nutritional counselling. Tartu, 2016, 207 p. 
250. Georgi Nellis. The use of excipients in medicines administered to neo-
nates in Europe. Tartu, 2017, 159 p. 
251.  Aleksei Rakitin. Metabolic effects of acute and chronic treatment with 
valproic acid in people with epilepsy. Tartu, 2017, 125 p. 
252. Eveli Kallas. The influence of immunological markers to susceptibility to 
HIV, HBV, and HCV infections among persons who inject drugs. Tartu, 
2017, 138 p. 
253. Tiina Freimann. Musculoskeletal pain among nurses: prevalence, risk 
factors, and intervention. Tartu, 2017, 125 p. 
254.  Evelyn Aaviksoo. Sickness absence in Estonia: determinants and 
influence of the sick-pay cut reform. Tartu, 2017, 121 p. 
255. Kalev Nõupuu. Autosomal-recessive Stargardt disease: phenotypic 
heterogeneity and genotype-phenotype associations. Tartu, 2017, 131 p. 
256. Ho Duy Binh. Osteogenesis imperfecta in Vietnam. Tartu, 2017, 125 p. 
257.  Uku Haljasorg. Transcriptional mechanisms in thymic central tolerance. 
Tartu, 2017, 147 p.  
258.  Živile Riispere. IgA Nephropathy study according to the Oxford Classi-
fication: IgA Nephropathy clinical-morphological correlations, disease 
progression and the effect of renoprotective therapy. Tartu, 2017, 129 p. 
259. Hiie Soeorg. Coagulase-negative staphylococci in gut of preterm neonates 
and in breast milk of their mothers. Tartu, 2017, 216 p. 
260. Anne-Mari Anton Willmore. Silver nanoparticles for cancer research. 
Tartu, 2017, 132 p. 
261.  Ott Laius. Utilization of osteoporosis medicines, medication adherence 
and the trend in osteoporosis related hip fractures in Estonia. Tartu, 2017,  
134 p.  
262. Alar Aab. Insights into molecular mechanisms of asthma and atopic 
dermatitis. Tartu, 2017, 164 p. 
263. Sander Pajusalu. Genome-wide diagnostics of Mendelian disorders:  
from chromosomal microarrays to next-generation sequencing. Tartu, 
2017, 146 p. 
